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ABSTRACT
Plant alkaloid biosynthesis produces many natural products with medicinal value. For
example, vinblastine and vincristine from Catharanthus roseus monoterpene indole
alkaloid biosynthesis, and camptothecin derivatives from Ophiorrhiza pumila quinoline
alkaloid biosynthesis, are anticancer agents currently used in the clinic. Strictosidine
synthase is a key enzyme in the biosynthesis of these medicinal natural products, but its
narrow substrate scope limits precursor-directed biosynthesis of alkaloid analogs in plant
cell cultures. I describe two new assays to monitor strictosidine synthase activity, which
enable the rapid screening of enzyme mutant libraries to identify two strictosidine
synthase variants that accept new substrates. A transgenic plant cell culture that contains
one of these mutants generated "unnatural" monoterpene indole alkaloids in C. roseus. I
also describe the characterization of 0. pumila strictosidine synthase, which has
considerably broader substrate specificity than the homologous enzyme from C. roseus.
This alternative catalyst is a candidate enzyme for construction of transgenic cell
cultures, and potentially useful as a biocatalyst, since it catalyzes the asymmetric Pictet-
Spengler reaction to form tetrahydro-p-carboline pharmacophores. I used computer
modeling to propose a model for how strictosidine synthase achieves its high
stereoselectivity; this model may be used to engineer a Pictet-Spenglerase that forms the
alternative stereoisomer. Such a stereocomplementary catalyst would be useful in
biocatalysis, giving the synthetic organic chemist access to both stereoisomers in high
enantiomeric purity. Finally, I describe the total synthesis of stereoisomer mixtures of
indole alkaloid precursors, and use these mixtures to determine the stereoselectivity of
strictosidine synthase and two subsequent enzymes in monoterpene indole alkaloid
biosynthesis. The combination of chemical synthesis and the recruitment of enzymes
from unrelated biosynthetic pathways could generate diverse alkaloid libraries,
containing different stereoisomers, for bioactivity evaluation.
Thesis Supervisor: Sarah E. O'Connor
Title: Associate Professor of Chemistry
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isotope signal (for 13C NMR signal). Compounds are numbered consecutively, starting
from 1 in each chapter; only compounds that are illustrated in Figures, Schemes, or
Tables (at some point) are numbered.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE
Part of this chapter is published as a review article in
Current Opinion in Chemical Biology 2009, 13, 35-42.
1.1 Natural products and biosynthetic pathways
Natural products are organic molecules not directly involved in the normal growth,
development or reproduction of organisms.E' Yet, natural products are prevalent in nature
and enable their producers to scavenge resources from the environment, and attract, repel,
or destroy other organisms.E1 Although the mode-of-action and assembly of many natural
products remain unknown, natural products have been a source and inspiration for human
medicines since ancient times. The discovery of new natural products and the ability to
make analogs of existing natural products are vital aspects of drug discovery and
development. -E4]
An SAR (structure-activity relationship) study assesses how structural variations of the
same natural product scaffold affect biological activity, and is an essential tool to
optimizing bioactivity. However, to perform rigorous SAR studies one needs methods
to access a large number of different natural product analogs. While total- and semi-
synthesis are useful tools to generate these modified structures, metabolic engineering is
emerging as a versatile and eco-friendly alternative. Unlike synthetic methods, however,
metabolic engineering strategies require a detailed understanding of the processes
involved in the assembly of natural products, and the development of tools to alter their
production.
Biosynthetic pathways assemble natural products in an orchestrated fashion using a series
of enzyme catalyzed and non-catalyzed reactions, starting from building blocks derived
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Figure 1.1 Bioactive molecules representative of the six classes of natural products are shown along with their common name, biological
activity, and producing organism. The diterpene unit of taxol is highlighted in blue.
from primary metabolism. 1 3 Natural products fall into six classes based on the primary
metabolites used in their construction: (i) fatty acids and polyketides, (ii) aromatic amino
acids and phenylpropanoids, (iii) terpenoids and steroids, (iv) alkaloids, (v) peptides
including non-ribosomal peptides, and (vi) carbohydrates (Figure 1. 1).[ By changing the
chemical transformations that construct natural products, it is, in theory, possible to form
any natural product analog.
1.2 Enzyme engineering in natural product biosynthesis
The following sections summarize two biosynthetic pathway classes and describe
selected recent examples of enzyme engineering, which are also published in Curr. Opin.
Chem. Biol. 2009, 13, 35-42.6]
I categorize natural product biosynthetic pathways into megasynthases or dissociated-
type pathways; each category offers unique challenges and opportunities for enzyme
engineering as a tool to generate natural product derivatives (Figure 1.2).[6]
1.2.1 Megasynthases
Megasynthases, large protein complexes that shuttle biosynthetic intermediates between
enzyme active sites, include polyketide synthases (PKSs)E7 3 and non-ribosomal peptide
synthetases (NRPSs).Ea8 The bacteria and fungi that harbor megasynthases often encode
these large enzyme complexes in colinear gene clusters that, typically, contain all of the
genes necessary for the assembly of a natural product. The colinearity of these clusters
Natural product megasynthases
domain-domain
interactions
megasynthase tailoring steps - f n product
product I ia aua rdc
Module 2
Typical natural product classes:
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- nonribosomal peptides
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- Maintain pro protein-protein interactions
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Enzyme-substrate
complementarity
Substrate(
Enzyme I
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- Treat enzymes in isolation
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-Often no gene clustering that facilitate cloning
Figure 1.2 Biosynthetic pathways can be grouped into two categories depending on how the core
structure of a natural product is assembled. (A) Megasynthases are modular structures where the
growing substrate is shuttled between different domains and protein-protein interactions are keyfor activity. (B) Dissociated pathways are arrays of individual enzymes that turn over a set ofgiven substrates. Substrate specificity is often tightly regulated, since enzyme-substrate
interactions determine the order of biosynthetic events.
Module I
and the modularity of their expression products enable the use of bioinformatics to assign
putative gene functions, and allows the rational targeting of mutations to produce natural
product analogs. Strategies to generate natural product analogs by engineering mega--
synthases include domain and module swapping,E9' 10] modification of domain-domain
interfaces, 1 1] and mutagenesis of individual domains.003 These engineering approaches
often have negative impact on product titers and enzyme activities, since megasynthases
depend on both covalent and non-covalent protein-protein interactions.[ 12 ,131
Multimodularpolyketide biosynthesis
Birch's model of the construction of polyketides (PKs),E14] inspired by early work on the
multiple keten group, [15] spurred efforts to investigate the details of PK biosynthesis.[71
However, reprogramming of PK biosynthesis remained elusive until the seminal
discovery that some PK synthases (PKSs) are modular; for example, 6-deoxy-
erythronolide B synthase from Saccharopolyspora erythraea, which makes the precursor
of erythromycin.E16' 17]
Multimodular PKSs consist of one or more polypeptide chains (typically >100 kDa),
where each polypeptide chain has protein domains that work together to catalyze one
cycle of carbon-carbon bond formation (Claisen condensation) and optional steps
catalyzed by ketoreductases (KRs), dehydratases (DHs) and enoyl-reductases (ERs).
Numerous genetic tools are available to make PK analogs that result in the production of
different PK backbones, reduction levels, ring sizes, and stereochemistry, including: in-
frame or site-directed functional deletions, 17'19] modification of module order,[20] addition
of non-natural modules,[2 1] and numerous examples of domain swapping.[ 8 ]
Ketoreductases (KRs) and enoyl reductases (ERs) are part of the PKS megasynthase, and
are responsible for modifying the p-ketoacyl group of the extending PK molecule. KRs
use the co-factor NADPH to reduce carbonyl groups in all PKS systems (Figure 1.3A).
KRs with different stereospecificity exist, and sequence patterns can predict which
hydroxyl group stereoisomer forms in the reduction reaction.2 2 Therefore, mutagenesis
of KR domains is an appealing method to alter the substituent chirality of PK products. [23.
25] After a dehydration reaction catalyzed by the dehydratase (DH) domain (Figure 1.3B),
a second group of NADPH-dependent enzymes, the enoyl reductases (ERs), generate a
fully saturated polyketide backbone (Figure 1.3B). ERs that act on an i-butenyl group (a
group derived from methyl malonyl-CoA) introduce a methyl substituent with either (S)
or (R) configuration (Figure 1.3B). If the ER active site contains a tyrosine residue, the
reduced product will contain a methyl group with (S) configuration. [26] By mutating Tyr
to Val in an ER from the erythromycin producer S. erythraea, the methyl group
configuration in the product becomes (R).[263 Other residues may be responsible for this
change in stereospecificity, since the Val to Tyr mutation of an (R)-selective ER from
rapamycin biosynthesis, is not sufficient to change its stereoselectivity.[ 261
A 00 OHs
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Figure 1.3 Simplified illustration of reactions catalyzed by megasynthase domains. (A) KR
domains use NADPH to reduce carbonyl groups to alcohols; here, an acetyl extender unit
(malonyl group). (B) The KR and DH domains convert a propionyl extender unit (methyl-
malonyl group) into an i-butenyl moiety. The NADPH-dependent, stereoselective, ER domain
reduces this olefin to form a fully saturated chain. (C) A typical NRPS module is composed of an
A domain (loading an amino acid onto the PCP domain), a C domain (catalyzing the peptide bond
formation), and a PCP domain (carrying the amino acyl chain). Terminal modules often have TE
domains, which hydrolyzes the thioester linkage to release the natural product.
Iterative polyketide biosynthesis
Eukaryotic iterative type I PKSs are monomodular megasynthases that produce aromatic
polyketides.[271 Crawford et al. reported the deconstruction and reassembly of selected
domains in Aspergillus parasiticus (fungal) PksA, which makes a precursor to the
environmental carcinogen aflatoxin.[28] By using high-resolution mass spectrometry
(HRMS), the authors show how individual domains control PK chain-length, cyclization,
and product release. A product template (PT) domain, previously identified in iterative
fungal PKSs, plays a central role in controlling product formation.[281 The crystal
structure reveals that the fully extended PK product of PksA binds to the PT domain
correctly oriented for two regiospecific intramolecular aldol condensations, including the
subsequent aromatization reactions (Townsend and Tsai, in press). Therefore,
mutagenesis of the PT domain may lead to altered regiospecificity and different product
outcome.
Bacterial iterative type 1I PKSs are non-modular and consist of individual protein
domains that form intimate non-covalent associations. Ames et al. obtained a 1.9 A
resolution x-ray structure of an aromatase in Streptomyces lividans tetracenomycin
synthase, Tcm. [29] Based on how the substrates dock into the active site of Tcm, the
authors constructed eleven mutations of five Tcm residues and analyzed the cyclization
pattern of the products. Two residues (Tyr35 and Arg69) did not change the cyclization
outcome, but were responsible for anchoring the substrate to the binding site. Several
other residues, however, had a marked effect on the product outcome. 2 9 ]
Nonribosomalpeptide biosynthesis
A prototypical NRPS contains a peptidyl carrier protein (PCP), a condensation (C)
domain, and an adenylation (A) domain (Figure 1.3C). In addition, the termination
module usually includes a thioesterase (TE) domain that releases the natural product from
the megasynthase by hydrolysis of a thioester linkage. Marahiel and co-workers recently
solved the x-ray crystal structure of the intact 144-kDa NRPS termination module (C-A-
PCP-TE) of surfactin synthetase, SrfA-C, to 2.6 A resolution (PDB ID: 2VSQ).[30 The
crystal structure shows the extensive contact interfaces between the different domains
and suggests that large structural reorganizations take place during the catalytic cycle.
The authors suggest that a promising approach to generate unnatural NRP derivatives via
domain swapping, is to exchange C-A domain pairs and then optimize the PCP/C-A
contact interactions using directed evolution: a cycle of mutagenesis and screening that
gradually improves production rates or titers.[301
The key challenge for using directed evolution to obtain improved catalysts is how to
develop a suitable high-throughput screening or selection method. Siderophores provide a
unique handle for selection, since they enable host organisms to survive on iron-limiting
media. For example, enterobactin synthetase (EntB-F) from Escherichia coli, 33 ] is a two-
module NRPS that allows the bacterium to grow under iron-limiting conditions by
secreting the NRP siderophore, enterobactin. EntB is an aryl carrier protein (ArCP) that
incorporates the 2,3-dihydroxybenzoyl group into enterobactin; the entB- knockout strain
requires iron as a supplement for survival. Walsh and co-workers used this E. coli strain
to select functional NRPS mutants by growing mutant libraries on low-iron-content
media. Application of this selection method on combinatorial mutagenesis libraries
allowed mapping of contact interfaces between EntB and neighboring domains,34 3 5 1 and
enabled the replacement of EntB with two mutated non-cognate ArCP domains.[36 ] For
example, three rounds of error-prone PCR on one entB gene homolog increased the rate
of formation of enterobactin by 500-fold compared to the wild-type protein.[ 63' The
results show that domain-domain and domain-module surface interactions impair NRPS
to recognize non-cognate ArCPs.[36]
Recent solution NMR structures of NRPSs shed light on the structural changes that occur
upon domain-domain interactions. [31,32] NMR structures of the PCP-TE bidomain of
enterobactin synthetase module EntF reveal that other proteins that participate in the
biosynthesis of enterobactin modulate the structure of the domain interface.[311 NMR
structures of the type II TE in Bacillus subtilis surfactin synthetase, which repairs
misprimed PCP-domains by hydrolyzing incorrect amino acyl thioester linkages, clarify
that appropriate protein-protein interactions are key for stabilizing a certain
conformation.[32] While multiple conformations are present when the type II TE domain
is free in solution, a single conformation is favored when the domain is in the presence of
its native substrate: a modified holo-PCP domain.32 Hence, replacing a cognate domain
with a non-cognate domain, as in the ArCP example, disrupts protein-protein interactions,
which may affect megasynthase catalysis.
1.2.2 Dissociated-type pathways
Examples of dissociated-type biosynthetic pathways are type III PKSs (chalcone
synthases), isoprenoid biosynthesis, and alkaloid biosynthesis. Substrate specificities of
enzymes are critical for determining the order of chemical transformations in dissociated-
type biosynthetic pathways, though there are several other factors to consider (Figure
1.2B). Dissociated-type biosynthetic pathways are present in eukaryotes and, thus,
biosynthetic pathway enzymes are often in several different compartments; the study of
dissociated-type pathways must consider enzyme location (membrane, cytosol, or
organelle), enzyme environment, and metabolite transporter specificity. Nevertheless,
there are no, or fewer, protein-protein interactions to consider, which may render
dissociated-type pathway enzymes better suited as leads for biocatalysts.
While megasynthases typically generate a few products, most dissociated-type pathways
lead to a multitude of (structurally diverse) natural products from a central intermediate,
called the biogenetic compound. One strategy to generate natural product analogs in this
type of pathway, or network of pathways, focuses on manipulating enzymes that catalyze
the formation of the biogenetic compound. This approach assumes that a modified
biogenetic compound, when placed in a biosynthetic context, forms a range of modified
natural products. A key challenge is the potentially narrow substrate specificity of
enzymes in the biosynthetic pathway (both reactions preceding and succeeding the
biogenetic compound), which could lead to accumulation of intermediates, generation of
off-pathway products, and the absence of some or all natural products in biosynthetic
pathway branches.
Isoprenoid biosynthesis
Isoprenoids constitute the largest fraction of known natural products and include sterols,
carotenoids, and terpenes.[373 The carbon skeletons of isoprenoids are constructed from 3-
methyl-i -butyl units and four coupling reactions are responsible for all known isoprenoid
biosynthesis: chain elongation, branching, cyclopropanation and cyclobutanation (Figure
1.4A). Thulasiram et al. constructed eleven chimerae of chrysanthemyl diphosphate
synthase (CPPase), an enzyme with cyclopropanation activity, and farnesyl diphosphate
synthase (FPPase) with chain-elongation activity.[383 The authors show that hybrids of
CPPase and FPPase catalyze all four coupling reactions and suggest that the four
coupling reactions are evolutionarily related.E381
Isoprenoid biosynthetic enzymes are amenable to enzyme engineering, since a relatively
small number of targeted mutations can lead to significantly modulated activity and
specificity. y-Humulene synthase is sesquiterpene cyclase from Abies grandis that
catalyzes the cyclization of FPP to numerous different products.[391 Yoshikuni et al.
mutated nineteen residues near the active site that they believed would alter the product
spectrum. Four out of the nineteen residues have >100-fold effect on cyclization
selectivity, and recombination of these four residues by combinatorial mutagenesis
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Figure 1.4 Examples of previously published enzyme engineering work on dissociated pathways.
(A) Four coupling reactions assemble all isoprenoids: chain elongation, branching,
cyclopropanation, and cyclobutanation. Chimerae of CPPase and FPPase catalyze all four
coupling reactions. (B) OleD catalyzes the C-O bond formation between the C-2 hydroxyl group
of oleandomycin 1 (acceptor) and the anomeric carbon of UDP-glucose (donor). OleD is 300-fold
less efficient in transferring UDP-glucose onto 4-methylumbelliferone 2, a fluorescent surrogate
substrate.
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results in the optimized formation of different cyclization products. The authors used the
same approach to alter the specificity of seven other terpene cyclases; four of the evolved
enzymes form new natural products.[391 Therefore, the considerable plasticity of the
terpene cyclase active site allows several types of rearrangements and cyclizations,
demonstrating the opportunity to use enzyme engineering to construct new terpenoid
scaffolds. Chapter 3 describes enzyme engineering in alkaloid biosynthesis.
Tailoring enzymes
Tailoring enzymes catalyze reactions that modify completed megasynthase products. A
common tailoring step, which often modulates the bioactivity of megasynthase products,
is natural product glycosylation catalyzed by glycosyltransferases (GTs). Custom
glycosylation of natural products could be a means to diversify bioactivity, but the GTs
that transfer a sugar from a nucleotide-sugar donor to a natural product acceptor often
have narrow substrate specificity. Williams et al. expanded the substrate scope of OleD
from Streptomyces antibioticus, which transfers a UDP-Glc to oleandomycin 1 (Figure
1.4B).[403 They used three rounds of error-prone PCR on oleD and screened for activity
with a fluorescent surrogate acceptor substrate 2.[41] The result was a triple mutant of
OleD that increases the activity by 60-fold using 2 as the acceptor. The mutant accepts
twelve out of 22 unnatural UDP-sugar donors and also some alternate acceptors in
addition to 1 and 2. Williams et al. then subjected the three residues to site-saturation
mutagenesis to optimize the specificity toward an unnatural acceptor.[42 ]
1.3 Monoterpene indole alkaloid biosynthesis
Monoterpene indole alkaloids (MIAs) are products of dissociated-type biosynthetic
pathways and constitute a large family of structurally diverse plant-derived nitrogen-
containing natural products.[43-46 ] Several MIAs, including vinblastine 3, quinine 4,
camptothecin 5, ajmaline 6, and serpentine 7, have important pharmacological activities
(Figure 1.5).
All MIAs derive from tryptophan 8 and the seco-iridoid p-D-glucoside secologanin 9.[ 47~
49] Tryptophan decarboxylase (TDC), a pyridoxal dependent enzyme, [50-52] converts
tryptophan 8 to tryptamine 10.[531 The isoprenoid precursors of 9, isopentenyl
pyrophosphate (IPP) 11 and dimethylallyl pyrophosphate (DMAPP) 12 derive from the
MEP (non-mevalonate) pathway (Figure 1.6). [41 In the first committed step of the iridoid
terpene biosynthesis that leads to 9, geraniol-lO-hydroxylase (G1OH) hydroxylates
geraniol, which originates from isopentenyl pyrophosphate (IPP). [s5,56] Feeding
experiments with 3H-labeled terpene intermediates suggest that 10-hydroxygeraniol,
iridodial, and iridotrial are intermediates in the secologanin biosynthetic pathway, [57,58]
though the details of the transformations between these intermediates are unknown. After
oxidation of the iridotrial aldehyde to the carboxylic acid, followed by esterification and
glucosyl transfer to give deoxyloganin, subsequent hydroxylation of deoxyloganin yields
loganin. Secologanin synthase (SLS), an NADPH-dependent P450 oxidase isolated from
a cDNA library of an alkaloid-producing C. roseus cell culture, 5 91 then converts loganin
to secologanin 9, presumably via a radical-mediated, oxidative cleavage mechanism. 60 ]
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Secologanin 9 and tryptamine 10 are substrates for strictosidine synthase (STS), 61 ] which
catalyzes a Pictet-Spengler reaction to form strictosidine 13,62,63] the key intermediate for
all MIAs (Figure 1.6), including MIAs in Catharanthus roseus, [64-69 Rauvolfia
serpentina,[70-771 and Ophiorrhiza pumila.[78 The STS-catalyzed reaction only forms the
3(S) stereoisomer, whereas the Bronsted acid catalyzed reaction forms a mixture of 3(S)-
strictosidine and its 3(R) epimer, vincoside.1 79-8 4] In the second step of MIA biosynthesis,
strictosidine-p-D-glucosidase (SGD) deglucosylates strictosidine 13 with retention of
configuration to generate a hemiacetal. 85 -88 The hemiacetal rearranges spontaneously
into a mixture of products, where cathenamine 14 is likely the major product (Figure
1.7).[ 5 '89] The enzyme-catalyzed steps that follow deglucosylation of 13 are not well
understood. Pathway branches in C. roseus that utilize mainly reductive chemistry form
several alkaloids, including ajmalicine 15, isositsirikine 16, and yohimbine 17, but also
serpentine 7 via oxidation of 15 (Figure 1.7).[90-95] In a different set of pathways, one or
more oxidative branches form the so-called rearranged MIAs (Figure 1.8).[431 These
MIAs lead to vindoline 18 and catharanthine 19, and ultimately the anti-cancer agent
vinblastine 3. Although the details of most steps leading to the biosynthesis of these
MIAs are unknown, 4,21-dehydrogeissoschizine 20 may be the precursor.[96' 971 The
conversion of tabersonine 21 into vindoline 18 is perhaps the most well understood
biosynthetic pathway in C. roseus (Figure 1.8).[98,991 An oxidative dimerization reaction
initiates the formation of vinblastine 3 (via anhydrovinblastine 22) from vindoline 18 and
catharanthine 19.1100-04]
1.4 Biocatalysis
Biocatalysis is the use of enzymes to perform transformations on organic compounds,
encompassing the use of isolated and whole-cell catalysts. An ideal biocatalyst should
possess a broad substrate scope, a high total turnover number (TTN), and high
stereoselectivity.E105'1 06 3 Industrial biotransformations frequently employ hydrolases,
106 3
since they possess most of the qualities listed above. Furthermore, in addition to
hydrolysis, hydrolases also catalyze several related reactions: condensation, [1073
alcoholysis,[1083 and perhydrolysis. 10 93
The multitude of biosynthetic pathways in the three kingdoms of life certainly must
contain enzyme catalysts that are useful outside of the context of the biosynthetic
pathways. 110 3 For example, biosynthetic enzymes could be useful in stereoselective
organic synthesis of chemicals and pharmaceuticals "11 3 and for the conversion of
biomass. [12,113] Useful biocatalysts derived from biosynthetic pathways are rare, likely
because biosynthetic enzymes often have restrictive substrate scopes. Nevertheless, there
are several examples of promising biocatalysts in biosynthetic pathways, including y-
humulene synthase (section 1.2.2), lovastatin acyltransferase (LovD),[" 4' 1 153 GTs (section
1.2.3), and haloperoxidases (HPOs).J116'11 73 Chapter 4 describes an STS homolog from 0.
pumila with potential use as a biocatalyst for the asymmetric construction of tetrahydro-
p-carbolines.[ 1223
1.5 Research goals and thesis overview
The following goals motivate the research summarized in this thesis:
A: Increase natural product diversity in monoterpene indole alkaloid biosynthesis.
Precursor-directed biosynthesis of unnatural derivatives of monoterpene indole alkaloids
(MIAs) in C. roseus shows that only minor structural modifications of secologanin 9 and
tryptamine 10 are tolerated for conversion into higher alkaloids by the plant biosynthetic
pathways.El 18] These restrictions are primarily due to the narrow substrate specificity of
strictosidine synthase (STS). Chapter 2 describes the development of two assays to detect
STS activity.E 19,120] These assays are instrumental for the rapid screening of STS mutant
libraries for activity with tryptamine substrate analogs that wild-type STS does not
accept.E1191 Chapter 3 describes the identification of two STS variants (Val214Met and
Phe232Leu) that form novel strictosidine derivatives.El 193 This work was one of the first
examples of enzyme engineering in medicinal plant biosynthesis, which enabled the
production of "unnatural" natural products in plant cells. 1 2 13
B: Use of strictosidine synthase as a general biocatalyst for the formation of chiral
tetrahydro-p-carbolines. Chiral tetrahydro-p-carboline derivatives are important
pharmacophores and a general biocatalytic method to produce these molecules would be
useful. C. roseus STS, however, essentially only accepts secologanin 9, which makes it
unsuitable as a general biocatalyst. Chapter 4 describes the use of a STS homolog from
0. pumila that has considerably broader aldehyde substrate specificity than C. roseus
STS.E"'3 A series of new chiral tetrahydro-p-carbolines form as a result of 0. pumila STS
catalysis from achiral aldehydes and tryptamine or secologanin and tryptamine analogs.
C: Synthetic derivatives of secologanin to investigate the stereochemical restrictions in
monoterpene indole alkaloid biosynthesis. Different stereoisomers of pharmaceuticals
often possess different bioactivities. Natural products typically exist as single
stereoisomers, but not all natural products are bioactive or have undesired bioactivity. It
is reasonable to propose that an altered stereoconfiguration can render an otherwise
undesired or inactive natural product medicinally useful. Chapters 4-5 describe the first
steps on the way to construct stereoisomer libraries of MIAs. Chapter 4 describes the
total synthesis and biochemical evaluation of des-vinyl secologanin aglycone
stereoisomers with C. roseus STS.E"'I I observed that STS accepts alternate
stereoisomers when the glucose moiety is removed. Chapter 5 extends this work by
describing the synthesis and evaluation of glucosylated des-vinyl secologanin to identify
stereochemical restrictions in reconstituted heteroyohimbine alkaloid biosynthesis. 124 3
Chemo-enzymatic synthesis may in the future lead to the generation of stereoisomer
libraries for bioactivity evaluation.
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CHAPTER 2
DEVELOPING ASSAYS TO MONITOR STRICTOSIDINE SYNTHASE ACTIVITY
Part of this chapter is published as an article in
Chemistry & Biology 2007, 14, 888-897.
2.1 Introduction
Strictosidine synthase (STS) catalyzes a Pictet-Spengler reaction between tryptamine 1
and secologanin 2 to form strictosidine 3J1 Strictosidine 3 is the precursor for all
monoterpene indole alkaloids (MIAs) and numerous quinoline alkaloids found in
medicinal plants, such as Catharanthus roseus, Rauvolfia serpentina, Ophiorrhiza
pumila, and Chinchona officinalis (Chapter 1).[1
Precursor directed biosynthesis, which uses cell cultures to convert starting materials into
natural products, is a useful strategy to generate alkaloid analogs in C. roseus (Chapter
3).[2] However, the narrow substrate scope of STS limits the application of precursor-
directed biosynthesis in plant cell cultures from readily available tryptamine analogs.E3,43
This limitation can be circumvented by introducing STS variants with broad substrate
specificities into plant cells (Chapter 3).E4'
Enzyme engineering, as a method to broaden the substrate scope of STS, requires
efficient screening or selection methods to detect STS activity in mutant libraries. Since
the only available analytical technique to detect STS activity was an HPLC-assay,[63 I
sought higher-throughput methods. This chapter describes two visual detection methods
of Pictet-Spenglerase activity. The first assay uses a pigmentation reaction to detect STS
activity in the supernatant of yeast cell cultures that export STSJ43 The second assay
depends on a dye that increases the assay sensitivity and enables activity screening
directly on agar plates.E73
2.2. Results and discussion
2.2.1 Development of a yeast expression system for STS activity
Saccharomyces cerevisiae is a useful microorganism for protein engineering, since a high
in vivo homologous recombination frequency allows the ligation-independent library
construction via co-transfomation of a linearized expression vector and a pool of mutated
genes. S. cerevisiae also facilitates activity screening because a protein of interest can be
exported by appending an N-terminal Mating Factor (MF)-Alpha signal sequence.8 ]
The sts gene from C. roseus encodes a putative signal peptide (residues 1-26) for
localization to the vacuole. Deletion of these 26 residues and insertion of the resulting sts
gene in-frame with an encoded MF-Alpha signal sequence enabled the export of STS to
the culture media after expression in S. cerevisiae (Figure 2.1, Lane 2). A C-terminal
FLAG-peptide allowed purification by anti-FLAG affinity chromatography (Figure 2.1,
Lanes 3-4).[9]
Characterization of wild-type STS purified from the yeast culture supernatant by a
quantitative HPLC assay afforded kinetic constants for tryptamine 1 (Table 2.1). The
kinetic parameters of this yeast construct are similar to parameters reported for STS
isolated from C. roseus cells 10 ] and heterologously expressed STS from R. serpentina
(88% sequence similarity to C. roseus STS).E"'
1 2 3 4
50 kDa O
37 kDa 01"'AS
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Figure 2.1 SDS-PAGE of STS expressed in S. cerevisiae BJ5465. STS has a calculated
molecular weight of 37 kDa. Lane 1: Relative mass marker. Lane 2: STS found in the supernatant
after expression (no FLAG-tag). Lane 3: STS found in the supernatant after expression (with
FLAG-tag). Lane 4: STS purified from the supernatant by anti-FLAG antibody affinity
chromatography. FLAG-tag: Asp-Tyr-Lys-Asp 4-Lys.
owl
Mutagenesis of R. serpentina STS suggested that Glu309 is important for catalysis
(corresponding to Glu315 in C. roseus).1"I The >3,000,000 reduced catalytic efficiency
of the analogous mutant of C. roseus STS confirms that Glu315 is key for catalysis also
in C. roseus STS .4
Table 2.1. Kinetic constants for STS with tryptamine l.a
Enzyme Vmax Km Vmax/KM
[U mg-1] b [1AM] [U mg-I mM-1] b
C. roseus STS 1.6 ± 0.1 1.5 ± 0.4 1000 ± 600
heterologous expression
R. serpentina STS 2.1 6.0 350
heterologous expression C
C. roseus STS 10 7.0 1400
cell culture d
Glu3l5Ala C. roseus STS 0.00023 ± 0.00001 440 ± 50 0.0005 ± 0.0001
Glu309Ala R. serpentina STS * 0.0024 0.0054 0.45
[a] Kinetic assays were performed in sodium phosphate buffer (0.1 M, pH 7.0) using an internal standard (NAA, 0.075
mM). Samples were analyzed by HPLC for formation of product and the product was quantitated by peak integration;
[b] 1 U = 1 [tmol product formed per minute at pH 7.0 and 30 *C; [c] Reference 11; [d] Reference 10 - average of
several isoforms; [e] Reference 11.
2.2.2 Development of a pigment-forming assay to detect STS activity
A yellow pigment forms when loganin is added to yeast cells that express secologanin
synthase (SLS), STS, and strictosidine glucosidase (SGD). 12 13 ] I observed that a pigment
also forms in assays containing tryptamine 1, secologanin 2, STS, and SGD, and
hypothesized that this yellow pigment is related to a previously described amine adduct
that appear when deglycosylated 3 is incubated in the presence of ammonium sulfate.1 4
The SGD-catalyzed deglucosylation reaction of strictosidine 3 yields an unstable hemi-
acetal 6 that rearranges into an equilibrium mixture of isomers, including 4,21-
dehydrogeissoschizine 4 and cathenamine 5 (Figure 2.2).' 151 LC-MS analysis, however,
showed that compounds with m/z 493, 491, and 489 form in the pigmentation reaction at
the expense of 4 and 5 (m/z 351, Figure 2.3). The additional 142 a.m.u. may derive from
the Schiff-base condensation between the deglucosylated intermediate and tryptamine 1.
Thus, instead of ammonium sulfate, 1 4 tryptamine is a suitable amine donor for pigment
formation. I also examined the products in the pigment reaction using 5(R)-
hydroxymethyl strictosidine 3b (m/z 561), which adds 60 a.m.u. to the mass of
strictosidine 3, and found that compounds with m/z 553 and 551 form in the presence of
2'(R)-tryptophanol 1b, consistent with the formation of a tryptamine adduct (Figure 2.4).
The gradual appearance of m/z 491 and 489 at the expense of m/z 493 (not shown)
suggests that the tryptamine adducts oxidize. Amine adducts with deglucosylated
strictosidine 3 can rearrange to form a dihydropyridine ring in the presence of ammonium
sulfate; the dihydropyridine easily oxidizes to give a pyridinium ring. [14] Partial
purification of the compounds corresponding to m/z 491 and 489 by preparative HPLC
verified that these compounds are yellow-colored; the UV-VIS spectrum of the
compound corresponding to m/z 489 shows absorption maxima at 314 nm and 427 nm
and m/z 491 has one absorption maximum at 470 nm. IH NMR signals characteristic of
indole and pyridinium protons support the assignment of the chromophore (Figure 2.2
and section 2.4.4).
Any screening method that employs this pigmentation assay relies on the substrate scope
of SGD and that a pigment forms with alternative amines. I therefore synthesized and
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Figure 2.2 STS catalyzes the Pictet-Spengler reaction between tryptamine 1 and secologanin 2 to
form strictosidine 3. SGD catalyzes the deglucosylation of 3 and generates a mixture of products
(the hemi-acetal that initially forms rearranges in different ways), including 4,21-
dehydrogeissoschitzine 4 and cathenamine 5 (enamine form of 5 is shown). In vitro, the aglucone
intermediate can react with excess amine substrate to form an adduct; for example, the
chromophore utilized in the pigmentation assay. In vivo, the deglucosylated product mixture is
channeled into the various branches of monoterpene indole alkaloid (MIA) biosynthesis.
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Figure 2.3 LC-MS traces. Formation of a tryptamine adduct (m/z 493) is strictly dependent on the
presence of both strictosidine synthase (STS) and strictosidine glucosidase (SGD) (top trace). The
adduct is not observed when either STS (middle trace) or SGD (bottom trace) is absent. The
second, smaller, peak is the 493-isotope of m/z 491 that is also formed in the pigmentation assay.
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Figure 2.4 LC-MS traces. (A) Purified 5(R)-hydroxymethyl strictosidine 3b (m/z 561) and SGD
were reacted for 3 h in the absence of 2'(R)-tryptophanol 1b. Only the corresponding
deglucosylated strictosidine analog is present (m/z 381) (trace a) and no adducts with 2'(R)-
tryptophanol lb (m/z 553 or 551) are observed (traces b and c). (B) After addition of lb to a
reaction containing deglucosylated 3b (m/z 381), two new masses (m/z 553 and 551) are formed
at the expense of the initial deglucosylated product (m/z 381).
M
purified diastereomeric mixtures of a variety of strictosidine analogs, including those
derived from 5-methyl-, 5-methoxy-, and 2'(R)-tryptophanol 1b. Pigments formed when I
incubated the synthetic strictosidine analogs with SGD and an excess of the tryptamine
analog (2 eq), suggesting that the assay is useful for screening enzyme libraries with
tryptamine analogs. I replaced wild-type STS with Glu315Ala STS in the assay, and
found that the weakly active mutant lead to the formation of a faint pigment (not shown),
suggesting that this screen is sufficiently sensitive to screen for mutants with low activity.
2.2.3 Validation of the pigment-forming assay
Saturation mutagenesis introduces a degenerate codon into a gene, which after expression
results in a protein library that contains all twenty naturally occurring amino acids at one
specific position. [163 To validate the expression system and screening method, I
constructed a saturation mutagenesis library of a tyrosine residue distant from the active
site (Tyrl67Ala reduces STS catalytic activity by 40-fold compared to wild-type STS,
unpublished data) (Figure 2.5), expecting a pigmentation pattern where a different color
intensity corresponds to a different catalytic activity. I constructed the gene library by in
vivo homologous recombination in S. cerevisiae BJ5465 by co-transforming the
linearized expression vector, pGAL-MF, and the mutated sts gene (Figure 2.5 and section
2.4.6). Inoculation of 88 colonies - an oversampling that ensures the library is >94%
complete 17 - in expression media in 96-well deep-well plates and induction of protein
expression, gave an STS mutant library. After centrifugation to remove the cells, I
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Figure 2.5 Saturation mutagenesis approach to construct STS mutant libraries. Three PCR
reactions were used to assemble the mutated gene (using the NNK degenerate codon) with
regions that flank the plasmid. The plasmid library was constructed by homologous
recombination of the linearized experssion vector, pGAL-MF, and the mutated gene in S.
cerevisiae BJ5465.
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Figure 2.6 Tyrl67Xxx STS library screened using the pigment-forming assay. Column 1
contains positive (wild-type STS) and negative (no-insert) controls. Several wells are yellow
colored and contain either wild-type STS or other active STS variants. See Chapter 3 for an
application of this screening method to expand the substrate scope of STS.
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assayed the supernatant, which contains the exported enzyme, with tryptamine 1,
secologanin 2, and SGD (Figure 2.6, section 2.4.6). DNA sequencing showed that wells
that produce a strong yellow pigment in the assay contain yeast cells that export wild-
type STS. Conversely, wells that have weaker or no pigmentation contain yeast cells that
export STS variants with different mutations at tyrosine 167. This test-assay, which
revealed different color intensities for different levels of activity with the natural
substrates, indicated that the library construction-screening approach could be used to
search for STS variants with altered substrate specificities (Chapter 3).
2.2.4 Use of bromothymol blue to monitor STS activity
pH-indicators can monitor enzymatic reactions that produce or consume protons. [18,19]
Selected examples include glycosyl transferases, 20 1 hydrolases, 2 1 ,22  haloalkane
dehalogenases,[23] and kinases.2 ' The STS-catalyzed Pictet-Spengler reaction, and the
subsequent SGD-catalyzed deglucosylation reaction, are proton neutral and it is not clear
whether a pH-indicator can detect STS or STS-SGD-coupled activity. Nevertheless, when
I incubated STS and SGD in a buffer at pH 7.1 with tryptamine 1 (1 mM) and
secologanin 2 (1 mM) in the presence of the pH-indicator bromothymol blue 7 (BTB, pKa
7.1; visual transition interval: pH 6.0-7.6), I observed a rapid color change (within a few
minutes) from blue to yellow (relative to the pigmentation assay; see Figure 2.7). Control
experiments showed that the color change is dependent on the deglucosylation of
strictosidine 3 (Figure 2.7).
BTB STS
+ +4h
+
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tryptamine + + -
secologanin + + +
- + -
- + +
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Figure 2.7 Comparison of the pigmentation assay (top row) and the indicator assay (middle row).
The response time is significantly faster in the presence of the indicator BTB 7. Omission of STS
results in no color change; both substrates and SGD are necessary for the color change.
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Figure 2.8 Structures of the deprotonated form of indicators mentioned in the text. The atom that
becomes protonated is highlighted in blue; the color of the deprotonated species is indicated in
parenthesis. Bromothymol blue (BTB, 7): p-nitrophenolate (pNP, 8); phenol red (9); and neutral
red (NR, 10).
During reactions where protons are released, the proton can add to the indicator or to the
basic form of the buffering agent. Protonation of the indicator is what results in a color
switch; thus, a low buffer strength is required for good sensitivity. Unlike known pH-
indicator assays, however, the color change I measured at 616 nm is buffer-strength
independent because buffer concentrations of >0.2 M still allowed a rapid color change.
Although the oxidation reactions that result in the formation of the yellow-colored
pigment (section 2.2.2) generate protons, they occur after several hours, and are therefore
not on the time-scale of the blue-to-yellow color change, which is complete after a few
minutes with sufficient amounts of substrates.
Two other pH-indicators have pKa-values of approximately 7: p-nitrophenol (8, pNP, pKa
7.1; visual transition interval: pH 5.0-7.0) and phenol red (9, pKa 7.7; visual transition
interval: pH 6.8-8.2) (Figure 2.8). pNP 8 has an absorption maximum at 404 nm and is
unsuitable for use in the STS-SGD coupled assay, since the yellow-colored pigment,
which also forms in the assay, absorbs at 404 nm (section 2.2.2). Phenol red 9 has a
maximum absorbance at 563 nm and is therefore an alternative to BTB 7. Titration of 9
by hydrochloric acid (1 mM) at pH 7.1 resulted in the expected, linear, proton-dependent
blue shift. However, there was no corresponding color change in the enzymatic reaction
at the same pH and buffer and indicator concentrations. Therefore, the color switch is
likely a BTB-specific response.
The blue-to-yellow color switch corresponds to a negative to netural charge change of
BTB 7. Conversely, the red-to-yellow color change of phenol red 9 occurs when the
indicator becomes a positively charged ion (Figure 2.8). Previous reports indicated that
BTB 7 can quantify the amount of positively charged active components in
pharmaceutical preparations by forming an ion pair.[253 Therefore, the color change
observed in the STS-SGD coupled assay may be the result of an ion pair formation
between the BTB indicator and a positively charged deglucosylated product.
2.2.5 Detection of STS activity on agar plates
Qualitative detection of a color change directly on agar plates is useful for high-
throughput screening. After considerable experimentation using contrasting dyes, I found
a combination of neutral red (10, NR) and BTB 7 that results in a blue-green to pink-
brown color transition and that thereby can detect STS activity on BTB-dyed agar plates
(Figure 2.9 and section 2.4.7). Yeast colonies that export the wild-type enzyme to the
surrounding agar-medium, produce a zone of pink-brown color. Conversely, yeast
colonies that export inactive enzyme form no color zones (Figure 2.9). Since the screened
yeast colonies are viable, this method does not rely on replica plating.
To demonstrate the application of the indicator assay, I screened a triple-site saturation
mutagenesis library of the sts gene, leading to Val2l4Xxx-Pro2l5Xxx-Gly2l6Xxx C
roseus STS, using tryptamine 1 and secologanin 2 (section 2.4.8). DNA sequencing of
halo-forming colonies identified that Val2l4Met STS is active, which is the same mutant
Wild-type STS
(active)
Glu315Ala STS
(inactive)
Figure 2.9 S. cerevisiae BJ5465, containing plasmids that encode either inactive (Glu315Ala) or
active (wild-type) STS, were spread as a 1:1 mixture on yeast minimal media containing agar
(1%), potassium phosphate buffer (0.15 M, pH 7.1), galactose (2%), glucose (0.8%), and BTB 7.
During a 72 h incubation at 30 *C, yeast colonies appear that continuously export STS to the
surrounding media. The activity of the exported enzymes is assayed by pouring a molten solution
(~3 mL) of agarose (0.5%), BTB 7 (60 mg L'), NR 10 (20 mg L]'), tryptamine 1 (2 mM),
secologanin 2 (1 mM), and SGD (-10 Ig) in potassium phosphate buffer (20 mM, pH 7.1). After
the agarose top layer had solidified, the plate was incubated for I h at 30 *C. DNA sequencing of
plasmids isolated from yeast cells showed that colonies that express wild-type STS result in a
colored zones on the screening plate, whereas yeast colonies that express Glu315Ala STS result
in no colored zones.
identified in the single-site saturation mutagenesis library, Val214Xxx STS (Chapter 3).
The screening also identified double mutants (Val214Gly/Pro215Gly,Ala) that retain the
hydrophobic character of the tryptamine binding site (section 2.4.8). This shows that a
triple-NNK approach can identify variants not identified using single-NNK library
construction (Chapters 3). Chapter 7 describes several future directions that apply the
indicator screening method for enzyme engineering.
2.3. Conclusions
This chapter describes the development of two new methods to detect STS activity in the
culture supernatant after expression in S. cerevisiae. The pigment assay, which relies on
the formation of an adduct between tryptamine 1 and deglucosylated strictosidine 3, is
useful for the 96-well plate screening of STS activity in saturation mutagenesis libraries.
This assay was instrumental for changing the substrate scope of C. roseus STS (Chapter
3).
Addition of a pH-indicator, bromothymol blue (BTB), to the STS-SGD-coupled activity,
dramatically increases the screening throughput and sensitivity, compared to the pigment
assay. Although the pigment eventually reinforces the blue-to-yellow color change of the
indicator, the time-scale of the indicator color change is very different from that of the
pigment, suggesting an independent mechanism of color change. Although this
mechanism remains unclear, the response is BTB-specific and may involve the formation
of an ion pair between the negatively charged BTB species and a positively charged
deglucosylated product. I applied the agar plate adapted indicator method to screen a
triple-site-saturation mutagenesis library; future experiments that use this assay are in
progress.
2.4 Experimental methods
2.4.1 General methods and analytical techniques
Secologanin 2 was obtained by MeOH-extraction of Lonicera tatarica as described
previously.[263 Tryptamine 1 and tryptamine analogs were purchased in highest available
purity and used without further purification.
LC-MS analysis was performed on a Waters LC-MS system. Compounds were separated
by an Acquity UPLC BEH C18-column (1.7 tm, 2.1 x 100 mm) equipped in tandem with
an MS technologies Micromass LCT Premier with an electrospray ionization (ESI)
source and time-of-flight (TOF) detector. The chromatography solvent system consisted
of MeCN in water with 0.1% formic acid. The capillary and sample cone voltages were
2000 V and 30 V, respectively. The desolvation and source temperature were 350 "C and
100 *C, respectively. The cone and desolvation gas flow-rates were 20 L W and 700 L/h,
respectively. HRMS spectra were obtained in accurate mass mode (W-mode) with
reserpine (m/z 609.2812, as 1 nM solution, 40 tL min-) as reference. The HPLC-based
assay was carried out on a Beckman-Coulter System Gold system equipped with a 125
solvent module, 125 autosampler and a 168 detector. Data was processed (integrated)
using 32Karat (v 7). A solvent system composed of MeCN in water with 0.1% TFA was
used with a reverse-phase column (HiBar RT 250-4, RP-select B, 5 [tm). NMR spectra
were acquired on Varian Inova 500 MHz or Bruker 600 MHz spectrometers.
2.4.2 Heterologous expression of C. roseus STS in S. cerevisiae
pGAL-MF (Dualsystems Biotech AG) is an expression vector for S. cerevisiae that
encodes an MF-alpha signal-peptide directly upstream of the multiple cloning site. This
yeast signal sequence enables secretion of heterologously expressed protein into the
culture media during expression. pGAL-MF also contains a galactose-inducible promoter
and confers resistance to ampicillin (bacteria) or growth in uracil dropout media (yeast,
deficient in the biosynthesis of uracil). S. cerevisiae cells without pGAL-MF are
maintained in yeast-peptone-dextrose media (YPD, composition per liter: 10 g yeast
extract, 20 g peptone and 2% (w/v) glucose); cells with pGAL-MF are maintained on a
minimal media depleted of uracil (SCMM-U, S. cerevisiae minimal media, composition
per liter: 6.7 g yeast extract without amino acids, 1.92 g yeast supplemental media
without uracil, and 2% (w/v) glucose). To induce expression the SCMM-U media is also
supplemented with 2% (w/v) galactose (glucose may be replaced with raffinose for
optimized protein expression).
A synthetic gene encoding C. roseus STS, codon-optimized for expression in yeast was
amplified from the lab-stock-plasmid pMCR (KanR) with PCR primers that introduce
recognition sites for Xho I and Hind III (underlined) and the FLAG-tag epitope (italics):
5'-CCGAAG CTTTCACCAATCTTGAAGAAG-3'
5'-TCCTACGTTTCCTCCGGATCTGACTACAAGGATGACGACAACAAGTAG
CTCGAG CGG-3'
These primers were designed to eliminate the first 26 residues corresponding to a putative
native N-terminal signal sequence for vacuolar localization. The PCR product was
purified using a PCR cleanup kit (Aldrich) and subcloned into the pGEM-T Easy Vector
(Promega, Madison, WI) using the manufacturer's instructions. After DNA sequencing,
which verified the integrity of the TA-region, the gene was cloned from the shuttle vector
into pGAL-MF (Dualsystems Biotech AG) to obtain pSTSMF-FLAG, which was
transformed into electro-competent TOP1O E. coli cells. After DNA sequencing, the
correct construct was transformed into the expression host, S. cerevisiae BJ5465.
Transformed S. cerevisiae BJ5465 harboring pSTSMF-FLAG was grown overnight in
SCMM-U supplemented with 2% glucose. The cells were recovered from an overnight
culture (OD 600 ~ 10) and washed in SCMM-U without any carbon source to remove the
glucose. The overnight culture was then diluted with SCMM-U media containing 2%
(w/v) raffinose and 2% (w/v) galactose to yield a culture with an OD600 = 1. The culture
was incubated at 25 *C for 72 h at 225 rpm. The cells were then removed by
centrifugation (5 min, 3,000g, 4 C) and the supernatant was concentrated and buffer
exchanged to give an enzyme preparation in sodium phosphate buffer (0.05 M, pH 7.0).
The enzyme preparation was then subjected to purification using anti-FLAG M2 resin
(Sigma) according to the manufacturer's instructions. STS was eluted with FLAG
peptide, buffer exchanged to sodium phosphate buffer (0.05 M, pH 7.0, 20% glycerol)
and stored in 0.02 mL aliquotes at -20 *C.
2.4.3 Site-directed mutagenesis
The Glu315Ala mutant of STS was constructed using the complementary primer
approach applying Stratagene's site-directed mutagenesis kit according to the
manufacturer's instructions. The following primer-pair was used:
5'-GAAGGTGAACACTTCGCTCAAATTCAAGAGCAC-3'
5'-GTGCTCTTGAATTTGAGCGAAGTGTTCACCTTC-3'
2.4.4 Expression and purification of SGD
C. roseus SGD was expressed as a 6x-His construct in E. coli as described previously,2 7 ]
except that elution from the column was accomplished by a step-wise increase in
imidazole concentration.
2.4.5 HRMS and NMR of tryptamine adducts
The tryptamine adducts were analyzed by HRMS: ESI-MS(C 31H33N402+) m/z calculated:
493.2604 [M+H]*, found: 493.2579 [M+H]*; ESI-MS(C 3 H31 N402+) m/z calculated:
491.2447 [M]*, found: 491.2458 [M]*; ESI-MS(C 3 H29 N402 ) m/z calculated: 489.2291
[M]*, found: 489.2290 [M]*. A pyridinium protons exist in m/z 491; NMR (600 MHz,
CH 3CN): 6 9.50 (s, indole-NH), 9.26 (s, indole-NH), 7.78 (s, 1H, pyridinium-H), 7.57 (d,
1H, J = 7.7, Ar-H, cosy: indole a), 7.43-7.40 (m, 3H, Ar-H, cosy: indole a,b), 7.20 (dt,
1H, Ar-H, J= 0.9, 7.7 cosy: indole a), 7.13 (t, 1H, J= 0.8, 7.8, Ar-H, cosy: indole a),
7.07 (t, 1H, J= 0.8, 7.9, Ar-H, cosy: indole b), 7.06 (d, J= 1.5, pyrrole-H), 6.94 (t, 1H, J
= 0.8, 7.9, Ar-H, cosy: indole b), 6.82 (s, 1H, pyridinium-H). A pyridinium ring also
exists in m/z 489: NMR (600 MHz, CD 3 Cl): 8 9.86 (s, indole-NH), 9.14 (s, indole-NH),
8.44 (s, 1H, pyridinium-H), 7.82 (s, 1H, pyridinium-H), 7.61 (d, 1H, Ar-H), 7.45 (t, 1H,
Ar-H), 7.37 (t, 1H, Ar-NH), 7.30-7.16 (m, 4H, Ar-H, pyrrole-H), 6.91 (t, 1H, Ar-H), 6.74
(t, 1H, Ar-H).
2.4.6 Construction of the saturation mutagenesis library
Two flanking primers (pGALMFfwd, pGALMFrev, Table 2.2) and complementary
mutagenic primers for the Tyr167Xxx saturation mutagenesis library were designed to
incorporate the NNK (MNN, reverse sense, N = A, C, G, T; K = G, T; M = A, C). PCR
reactions were carried out using Expand High-Fidelity PCR Kit (Roche Biosciences, Inc.)
following the manufacturer's instructions, except that 1.0 p1 DMSO was added to each
50 [1 PCR reaction. The thermocycling program started with denaturation (94 *C, 3 min),
followed by 29 cycles of denaturation (94 *C, 30 s), annealing (55 'C, 30 s) and extension
(72 C, 1 min) and ended with an extension (72 *C, 7 min). Increased product yield was
sometimes achieved by lowering the annealing temperature to 52 0C.
Table 2.2. PCR primers for saturation mutagenesis.
Primer name Primer sequence (5'->3')
pGALMFfwd GGGGTATCTTTGGATAAAAGAGAGGCTGAAGCTGAATTCGATATC
pGALMFrev GGGAGGGCGTGAATGTAAGCGTGACATAACTAATTACATGAC
Tyr167Xxx_fwd GGTAGATTGATGAAGNNKGACCCATCCACTAAG
Tyr167Xxx rev CTTAGTGGATGGGTCMNNCTTCATCAATCTACC
PCR products were separated by agarose gel (1%) electrophoresis and the excised gel
bands were extracted and purified using GenElute Gel Extraction Kit (Sigma-Aldrich, St.
Louis, MO). In the first PCR reaction, the forward flanking primer (pGALMFfwd) was
added in equimolar concentration to the reverse mutagenic primer. The reverse flanking
primer (pGALMFrev) was likewise added with the forward mutagenic primer in a
second PCR reaction. The two resulting PCR fragments both contained the degenerate
codon (Figure 2.5). The PCR products were purified by spin-column (after digestion by
Dpn I to remove parental plasmid DNA) and then added together in a splicing-overlap
extension (SOE) PCR, to produce the full-length mutated gene. The mutated gene was
separated using agarose (1%) gel electrophoresis and the 1.1-kb DNA band was excised
and purified. The pGAL-MF plasmid was digested with Hind III and Xho I restriction
enzymes in the recommended buffer and purified by agarose gel electrophoresis.
The purified and digested vector and the mutated gene were added in ratios ranging from
1:8-1:2 to electro-competent S. cerevisiae BJ5465 cells, subjected to electroporation,
diluted in 1 mL, 1 M ice-cold sorbitol and then plated onto two Petri dishes (15-cm in
diameter) with SCMM-U agar media supplemented with 2% (w/v) glucose. The plates
were incubated at 30 *C and colonies appeared after 48-72 hours. The 42-45 base pair
overlap between the vector and the gene allowed homologous recombination in S.
cerevisiae, which produced a plasmid with the mutated inserted gene (Figure 2.5). The
recombined plasmid allowed growth on the uracil-deficient (selection) media.
2.4.7 Expression and screening of saturation mutagenesis libraries
Individual colonies from the library of S. cerevisiae, containing pGAL-MF with mutated
sts (section 2.4.6), were inoculated in 96-well flat-bottom deep-well plates with 0.2 mL
SCMM-U broth supplemented with 2% (w/v) glucose and incubated at 30 'C for 24 h at
225 rpm in a 96-well deep-well plate. To this seed culture, 0.8 mL SCMM-U broth
containing 1% (w/v) glucose and 2% (w/v) galactose was added and the plate was
incubated at 20 'C for an additional 72 h. The minimal amount of sodium phosphate
buffer (1 M, pH 7.0) was added using a multi-channel pipette to adjust to neutral pH and
the 96-well expression plate was then centrifuged (4 'C, 3,000g, 10 min) to pellet the
cells.
The buffered yeast culture supernatant (50 pl) was added to a two-fold concentrated
assay solution (relative the final concentrations) (50 [tl) in 96-well microtiter plates (0.25-
mL well volume) containing the following: tryptamine 1 (4 mM), secologanin 2 (2 mM),
and SGD in sodium phosphate buffer (50 mM, pH 7.0). The plates were incubated at 30
C for up to 48 hours during which time active STS variants produced a yellow color
(Figure 2.6). Wells on the expression plate corresponding to color formation on the
screening plate were recultured in SCMM-U media supplemented with 2% (w/v) glucose.
Plasmid was extracted from the yeast cells using a Zymoprep Plasmid Extraction Kit
according to the manufacturer's instructions (Zymo Research). Plasmid was transformed
into and isolated from E. coli TOP10 (this results in cleaner DNA isolation) and then
submitted for sequencing analysis using the following sequencing primers:
5'-GCTAAAGAAGAAGGGGTATCT-3'
5'-GGAGGGCGTGAATGTAAGCG-3'
2.4.8 Media recipes and agar plate screening-procedure using bromothymol blue
Agar (7.5 g), yeast supplemental media (1.44 g), yeast nitrogen base (5.03 g), and dd-
water (0.53 L) was added to a 1 L Erlenmeyer flask. After autoclaving, the agar solution
was supplemented with potassium phosphate buffer (0.115 L, 1 M, pH 7.0), galactose
(0.075 L, 20% filter sterilized), glucose (0.03 L, 20% filter sterilized), and BTB 7 (to a
final concentration of 60 mg L 1). The solution was suspended in petri dishes (0.75 L
makes around 30 standard plates) giving agar plates with the following final
concentrations: agar (1%), phosphate buffer (0.15 M), 2% (w/v) galactose, 0.8% (w/v)
glucose, and BTB 7 (60 mg L-).
S. cerevisiae cells, e.g. electroporated with DNA, were spread on the agar-indicator
plates. After 72 h at 30 *C the yeast colonies had exported sufficient amounts of STS in
their surroundings to be screened. An agarose solution was first prepared in a 25-mL
autoclaved Erlenmeyer flask, containing agarose (0.5 g), BTB 7 (24 mL of 0.25 g L 1
autoclaved stock solution), neutral red 10 (2 mL of 1 g L- autoclaved stock solution),
potassium phosphate buffer (50 mL, 0.05 M, pH 7.0), and dd-water (24 mL). The
solution was heated to a boil until the agarose had completely dissolved. The molten
agarose solution was equilibrated to 55 "C in a water bath. About 8 mL of agarose
solution was required to screen two standard 8.4-cm in diameter plates with yeast
colonies. Tryptamine 1 (0.15 mL, 0.05 M filter sterilized stock), secologanin 2 (0.15 mL,
0.05 M filter-sterilized stock), and SGD (~10 [g) were added to 7.7 mL of the indicator-
buffer-agarose solution. This mix was then immediately added on top of the agar plates
with the yeast colonies. After the agarose had solidified, the plate was incubated at 30 'C;
colored zones appeared after about 1 h (Figure 2.7).
2.4.9 Construction of triple-NNK focused libraries
A triple-NNK library of the sts gene was constructed using Stratagene's site-directed
mutagenesis kit according to the manufacturers instructions using the following two
primers that encode STS Val2l4Xxx, Pro215Xxx, Gly216Xxx:
5'-GAAGGAGTTGCACNNKNNKNNKGGTGCTGAGATTTC-3'
5'-GAAATCTCAGCACCMNNMNNMNNGTGCAACTCCTTC-3'
The wild-type template was digested using Dpn I and the mutated plasmid was
transformed into the XL-1 Blue cells. Plasmid isolated from the bacterial cells was
transformed into S. cerevisiae BJ5465 and sorbitol (1 M, 1 mL) was added. After
incubation at 30 *C for 48 h, the cells were pelleted and diluted 1000-fold in sterile water.
This dilution was spread on 8.4-cm in diameter agar-indicator plates (section 2.4.8) and
the plates were incubated at 30 'C for 72 h (colonies appear after 48 h). The agarose
assay solution described in section 2.4.8 was aliquoted (4 mL) onto the colony-containing
agar plates and the plates were incubated at 30 'C. Halo-formation was observed and
noted up to 24 h after incubation. Active colonies were picked from underneath the
agarose top-layer and restreaked on SCMM-U agar plates supplemented with 2% (w/v)
glucose. Colonies were inoculated in SCMM-U broth with 2% (w/v) glucose and the
resulting cells were harvested from the yeast culture (1 mL) using a yeast miniprep kit
(Zymoprep, Zymo Research). The plasmid obtained from yeast was transformed (3 [tL)
into electrocompetent E. coli TOP10 cells. After selection of plasmid-harboring E. coli
cells, plasmid was isolated and submitted for sequencing. The sequencing data for ten
representative colonies are given below. In summary, the sampled active colonies
consisted of 50% unique active variants, 70% non-wild-type active variants, and 30%
wild-type sequences.
Sample DNA sequence Peptide sequence
WT GTT CCA GGT V-P-G
1 GTT CCA GGT V-P-G
2 GTT CCA GGT V-P-G
3 GGT GTG CAT G-V-H
4 GTT CCA GGT V-P-G
GGT GGG GGG
GGG GCG GGT
GGT GGG GGG
GGG GCG GGG
GGG GGG GCT
ATG CCA GGT
G-G-G
G-A-G
G-G-G
G-A-G
G-G-A
M-P-G
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CHAPTER 3
REENGINEERING STRICTOSIDINE SYNTHASE
Part of this chapter is published as an article in
Chemistry & Biology 2007, 14, 888-897.
3.1 Introduction
Monoterpene indole alkaloids (MIAs) from Catharanthus roseus (Madagascar
periwinkle) are structurally complex natural products.1 3 Several MIAs have important
biological activities, 2 3 including the anti-hypertensive compound ajmalicine 1, the
topoisomerase type-II inhibitor serpentine 2, and the anticancer agents vinblastine 3 and
vincristine 4 (Figure 3. 1).E243 Derivatives of vinblastine 3, such as Vinflunine 5 (4'-
deoxy-20',20'-difluoro-C'-norvincaleukoblastine), show improved anti-cancer activity
compared to vinblastine 3, indicating that small changes to an alkaloid scaffold can
improve or modulate bioactivity (Figure 3.1). The current supply of MIA analogs,
however, depends on low-yielding semi-syntheses from isolated pathway intermediates.
Metabolic engineering of C. roseus to obtain natural product analogs is an
environmentally friendly and potentially efficient alternative to semi-synthesis and total-
synthesis.
Precursor-directed biosynthesis with C. roseus hairy-root cultures and seedlings utilizes
the plant biosynthetic pathways to convert precursor derivatives into MIA analogs.E83
However, the narrow substrate scope of strictosidine synthase (STS), the enzyme at the
entry point in the pathway, limits precursor-directed biosynthesis efforts.J93 STS catalyzes
a stereoselective Pictet-Spengler reaction between tryptamine 6a and secologanin 7 to
yield the tetrahydro-p-carboline 3(S)-strictosidine 8a as a single stereoisomer (Figure
3.2).13 Expanding the substrate scope of STS may be instrumental in bestowing the plant
- or a microbe with a reconstituted plant pathway - the ability to make unnatural MIA
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Figure 3.1 Structures of selected medicinal MIAs produced by, or derived from, C. roseus.
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Figure 3.2 Strictosidine synthase (STS) catalyzes the Pictet-Spengler reaction between
tryptamine 6a and secologanin 7 to form strictosidine 8a. Strictosidine glucosidase (SGD)
catalyzes the deglucosylation of 8a to form aglucone 9, which is channeled into different pathway
branches to form the monoterpene indole alkaloids (MIAs).
derivatives. Deglucosylation of strictosidine 8a by the second enzyme of the pathway,
strictosidine glucosidase (SGD), leads to aglucone 9 that is converted into the structurally
diverse group of MIAs produced in C. roseus (Figure 3.2).E' 2 3
Semi-rational design of enzyme catalysts combines the benefits of rational design and
random mutagenesis and relies in part on structure and sequence information.13 I Semi-
rational design is more efficient than random mutagenesis in improving properties such
as substrate- and stereoselectivity.E14 3 Site-directed mutagenesis in the secologanin
binding site of STS can alter the aldehyde specificity;E"1 3 for example, Chen et al.
reported an STS mutant (Aspl77Ala) that selectively turns over a secologanin analog,
which the wild-type enzyme already accepted.11 3 The authors rationalized the change in
specificity based on the x-ray crystal structure of Rauvolfia serpentina STS in complex
with secologanin (PDB ID: 2FPC).1 ' 12 3 The crystal structure of R. serpentina STS in
complex with tryptamine (PDB ID: 2FPB) is also available (Figure 3.3A), 1 2] though the
structure does not fully explain the amine substrate specificity of STS. For example, it is
not clear why STS accepts 5-hydroxytryptamine 6f but not 5-methyltryptamine 61 (Figure
3.3A)J" To obtain a STS-catalyst with broader tryptamine substrate specificity, I used a
semi-rational strategy, saturation mutagenesis, E15] to probe all twenty naturally occurring
amino acids at four amino acid positions in the tryptamine binding site.E163 This chapter
describes the identification and characterization of two STS mutants and the products of
their new catalytic abilities.[163
3.2 Results and discussion
3.2.1 Selection of substrates for screening
I selected amine substrates for screening based on the known substrate specificity of STS
(Figure 3.3B).E93 C. roseus STS accepts tryptamine analogs with a fluorine substitution
(6b, 6e, 6g, and 6i) and analogs with a methyl substituent at the 4- or 7-position (6c and
6j).E93 STS, however, imposes more restrictions to substitutions at the 5- and 6-positions
of tryptamine, accepting 5-hydroxytryptamine 6f and 6-methoxytryptamine 6h, but not 5-
methyltryptamine 61. Therefore, I selected 5-methyltryptamine 61 to screen STS mutant
libraries for increased tolerance of indole-5-substitutions.
STS also discriminates against substitutions at the 2'-position of the tryptamine side-
chain; only a methyl substitution is accepted.E93 I assayed wild-type STS with several
tryptamine analogs and found that STS does not turn over 2'(R)-trytophanol 6m, 2'(S)-
tryptophanol, 2'(R)-tryptophan, 2'(S)-tryptophan, and 2'(R)-tryptophan methyl ester.
2'(R)-tryptophanol 6m has the smallest substituent size and I selected 6m to screen STS
libraries for increased acceptance of 2'-substitutions.
3.2.2 Selection of residues for saturation mutagenesis
The B-factor of tryptamine 6a in the crystal structure of R. serpentina STS is
approximately three-fold higher than the remainder of the protein, suggesting that the
orientation of 6a in the binding site is flexible.E12 With the exception of Glu315, which is
crucial for catalysis of the Pictet-Spengler reaction, [12,17] the tryptamine binding site
consists primarily of hydrophobic and aromatic residues, including Trp153, Tyr155,
Vall7l, Vall82, Val214, and Phe232 (Figure 3.3A). 12 3 Hydrophobic active site residues
tend to favor non-specific enzyme-substrate interactions, and therefore, the tryptamine
binding pocket may foster flexible binding of tryptamine 6a and then accommodate the
structural changes that occur during iminium formation and cyclization to form the
tetrahydro-p-carboline product.[173
STS may prevent substitutions at the 5-position of tryptamine by the proximity of Vall7l
and Val214; the closest distances between these residues and the 5-position are 4.4 A and
3.2 A, respectively. Similarly, STS may prevent large substitutions at the 2'-position of
tryptamine, since the 2'pro(S) hydrogen atom is 3.3 A from the carboxylate oxygen of
Glu315 and the 2'pro(R) hydrogen atom is 3.8 A from the phenyl ring of Phe232. I
hypothesized that saturation mutagenesis of residues Val171 or Val214 allows turnover
of 5-methyltryptamine 61 and that mutagenesis of Phe232 or Glu315 would allow
turnover of 2'(R)-tryptophanol 6m (Figure 3.3.A).
3.2.3 Screening of saturation mutagenesis libraries
I constructed saturation mutagenesis libraries of STS, randomized at Val171, Val214,
Phe232, and Glu315 using methods described in Chapter 2. After protein expression, the
media containing the enzyme was transferred to microtiter plates for screening using the
pigment assay solution (section 2.4.7). The Vall7lXxx and Glu3l5Xxx STS libraries did
not produce positive hits when screened with 5-methyltryptamine 61 and 2'(R)-
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tryptophanol 6m. Nevertheless, several members of the Val214Xxx STS library showed
activity with 61. Sequencing of three active mutants revealed a Val214Met mutation; the
Met substitution removes the p-branching of Val, which could hinder reaction between 61
and 7 in wild-type STS. Since no mutants containing smaller amino acid residues at
position 214 were isolated from the screen, I speculate that a longer side-chain is key for
orienting the tryptamine analog optimally for catalysis. St6ckigt and co-workers
independently identified that the Val208Ala mutant of R. serpentina STS (corresponding
to Val214Ala in C. roseus STS) accepts 61 and 5-methoxytryptamine. [20] The Val214Ala
mutant of C. roseus STS does not endow STS with a broadened substrate scope. Further
evaluation of the Val214Met STS mutant showed that it also accepts 5-chlorotryptamine
6n and 5-bromotryptamine 6o. Halogenated metabolic precursors are useful because aryl
chlorides and bromides can be derivatized by cross-coupling reactions; 18 1 also, there is
evidence that bromination of synthetic vinblastine analogs at this position increases anti-
tumor activity.[19]
The pigment assay indicated that members of the Phe232 library accept 6m (Figure
3.4B). Sequencing of six active clones showed a substitution at residue 232 to leucine
(four of the six sequenced genes) or methionine (two of the six sequenced genes). The
2'pro(R) hydrogen atom projects toward Phe232 (closest distance: 3.4 A) and
mutagenesis of Phe232 to the smaller leucine or methionine residue may help
accommodate the hydroxymethylene substituent. I selected the Phe232Leu mutant of
STS for further characterization, and found that it is not active toward tryptamine analogs
with a 2'pro(S) hydrogen substitution, likely since this substituent points toward the
catalytic Glu315 residue. Turnover of L-tryptophan by STS could impact the cellular
supply of tryptophan and the enzyme may have evolved to discriminate against
tryptophan in the plant cell.
3.2.4 Kinetic analysis of Val214Met and Phe232Leu STS
I expressed the Val214Met and Phe232Leu STS variants in S. cerevisiae BJ5465,
concentrated the supernatant, and purified the FLAG-tagged protein by anti-FLAG
affinity chromatography (section 3.4.3). Pseudo-steady-state kinetics of Val214Met and
Phe232Leu C. roseus STS, shows that both mutations significantly impact the activity of
STS (Table 3.1). Both decreased Vnax-values (5-100-fold) and increased Ku-values (200-
1000-fold) contribute to the decreased catalytic efficiencies (7,000-150,000-fold) of the
mutant enzymes with tryptamine (Table 3.1).
Table 3.1. Kinetic constants for STS.a
Variant, substrate Vax Km Vmax/KM
[U mg-1] b [M] [U mg- M1I] b
Wild-type, 6a 1.6 ± 0.1 1.5 0.4 1,0000000 + 600,000
Val214Met, 6a 0.32 ± 0.03 600 ± 200 500 100
Val2l4Met, 61 c 0.0067 ± 0.0003 800 ± 100 8 ± 2
Phe232Leu,6a 0.015 0.001 900 200 17 6
Phe232Leu, 6m c 0.0057 ± 0.0003 1800 ±300 3.2 ± 0.8
[a] Kinetic assays were performed in sodium phosphate buffer (0.1 M, pH 7.0) using an internal standard (NAA, 0.075
mM) and analyzed by HPLC for formation of product; [b] 1 U = formation of 1 [tmol product (6a or analog of 6a) per
minute at pH 7.0 and 30 "C; [c] Compounds 61 and 6m are not accepted by wild-type STS.
Phe232 may help orient the substrate correctly for catalysis and stabilize high-energy
intermediates in the reaction pathway; therefore, a leucine in its position can dramatically
reduce the catalytic activity of STS. The 60- and 5-fold lower Vmnax/Kv-values for
Val2l4Met and Phe232Leu, respectively, show that both mutants prefer tryptamine 6a to
the unnatural analogs (Table 3.1).
3.2.5 Preparative enzymatic synthesis of strictosidine analogs 81-n
To show that the enzyme mutants form true tetrahydro-p-carboline products, I used
Val214Met and Phe232Leu STS in the mmol-scale synthesis of 10-methylstrictosidine 81,
5(R)-hydroxymethyl strictosidine 8m, and 10-chlorostrictosidine 8n. I cloned the sts gene
from C. roseus into the Escherichia coli expression vector pET-28 and introduced both
mutations into this bacterial construct using site-directed mutagenesis (section 3.4.5).
Expression of the STS mutants in E. coli, followed by biocatalytic transformations in
cleared E. coli cell lysates, afforded milligram quantities of each strictosidine analog after
preparative HPLC purification. 1H NMR confirmed the structure of the enzymatic
products (section 3.4.5).
3.2.6 Feeding strictosidine analogs 8m and 8o to C. roseus hairy-root cultures
C. roseus plant cell cultures can take up the relatively large strictosidine biosynthetic
intermediate,[2 1] and the MIA biosynthetic pathways can convert tryptamine and
secologanin analogs to higher alkaloid derivatives.E1' 11] Prior to constructing transgenic
plants with Val2l4Met and Phe232Leu STS, however, it is important to validate whether
subsequent MIA biosynthetic enzymes process the new strictosidine analogs. Therefore, I
studied which MIA analogs formed after feeding 5(R)-hydroxymethyl strictosidine 8m
and 10-bromomstrictosidine 8o to two-week-old C. roseus hairy-root cultures.
I used established protocols to extract the hairy-root cultures one week after feeding, [22,23]
and used the available information on naturally occurring MIA metabolites to analyze the
culture extracts by LC-MS.[2,"1 The extract of the control culture, supplemented with
tryptamine 6a, contained alkaloids such as ajmalicine 1 (m/z 353), serpentine 2 (m/z 349),
yohimbine 10 (m/z 355), and akuammacine 11 (m/z 323) (Figures 1.5, 1.6, 1.8, and
3.1).[8] The culture extracts of the 8m- and 8o-supplemented hairy-root cultures, however,
contained compounds with masses corresponding to MIA analogs (expected masses of
analogs: 8m: M+30; 8o, M+78/80) not present in the control culture (Appendix A).
MIA analogs derived from halogenated strictosidine precursors have characteristic
isotope patterns, e.g. the equal abundance of 79Br and 8 1Br, and based on this information,
I found that C. roseus converted 8o into analogs of known MIA: ajmalicine 1, serpentine
2, yohimbine 10, and akuammacine 11 (Figure 3.5A and Appendix A).[ 161 The recent
construction of a transgenic C. roseus hairy-root line that expresses Val214Met STS,
validated that the Val214Met enzyme mutant functions in vivo to produce methylated,
chlorinated, and brominated MIA analogs that the plant cell normally cannot produce. 2 4 -
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Figure 3.5 LC-traces of selected alkaloid analogs formed by feeding strictosidine analogs to two-
week-old C. roseus hairy root cultures. (A) Formation of a putative serpentine or serpentine
isomer analog upon feeding of 10-bromostrictosidine 8o to periwinkle. The two top traces show
that no compounds corresponding to m/z 427 and 429 exist in the culture supplemented with
tryptamine 6a. The bottom trace shows the elution of an authentic standard of serpentine 2. The
remaining two traces show the formation of an alkaloid analog displaying the expected isotopic
pattern that could be a brominated MIA analog. (B) Formation of isositsirikine analog 13 in a
feeding study of 5(R)-hydroxymethyl strictosidine 8m. The top trace shows the expected mass of
13; the bottom trace shows that no naturally occurring alkaloid of m/z 385 co-elutes with 13.
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LC-MS analysis of hairy-root cultures supplemented with 5(R)-hydroxymethyl
strictosidine 8m showed three new peaks, not found in the control culture supplemented
with tryptamine 6a, containing compounds with m/z 383 (12), 385 (13), and 326 (14).
Compound 12 may be an ajmalicine analog (ajmalicine: m/z 353), but the low production
titer of 12 precluded isolation and structural characterization. I isolated compounds 13
(2 mg, 3% isolated yield) and 14 (1 mg, 1%) from 0.5 L hairy-root cultures by
preparative HPLC. Compound 14 (m/z 426) consisted of several stereoisomers; 1H-NMR
signals for the indole ring strongly suggest the assignment as an MIA derivative (section
3.4.6). Compound 13 is an isositsirikine analog with a hydroxy-methylene substitutent
(Figure 3.5B), 27 1 since it contained an unsubstituted indole (7.5-7.1 ppm, 4H), an intact
hydroxymethylene group (4.0 and 3.8 ppm, 2H; compared to 4.0 and 3.8 ppm for 8m),
and a methyl ester (s, 3.8 ppm, 3H), as well as an ethylidene group containing a
trisubstituted alkene, since one olefinic hydrogen atom appears as a quartet (6.0 ppm, J
6.8) coupled to three hydrogen atoms that appear as a doublet (1.9 ppm, J = 6.8).[27
The hairy-root culture supplemented with 8m does not form a serpentine analog,
suggesting that the oxidation reaction of ajmalicine 1 to form serpentine 2 requires a
5'pro(R)-hydrogen atom (Figures 1.7 and 3.4A). Furthermore, the culture does not form
analogs of akuammicine 11, suggesting that the unknown enzyme(s) forming 11 does not
accept 8m as a precursor. McCoy and O'Connor observed that MIA biosynthetic
pathways in hairy-roots and seedlings often channel supplemented precursor analogs -
particularly those with large substituents that cannot be converted into "normal" MIAs
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such as serpentine 2 and akuammacine 11 - into the reduction steps that form
isositsirikine. 2 81 I observed that MIA derivatives 13 and 14 are present in both the culture
media and the cells, while natural alkaloids are not found in the culture media; I speculate
that the plant cell cultures have a mechanism to export accumulated or unwanted
compounds into the culture media.
3.3 Conclusions
This chapter describes the first example of enzyme reengineering in plant alkaloid
biosynthesis. I expanded the substrate specificity of C. roseus STS - a critical first step
toward pathway engineering - using saturation mutagenesis. Two STS mutants
(Val2l4Met and Phe232Leu), identified using the expression system and pigment assay
described in Chapter 2, catalyze the formation of strictosidine analogs that are not
catalyzed by wild-type STS.
The Val214Met mutant of STS catalyzes the formation of methylated and halogenated
strictosidine derivatives; C. roseus hairy-root cultures supplemented with 10-
bromostrictosdine 8o incorporate the bromine atom into higher MIAs. The Phe232Leu
mutant of STS mutant triggered the formation of a hydroxylated strictosidine analog.
Feeding studies of 5(R)-hydroxymethyl strictosidine 8m show that the addition of a
hydroxyl group causes major perturbations of the alkaloid profile of C. roseus.
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Runguphan et al. recently demonstrated that the Val214Met mutant of STS functions in a
cellular context, producing natural product analogs that the plant cannot normally
produce.[253 Runguphan et al. also developed a transgenic C. roseus cell culture without
alkaloid production (obtained by RNAi-silencing of tryptophan decarboxylase
transcripts); MIA biosynthesis commences when tryptamine substrates are supplemented
to this transgenic cell culture.[2 63 Therefore, the silenced strain, in conjunction with
reengineered STS variants, will likely lead to the efficient transgenic production of MIA
derivatives.
3.4 Experimental methods
3.4.1 General methods and analytical techniques
Tryptamine 6a and analogs of 6a were purchased in highest available purity and used
without further purification. Secologanin 7 was obtained by MeOH-extraction of
Lonicera tatarica as described previously. 293
LC-MS analysis was performed on a Waters LC-MS system. Compounds were separated
by an Acquity UPLC BEH C18-column (1.7 tm, 2.1 x 100 mm) equipped in tandem with
MS technologies Micromass LCT Premier with an electrospray ionization (ESI) source
and time-of-flight (TOF) detector. The chromatography solvent system consisted of
MeCN in water with 0.1% formic acid. The capillary and sample cone voltages were
2000 V and 30 V, respectively. The desolvation and source temperature were 350 "C and
100 0C, respectively. The cone and desolvation gas flow-rates were 20 L h-1 and 700 L/h,
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respectively. HRMS were obtained in accurate mass mode (W-mode) with reserpine (m/z
609.2812, as 1 nM solution, 40 RL min-1) as reference. The HPLC-based assay was
carried out on a Beckman-Coulter System Gold system equipped with a 125 solvent
module, 125 autosampler and a 168 detector. Data was processed (integrated) using
32Karat (v 7). A solvent system composed of MeCN in water with 0.1% TFA was used
with a reverse-phase column (HiBar RT 250-4, RP-select B, 5 [tm). NMR spectra were
recorded on Varian 500 MHz or Bruker 600 MHz spectrometers.
3.4.2 Construction, expression, and screening of saturation mutagenesis libraries
Saturation mutagenesis libraries were constructed according to the procedure described in
section 2.4.6, using the primers listed in Table 3.2. Expression and assays of saturation
mutagenesis libraries were conducted in 96-well plates as described in section 2.4.6.
Table 3.2. PCR primers for saturation mutagenesis.
Primer name Primer sequence (5'->3')
pGALMFfwd GGGGTATCTTTGGATAAAAGAGAGGCTGAAGCTGAATTCGATATC
pGALMFrev GGGAGGGCGTGAATGTAAGCGTGACATAACTAATTACATGAC
Vall7lXxx fwd CTTCACTGACNNKTCCTCTATTC
Val171Xxx rev GAATAGAGGAMNNGTCAGTGAAG
Val2l4Xxx fwd GAAGGAGTTGCACNNKCCAGGTGGTGCTG
Val2l4Xxx rev CAGCACCACCTGGMNNGTGCAACTCCTTC
Phe232Xxx fwd GTTGTTGCTGAGNNKTTGTCCAACAGAATC
Phe232Xxx rev GATTCTGTTGGACAAMNNCTCAGCAACAAC
Glu3l5Xxx fwd GAAGGTGAACACTTCNNKCAAATTCAAGAGC
Glu3l5Xxx rev GCTCTTGAATTTGMNNGAAGTGTTCACCTTC
3.4.3 Expression and purification of FLAG-tagged STS mutants
To ensure that no other mutations were responsible for the activity observed in the
screening, the Val214Met- and Phe232Leu-encoding mutations were introduced into
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pSTSMF-FLAG using Stratagene's site-directed mutagenesis kit (Table 3.3). A mutation
of the sts gene that results in Val214Ala STS was also introduced to test if this mutant
enzyme accepts new substrates (Table 3.3).
Table 3.3. PCR primers for site-directed mutagenesis.
Primer name Primer sequence (5'->3')
Val214Alafwd GAAGGAGTTGCACGCCCCAGGTGGTGCTG
Val214Ala-rev CAGCACCACCTGGGGCGTGCAACTCCTTC
Val214Met-fwd GAAGGAGTTGCACATGCCAGGTGGTGCTG
Val214Met-rev CAGCACCACCTGGCATGTGCAACTCCTTC
Phe232Leu fwd GTTGTTGTTGCTGAGCTGTTGTCCAACAGAATC
Phe232Leu rev GATTCTGTTGGACAACAGCTCAGCAACAACAAC
S. cerevisiae BJ5465 harboring pSTSMF-FLAG with the indicated mutations were grown
overnight in SCMM-U supplemented with 2% (w/v) glucose. The cells were recovered
from an overnight culture (OD600 ~ 10) and washed in SCMM-U without any carbon
source to remove the glucose. The overnight culture was then diluted with SCMM-U
containing 2% (w/v) raffinose and 2% (w/v) galactose to yield a culture with an OD600 =
1. The culture was incubated at 25 *C for 72 h shaking at 225 rpm. The cells were then
removed by centrifugation (5 min, 3,000g, 4 *C) and the supernatant was concentrated
and buffer exchanged to afford enzyme preparations in sodium phosphate buffer (0.05 M,
pH 7.0) The concentrated STS mutant preparations were then purified using anti-FLAG
M2 agarose beads (Sigma Aldrich, St. Louis, MO) according to the manufacturer's
instructions (the column-bound protein was eluted with FLAG-peptide). The eluted
enzyme was buffer exchanged to sodium phosphate buffer (0.05 M, pH 7.0) and stored in
20% glycerol at -20 *C.
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Figure 3.6 HPLC trace (280 nm) of a representative spectrum used in analysis of 5-
methyltryptamine 61 kinetics using the Val2l4Met mutant of STS. The top trace (brown)
represents the chemical reaction control, which shows formation of two peaks corresponding to
the two diastereomers, 10-methylstrictosidine 81 and 10-methylvincoside, respectively. The blue
trace represents the enzymatic reaction with Val2l4Met STS and 5-methyltryptamine 61 in which
only one diastereomer is formed. NAA is added as an internal standard. Retention times: 61 (r, =
7.1 min), secologanin 7 (r, = 7.6 min, low absorbance at 280 nm), 3(S)-epimer of 81 (r,= 8.8 min),
3(R)-epimer of 81 (r, = 9.2 min), and NAA (r, = 9.8 min).
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3.4.4 HPLC-kinetics of Val214Met and Phe232Leu STS
All enzyme assays (0.100 mL) contained secologanin 7 (4.0 mM) in sodium phosphate
buffer (0.1 M, pH 7.0) with internal standard (0.075 mM naphthylacetic acid, NAA) and
one of several tryptamine or tryptamine analog concentrations (added from a 10-fold
concentrated stock solution). Product formation was monitored by reverse-phase HPLC
at 280 nm (section 3.4.1); the detection-limit precluded the use of substrate
concentrations <1 RM. Wild-type STS reactions were quenched by two equivalents of
sodium hydroxide (relative to the buffer concentration); a quench that resulted in the
quantitative formation of strictosamide [ESI-MS(C 2 H31 N2 8 ) m/z calculated: 499.2091
[M+H]*, found: 499.2080 [M+H]*].J 301 The chromatogram peaks were integrated,
normalized by the internal standard (NAA), and converted to concentrations using a
response factor for strictosamide. Corrected experimental data were fit to the Michaelis-
Menten or Northrop equations by non-linear regression analysis using Origin (v 7.0552)
(OriginLab Corp., Northampton, MA) to directly get catalytic parameters Vm., Vma/KM,
and Km. All kinetic assays were repeated three times and only conversions below 15%
were considered. A representative HPLC trace using the Val214Met mutant and 5-
methyltryptamine 61 is shown in Figure 3.6.
3.4.5 Heterologous expression of C. roseus STS in E. coli and enzymatic syntheses
The following PCR primers were used to amplify the sts gene in pSTSMF-FLAG
(section 2.4.2) and introduce sites for Nco I and Xho I (underlined):
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5'-CAT GCC ATG GGC TCA CCA ATC TTG AAG AAG ATC-3'
5'-CCG CTC GAG GGA GGA AAC GTA GGA GTT TCC C-3'
The PCR product was cloned into pET-28a(+) in-frame with nucleotides in the vector
that encode for a hexa-histidine tag, resulting in construct pSTS-His. Mutations
Val214Met and Phe232Leu were introduced by Stratagene's site-directed mutagenesis kit
using pSTS-His as a template (Table 3.3). pSTS-His was transformed into E. coli
BL21(DE3) for protein expression. A single colony of plasmid-containing bacteria
encoding either mutant enzyme was inoculated in LB-media (30 ptg mL~1 kanamycin) and
incubated overnight at 37 'C and 200 rpm. The seed culture was then inoculated (1% v/v)
in fresh LB-media (4 L in 2.8-L Fernbach flasks, 30 pg mL~1 kanamycin) and incubated
until OD60 0 nm = 1 (approximately 2.5 h at 37 'C and 200 rpm). The culture was chilled to
4 'C, IPTG was added (1 mM final concentration) to induce protein expression, and the
culture was incubated at 18 'C for 24 h at 200 rpm. The cell material was recovered by
centrifugation (15 min, 3000g, 4 C) to an approximate wet-weight of 7 g L-1 culture. The
cells were resuspended in five volumes sodium phosphate buffer (0.1 M, pH 7.0) and
lysed by passing the suspension twice through a French (hydraulic) press. The DNA was
sheared using a 22-gauge syringe needle and the crude cell extract was recovered by
centrifugation (120 min, 10000g, 4 C). The cell extract was used directly for synthesis as
described below.
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10-methylstrictosidine 81
5-methyltryptamine 61 hydrochloride (105 mg, 0.5 mmol, 1 eq) and secologanin 7 (194
mg, 0.5 mmol, 1 eq) were dissolved in 225 mL sodium phosphate buffer (25 mM, pH
7.0). The cell-free extract containing Val214Met STS, prepared as described above, was
then added (25 mL, 10% v/v) and the reaction was stirred for 72 h at 30 'C. MeOH was
added (4 eq) to precipitate the protein, the resulting heterogenous mixture was filtered to
remove the particulates, and most of the solvent was evaporated in vacuo. Preparative
HPLC using a reverse-phase column, 1 mL injections, and a gradient of 20-90% MeCN
in water with 0.1% TFA over 20 min afforded 10-methylstrictosidine 81 (d.e. >99.5%).
'H NMR (MeOD, 500 MHz): 8 7.81 (s, 1H, H-17), 7.26 (s, 1H, H-9), 7.19 (d, 1H, J=
8.3, H-12), 6.98 (dd, 1H, J= 1.3, 8.4, H-11), 5.85 (ddd, 1H, J= 7.6, 10.6, 17.5, H-19),
5.84 (d, 1H, J= 9.1, H-21), 5.35 (dd, 1H, J= 1.3, 17.4, H-18trans), 5.28 (dd, 1H, J= 1.1,
10.6, H-18cis), 4.80 (d, 1H, J= 7.9, GlcH-l'), 4.64 (br-d, 1H, J 10.6, H-3), 3.98 (dd,
1H, J= 2.1, 11.8, GlcH-6'a), 3.80 (s, 3H, H-23), 3.73 (ddt, 1H, J= 5.0, 12.5, GlcH-6'b),
3.49-3.42 (m, iH, H-5a), 3.40 (tapp, iH, J= 9.1, GlcH-3'), 3.39-3.35 (m, iH, H-5b), 3.25-
3.19 (m, 2H, GlcH-2', GlcH-4'), 3.10-2.97 (m, 3H, H-6a, H-6b, H-15), 2.75 (ddd, IH, J=
5.1, 7.8, 8.7, H-20), 2.40 (s, 3H, H-23), 3.36-2.16 (m, 2H, H-14proS, H14proR); 13C
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NMR (MeOD, 125 MHz): 8 171.43, 157.05, 136.67, 135.62, 130.30, 130.03, 127.82,
125.24, 119.90, 118.91, 112.10, 109.08, 106.79, 100.56, 97.43, 78.96, 78.135, 74.80,
71.88, 63.15, 53.19, 52.74, 45.52, 42.80, 34.92, 32.75, 21.71, 19.71; ESI-
MS(C 28H37N209*) m/z calculated: 545.2499 [M+H]*, found: 545.2523 [M+H]*.
5(R)-hydroxymethyl strictosidine 8m
10 OH
5,,/, 23
N 3 NH 18
H H' 19 HO
14 20 'O , H21 0 OH
24 17 6' OH
HO
2'(R)-tryptophanol 6m (190 mg, 1 mmol, 1 eq) was added as a solution in MeCN (25 mL,
5% v/v final concentration of organic solvent) and secologanin 7 was added as a powder
(388 mg, 1 mmol, 1 eq) to 450 mL stirred sodium phosphate buffer (25 mM, pH 7.0).
Cell-extract containing Phe232Leu STS, prepared as described above, was then added
(25 mL, 5% v/v) and the reaction was stirred for 46 h at 30 'C. Some of the water was
co-evaporated in vacuo with toluene, after which MeOH was added (4 eq) to precipitate
the protein. After the resulting heterogenous mixture was filtered to remove the
particulates, most of the solvent was evaporated in vacuo. Preparative HPLC using a
reverse-phase column, 1 mL injections, and a gradient of 20-60% MeCN in water with
0.1% TFA over 20 min afforded 5(R)-hydroxymethyl strictosidine 8m (190 mg, 0.34
mmol, 43%, d.e. >99.5%). 1H NMR (MeOD, 500 MHz): 8 7.80 (s, 1H, H-17), 7.46 (td,
1H, J= 1.0, 7.8, H-9), 7.33 (td, 1H, J= 0.8, 8.2, H-12), 7.15 (ddd, 1H, J= 1.1, 7.1, 8.2,
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H-11), 7.05 (ddd, 1H, J= 0.9, 7.1, 8.2, H-10), 5.84 (ddd, 1H, J= 7.6, 10.6, 17.4, H-19),
5.80 (d, 1H, J= 8.8, H-21), 5.37 (ddd, 1H, J= 1.0, 1.3, 17.4, H-18trans), 5.28 (ddd, 1H,J
= 1.0, 1.3, 10.6, H-18cis), 4.78 (d, 1H, J= 7.9, GlcH-l'), 4.67 (dd, 1H, J= 4.0, 10.9, H-
3), 4.03 (dd, 1H, J= 3.4, 10.7, H-23), 3.94 (dd, 1H, J= 2.1, 11.8, GlcH-6'a), 3.84-3.75
(m, 2H, H-5a, H-23), 3.78 (s, 3H, H-24), 3.62 (dd, 1H, J 6.9, 11.9, GlcH-6'b), 3.40 (tapp,
1H, J = 9.1, GlcH-3'), 3.36-3.32 (m, 1H, GlcH-5'), 3.25-3.19 (m, 2H, GlcH-2',4'), 3.12
(dd, 1H, J= 4.8, 16.3, H-6a), 3.04 (td, 1H, J= 4.6, 11.2, H-15), 2.89 (dd, 1H, J= 8.9,
16.4, H-6b), 2.77 (ddd, 1H, J= 5.0, 7.8, 8.6, H-20), 2.32 (ddd, 1H, J= 4.4, 11.1, 15.2, H-
14proR), 2.24 (ddd, lH, J= 4.2, 11.4, 15.2, H-14proS); 1 3C NMR (MeOD, 125 MHz): 8
171.28, 156.93, 138.45, 135.51, 130.46, 127.50, 123.79, 120.76, 120.08, 119.24, 112.48,
108.84, 106.25, 100.56, 97.54, 78.82, 78.08, 74.78, 71.82, 63.02, 62.03, 54.10, 52.76,
51.16, 45.34, 35.38, 32.63, 21.89; ESI-MS(C 28H37N2 010*) m/z calculated: 561.2448
[M+H]*, found: 561.2448 [M+H]*.
10-chlorostrictosidine 8n
C1 10
5
N NH 18
H H' 19 HO
1 4 2 0 " * O H21 10 OH
O22 \ 0
23 17 6' OH
0 HO
5-chlorotryptamine 6n hydrochloride salt (230 mg, 1 mmol, 1 eq) and secologanin 7 (388
mg, 1 mmol, 1 eq) were dissolved in 450 mL stirred sodium phosphate buffer (25 mM,
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pH 7.0). The cell-free extract containing Val214Met STS extract, prepared as described
above, was then added (25 mL, 5% v/v) and the reaction was stirred for 72 h at 30 'C.
Some of the water was co-evaporated in vacuo with toluene, after which MeOH was
added (4 eq) to precipitate the protein. After the resulting heterogenous mixture was
filtered to remove the particulates, most of the solvent was evaporated in vacuo.
Preparative HPLC using a reverse-phase column, 1 mL injections, and a gradient of 20-
90% MeCN in water with 0.1% TFA over 15 min afforded 1 0-chlorostrictosidine 8n (d e.
>99.5%). 1H NMR (MeOD, 500 MHz): 8 7.81 (s, 1H), 7.47 (dd, 1H, J= 0.6, 2.1, H-9),
7.29 (dd, IH, J= 0.6, 8.7, H-12), 7.11 (dd, 1H, J= 2.0, 8.7, H- 11), 5.85 (ddd, 1H, J= 7.7,
10.7, 17.4, H-19), 5.84 (d, 1H, J= 9.1, H-21), 5.35 (dtapp, 1H, J= 1.4, 17.4, H-18trans),
5.28 (dtapp, 1H, J= 1.3, 10.7, H-18cis), 4.80 (d, 1H, J= 7.9, H-i'), 4.68 (br-d, 1H, J=
10.4, H-3), 3.98 (dd, 1H, J= 2.0, 11.8, H-6'a), 3.80 (s, 3H, H-23), 3.74 (td, 1H, J= 5.2,
12.5, H-5eq), 3.64 (dd, 1H, J= 7.1, 11.8, H-6'b), 3.47 (ddd, 1H, J= 5.6, 8.5, 12.5, H-
5ax), 3.40 (tapp, 1H, J= 9.1, H-3'), 3.39-3.34 (m, 1H, H-5'), 3.23 (dd, 1H, J= 8.9, 9.9, H-
4'), 3.22 (dd, 1H, J= 7.9, 9.3, H-2'), 3.13-3.05 (m, 2H, H-6ax, H-15), 3.02 (tdapp, 1H, J=
4.5, 16.3, H-6eq), 2.75 (dddd, 1H, J = 0.5, 5.0, 7.8, 8.8, H-20), 2.32 (ddd, 1H, J = 3.0,
12.1, 15.0, H-14proR), 2.23 (ddd, 1H, J= 3.7, 11.8, 15.2, H-14proS); 13C NMR (MeOD,
125 MHz): 8 171.40, 157.06, 136.70, 135.54, 132.19, 128.65, 126.51, 123.80, 119.97,
118.84, 113.67, 109.03, 107.19, 100.54, 97.41, 78.95, 78.12, 74.79, 71.87, 63.15, 53.05,
52.74, 45.50, 42.63, 34.82, 32.68, 19.52; ESI-MS(C27H 34N2 0 935Cl*) m/z calculated:
565.1953 [M+H]*, found: 565.1959 [M+H]*; ESI-MS(C 27H34N20 9 37 Cl*) m/z calculated:
567.1923 [M+H]*, found: 567.1945 [M+H]*.
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3.4.6 Feeding study and alkaloid isolation
5(R)-hydroxymethyl strictosidine 8m was synthesized enzymatically as described (see
section 3.4.5). C. roseus hairy-root cultures were inoculated in half-strength Gamborg
media (0.4 L), grown for two weeks (32 "C, 60 rpm), and then supplemented with 8m
(0.5 mM, 110 mg as filter-sterilized solution in water). After one week, the media was
separated from the hairy roots and the roots were washed in water several times. Hairy
roots were ground with a mortar and pestle in MeOH (3 x 30 mL) and after filtration, the
solvent was evaporated in vacuo to give a yellow residue. The residue was dissolved in
aqueous hydrochloric acid (10 mM, pH 2) and the acidified natural product mixture was
extracted with hexanes. The aqueous layer was basified (pH 9) with ammonium
hydroxide and then extracted with DCM. The organic solvent was evaporated to give a
yellow oil, which was dissolved in water and analyzed by LC-MS. Compounds 13 and 14
were isolated by preparative HPLC using the following gradients: (1) 20-40% MeCN in
water with 0.1% TFA for 15 minutes; then, (2) 30-40% MeCN in water with 0.1% TFA
for 10 minutes. This isolated isositsirikine analog 13 in 2.0 mg isolated yield (5 pmol,
3%): 1H NMR (600 MHz, MeOD): 8 7.51 (d, 1H, J= 7.7, H-9), 7.38 (d, 1H, J= 7.6, H-
12), 7.26 (t, 1H, J= 7.6, H-10), 7.09 (t, 1H, J= 7.4, H-11), 5.96 (q, 1H, J= 6.8, H-19),
4.94-4.87 (in, 1H, H-3), 4.20 (d, 1H, J= 14, H-21a), 4.13 (d, 1H, J= 14, H-21b), 4.04
(dd, 1H, J= 4.0, 12, H-17a), 3.82 (dd, 1H, J= 4.7, 12, H-17b), 3.99-3.85 (m, 2H, H-23a,
H-23b), 3.76 (s, 3H, H-22), 3.67-3.58 (m, 1H, H-5), 3.20 (dd, 1H, J = 7.0, 14, H-6a),
3.17-3.09 (m, 1H, H-16), 2.98 (dd, 1H, J= 7.0, 15, H-6b), 2.87-2.82 (m, 1H, H-15), 2.59-
2.42 (m, 2H, H-14), 1.87 (d, 3H, J = 6.8, H-18); ESI-MS(C 22H29N 204 ) m/z calculated:
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385.2127 [M+H]*, found: 385.2134 [M+H]*. HPLC-isolation of 14 and partial NMR
assignments show that this compound is also an indole-containing compounds: 1H NMR
(600 MHz, MeOD): 6 7.41 (d, 1H, J = 7.7), 7.34 (d, 1H, J= 8.2), 7.14 (t, 1H, J= 7.6),
7.04 (t, 1 H, J = 7.5). 1 0-bromostrictosidine 8o was chemically synthesized together with
its vincoside diastereomer (Dr. E. McCoy). Briefly, 5-bromotryptamine 6o hydrochloride
was added to secologanin 7 in maleic acid buffer (10 mM, pH 2.0) and reacted overnight
to afford the product [ESI-MS(C27H 34N2 0979Br*) m/z calculated: 609.1448 [M+H]*,
found: 609.1456 [M+H]*; ESI-MS(C 2 7H34N20981Br*) m/z calculated: 611.1427 [M+H]*,
found: 611.1453 [M+H]*]. The reaction was filter-sterilized and added to hairy root
cultures as described above (final volume 20 mL half-strength Gamborg media,
compound concentration 0.5 mM). After seven days the hairy roots were extracted into
MeOH, filtered and injected on the LC-MS. Assignments as brominated compounds are
based on isotopic signals of 79Br and 8 Br incorporated in the alkaloid analog. Bromine-
substituted analogs are expected to have later elution times (more hydrophobic) than the
natural MIA alkaloids. See Appendix A for LC-MS traces.
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CHAPTER 4
SUBSTRATE SPECIFICITY OF OPHIORRIZA PUMILA STRICTOSIDINE SYNTHASE
AND A STEREOCHEMICAL MODEL FOR STRICTOSIDINE SYNTHASE
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4.1 Introduction
The Pictet-Spengler reaction, a special case of the Mannich reaction, is where a p-
arylethylamine, such as tryptamine 1 or dopamine 4, undergoes ring closure after
condensation with an aldehyde.E1 3 This reaction generates one carbon-carbon bond and
one stereogenic center. There are several Pictet-Spengler reactions in natural product
biosynthetic pathways, including reactions between tryptamine 1 and secologanin 2 to
form strictosidine 3; between dopamine 4 and secologanin 2 to form deacetylisoipecoside
5; between dopamine 4 and 4-hydroxyphenyl acetaldehyde 6 to form norcoclaurine 7;
and, between dopamine 4 and 4-hydroxydihydrocinnamaldehyde 8 to form autumnaline 9
(Figure 4.1).E2
The tetrahydro-p-carboline moiety of strictosidine 3 is a heterocycle found in a wide
range of natural products and synthetic pharmaceuticals. Catalytic methodology exists to
stereoselectively generate the carbon-carbon bond formed in this Pictet-Spengler
reaction, E3-93 although these chemical methods often suffer from low stereoselectivity,
involve the use of organic solvents, and require activated amine substrates or harsh
reaction conditions. Since enzymes can be useful for preparative stereoselective synthetic
transformations, '10,113 and since natural product biosynthetic pathways are potentially rich
sources for new biocatalysts, I sought a biocatalytic alternative to forming tetrahydro-p-
carbolines.
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Figure 4.1 Pictet-Spengler reactions in natural product biosynthesis. The new carbon-carbon
bond is shown in red-bold and the new stereogenic center (C3) is marked with an asterisk. (a)
Formation of strictosidine 3 by strictosidine synthase; (b) formation of deacetylisoipecoside 5; (c)
formation of norcoclaurine 7; and (d) formation of autumnaline 9 by a set of unknown enzymes
(in addition to the Pictet-Spenglerase, two hydroxylases and two 0-methyl transferases may be
involved).
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Strictosidine synthase (STS) catalyzes the formation of strictosidine 3 in the biosynthesis
of monoterpene indole alkaloids (MIAs) and some quinoline alkaloids.[" Two STS
homologs from the medicinal plants Rauvolfia serpentina (RsSTS)[13] and Catharanthus
roseus (CrSTS),1 4 with 82% amino acid sequence identity and near-identical active sites,
have been studied in detail. RsSTS and CrSTS have narrow substrate scopes that preclude
their application as general biocatalysts, although mutagenesis can expand the substrate
scope somewhat.J"- 191 In this chapter I describe the characterization of Ophiorrhiza
pumila STS (OpSTS), which has a considerably broader substrate specificity compared to
RsSTS and CrSTS or any mutant of these two enzymes. 2 0] I also propose a model for
how STS achieves its high stereoselectivity; this model may be used to construct a Pictet-
Spenglerase with the alternative stereoselectivity.
4.2 Results and discussion
4.2.1 Sequence and homology model of 0. pumila STS
OpSTS, like CrSTS and RsSTS, also catalyzes the Pictet-Spengler reaction between
tryptamine 1 and secologanin 2 to form strictosidine 3, but has a lower sequence identity
to both CrSTS (54%) and RsSTS (60%), compared to the high sequence identity between
CrSTS and RsSTS (82%). [21 Specifically, sequence alignments showed that OpSTS has a
four-amino acid deletion that corresponds to A[GluLeuAspGly] 277 -28 0 in CrSTS and
A[GluLeuAspGly] 271 -27 4 in RsSTS, and several other differences in this sequence region
(Figure 4.2). The crystal structure of RsSTS in complex with secologanin 2 (PDB:
2FPC)2 2 ] suggests that the deletion in OpSTS is near the secologanin binding site.
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OpSTS ------- MHGSEJO WVS 1LCA L1FLS3LSL'V3SSPfF FET:EAPSYGPNAYAFB3DGE-:JY 52
crSTS MMESESASMMAVF"-FMF=,LL3333SSSSSSPI:a":F:ESPSYAPNAFTFD3TDKGFY GO
AsSTS ---- KAXLSDSgTMALrTWLLFLSSSLA-.SSIPI-.JKZ:L=EAPSYAPNSZ-TZ-DSTKKGFY 56
OpSTS 112
CrSTS TSVQDGRV:KYEGPKSG=rAYASPFWNXAZC--NSTDPEKRPLCGRTYDISYDYKNSQK 120
RsSTS TSVQ: GRV:XYEGIKSGZVDI-AYAS3PYWNXAYCENSTI>AEKRPLCGR7YDI S YMQNNQL 116
OPSTS Y: AD CYF S,.GFVr.PCGGEA IQL AT DV5TXYDD--R __.C
C.rSTS Y:VDGEYBLCVVGXEGGYATQLATSVQGVP"WLYAV-.VDQRTG=VY77DVSSIHDDSPE 180
AsSTS Y:' -DCYYBLSVVGSEGGEATQLATSVDGVPFXWLYAV.-VDQRTG--r-MDVSMYIOD--I:L 174
OpECTS GV" D I I R I ND TT,'GRL : K Y'"P S T E EVI:Pv'LM:<GLN I PGG:T V SK: -G S F"v'LVG-z- F ksH; _- L KY 71 S 0
CrSTS G%. EEINKTSDRTGRLMKYI>FSTKETTLLLXEIHVPGGAFISADGSFVVVA-vFL&KR ,4xy 240
RSSTS GVQgEMDTSDXTGRLIKYDPSTKETTLLL.XEIHVPGGAF-VSADSSFVLVA:---E-LSHIQ--vlKy 234
OpSTSE 2 IS 6
CrSTS WLz-7GPKKGSAEFI,-W-T--PWG-NIKRNSDGH-"MSSEEELDGGQHGRVVSRGIKFDGFGHIL 30C
RSST& W-GPKXGTAEV--V--,Ik!PNPGNIKR&NDGH'-WWSSSFIEliDGNMHGRVDPXGIKFDEFGNIL 294
OpSTS M*ATA ZPL P YX GEE:_"QVQZEDGALZ'%,G3 LT*11Zrv'G 11 M4YK S3 'MHEQ Z77US GGL-RA31-7 346
CrSTS QVIPLPPPY---GERF--Ql XBDGLLY=GSL--HSSVGILVYDDHZNKGNSYVSS------- 352
AsSTS Z:VIPLPPPI-AGE=. .QIQEEDG-.LY:G--LFHGSVGI.-JVYDKKGFTSFVSSH --------- 344
OpSTS Mrsor 3=i
CrSTS
AsSTS
Figure 4.2 Sequence alignments of OpSTS, CrSTS, and RsSTS. The four-amino acid deletion
and the Gly that replaces His283 in CrSTS are higWighted in yellow, the corresponding residues
in CrSTS and RsSTS are higlilighted in bold.C-
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Figure 4.3 (A) Crystal structure of RsSTS with the CrSTS amino acid sequence numbering. The
glucose moiety of secologanin 2 binds in a pocket defined by a loop-loop-helix motif, which
contains two histidine residues (His283 and His313). (B) Homology model of OpSTS based on
the crystal structure of RsSTS. The glucose moiety of secologanin 2 likely has fewer interactions
with this loop structure due to a four-amino acid deletion and histidine to glycine substitution.
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Moreover, His283 (His277 in RsSTS), which is substituted for a glycine in OpSTS
(Figure 4.2) and on the same loop as the deletion, is within hydrogen bonding distance to
the glucose moiety of 2.
To obtain further insight into the differences between OpSTS an RsSTS, I constructed a
homology model of OpSTS based on the crystal structure of RsSTS and the amino acid
sequence of OpSTS, using PHYRE (Figure 4.3B).[23,24] Since the amino acid sequence
and the amine and aldehyde substrate scopes of CrSTS and RsSTS are nearly identical, I
presumed that the structure of RsSTS is representative of CrSTS. The homology model of
OpSTS suggests that the region in the secologanin binding site is different in OpSTS
compared to RsSTS and these differences prompted me to assess whether OpSTS has a
broader, and therefore potentially more useful, aldehyde substrate scope.
4.2.2 Expression, purification, and kinetics of OpSTS
I codon optimized the gene encoding OpSTS for expression in Escherichia coli, removed
the nucleotides that encode the first 25 amino acids in the published peptide sequence
(GI: 13928598) to remove a putative signal peptide,[25 ,2 6] and then cloned the optimized
opsts gene into the E. coli expression vector pET-28 (section 4.4.3). After overexpression
of OpSTS and a similar construct of CrSTS in E. coli (Chapter 3), I purified both
enzymes using affinity chromatography (section 4.4.3).1" Pseudo steady-state kinetics
for secologanin 2 with OpSTS and CrSTS verified that heterologously expressed OpSTS
and CrSTS have similar catalytic efficiencies (Table 4. 1).[20]
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aTable 4.1. Kinetic constants.
Enzyme, substrate Vm. Km Vma/KM
[U mg~1] b [M] [U mg- mM-] b
CrSTS, secologanin 2 7.4 ± 0.6 40 ± 20 200 ± 150
OpSTS, secologanin 2 1.7 ± 0.1 21 5 80 ± 30
OpSTS, 5-methoxytryptamine 24 0.0043 ± 0.0003 40± 10 0.11 ± 0.04
OpSTS, 2'(R)-tryptophanol 25 0.0359 ± 0.0003 18 + 1 2.0 ± 0.2
[a] Kinetic assays were performed in sodium phosphate buffer (0.05 M, pH 7.0) using an internal standard (NAA,
0.075 mM) and analyzed by HPLC for formation of product; [b] 1 U = formation of 1 imol product per minute at pH
7.0 and 30 "C.
4.2.3 Aldehyde substrate scope of OpSTS
To examine the aldehyde substrate scope of OpSTS, I selected a series of aldehydes 10-
20 with the following properties: aliphatic, aromatic, linear, branched, hydrogen bond-
accepting, and functionalized (Table 4.2). I then incubated aldehydes 10-20 (1 mM) and
tryptamine 1 (1 mM) with OpSTS (0.2 mol% catalyst, 2 pM) or CrSTS (1.0 mol%
catalyst, 10 pM) in aqueous buffer (pH 7.0). Analysis of organic extracts of the reaction
mixtures showed that OpSTS is capable of catalyzing the conversion of aldehydes 10-16
and 19-20 into the corresponding tetrahydro-p-carboline products, as evidenced
HRMS.
I prepared authentic standards of tetrahydro-p-carbolines resulting from reaction of
aldehydes 10-16 and tryptamine 1 using conditions where the product precipitates during
the reaction or on standing, presumably by forming a hydrochloride salt. This method is
compatible with green chemistry, as no organic solvent is required for either reaction or
workup. I characterized the racemic mixtures by chiral HPLC, HRMS, and NMR (section
4.4.2 and Appendix B), and found that the tetrahydro-p-carboline standards co-elute with
the products resulting from OpSTS catalysis.
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Table 4.2 Aldehyde scope for OpSTS and CrSTS
0
strictosidine synthase NH
R\AH INH
10-20 1 N
R
Starting material k,b [min-l]a Starting material ko, [min-lia
R = OpSTS CrSTS R = OpSTS CrSTS
o 10 0.048 0.0002 16 <.0001c not obsyd.b
11 0.037 not obsvd.b 17 not obsvd.b not obsvd.b
12 0.032 not obsvd.b 18 not obsvd.b not obsvd.b
13 0.022 not obsvd.b
S 019 n.d.d not obsyd.b
14 0.013 not obsvd.b
15<0.0001c not obsvd.b NN 20 n.d.d not 
obsvd.b
[a] kob, measured by monitoring product formation with 1 at 280 nm using reverse-piase JIPLC with a
PDA detector; [b] not observed, detection limit 10-5 min- ; [c] quantification limit -10- min . kO,, of 10 is
230-fold higher for OpSTS tpan CrSTS; k,,b of 11-14 is > 3700-fold higher with OpSTS than CrSTS, given
a detection limit of 10~ min- ; [d] not determined.
Poor solubility of the aldehyde analogs precluded a full kinetic analysis (estimated KMr
values for the aldehydes are >10 mM). However, I derived kob-values by HPLC kinetics
at 1 mM substrate concentration (section 4.4.7). Although OpSTS favors the natural
substrate, secologanin 2, by at least 1000-fold, it catalyzes the conversion of a relatively
broad range of aldehyde substrates, including hydrogen bond-accepting (10), aliphatic
(11-12 and 14), and aromatic (13) aldehydes with similar rates (kobs = 0.013-0.048 min-').
The kinetics also demonstrated that OpSTS clearly prefers aldehydes 10-14 to aldehydes
15-16; particularly aldehydes unsubstituted at the alpha position (compare 10-14 with 16-
18). CrSTS accepts substrate 10, although kobs is 230-fold higher for OpSTS than CrSTS,
but not aldehydes 11-14 since kobs is >3700-fold higher for OpSTS compared to CrSTS
(Table 4.2).
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The enantiomeric excess (ee) of the tetrahydro-p-carboline products derived via OpSTS
catalysis is >98% as evidenced by chiral HPLC (section 4.4.5 and Appendix B). To
determine the absolute configuration of the enzymatic products, I immobilized OpSTS
onto solid support (CNBr-activated Sepharose, section 4 .4.4)273 and used this
immobilized catalyst to catalyze the 1-mmol scale reaction between tryptamine 1 and n-
hexanal 14. Chiral HPLC analysis of the enzymatic product and an authentic 3(S)-
standard obtained by Jacobsen's organocatalytic method (section 4.4.6) ,33 showed that the
absolute configuration is 3(S), which is the configuration observed with the natural
substrate, secologanin 2. The absolute configuration is assumed 3(S) for all enzymatic
products.
4.2.4 Tryptamine substrate scope of OpSTS
I hypothesized that specific interactions between tryptamine 1 and the enzyme active site
entrance partly determine the amine substrate specificity. Hence, if the secologanin
binding site, which is closer to the surface of the enzyme (PDB ID: 2FPC), is different in
OpSTS compared to CrSTS it is possible that the tryptamine substrate scope is altered.
I assayed a series of tryptamine analogs 21-28 - which previous studies showed that
CrSTS or RsSTS do not accept - with secologanin 2 and OpSTS (Table 4.3). LC-MS
analysis showed that OpSTS has a different tryptamine substrate scope than CrSTS or
any CrSTS mutant. While 5-methyl- 21, 5-chloro- 22, and 5-bromotryptamine 23 are not
substrates for OpSTS, 5-methoxytryptamine 24 is a substrate (Table 4.3); conversely,
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Val214Met CrSTS accepted 21-23, but not 24 (Chapter 3).E"7 In addition, 2'(R)-
tryptophanol 25, which is converted by the Phe232Leu mutant of CrSTS but not wild-
type CrSTS,[1 ] is a substrate for OpSTS (Table 4.3).
Table 4.3 Tryptamine scope of OpSTSa
R,
R R2
5 R2 OpSTS H ,OGlc
N NH 2  2 -
MeO 2C
Starting material Outcome Starting material Outcome
Rj= R2 = R1 = R,=
21 Me H - 25 H (R)-CH2 OH +
22 C1 H - 26 H (S)-CH 2OH -
23 Br H - 27 H (R)-CO 2H -
24 OMe H + 28 H (S)-CO 2H -
[a] The reaction outcome was determined by monitoring product appearance by LC-MS; CrSTS does not
catalyze the Pictet-Spengler reaction with any of the assayed tryptamine analogs 21-28.
Pseudo steady-state kinetics with OpSTS using 24 and 25 showed that both substrates
follow the Michealis-Menten model (Table 4.1 and section 4.4.7)J2 0] The catalytic
constants suggest that OpSTS is a significantly better catalyst than Phe232Leu STS with
2'(R)-tryptophanol 25 (Chapter 3).[17]
The factors that contribute to the dramatic changes in tryptamine substrate scope are at
present unknown, though I speculate that the electronic properties of the substrate and the
enzyme are important in the binding of tryptamine substrates to OpSTS. Therefore,
monitoring the effects on the substrate specificity of CrSTS, as a result of mutations of
residues at the entryway to the active site, may lead to insights into the mechanism of
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tryptamine substrate specificity. Nevertheless, the broader tryptamine substrate
specificity of OpSTS renders this enzyme a candidate for metabolic engineering of C.
roseus cell cultures to produce new MIA.[28]
4.2.5 Towards elucidating the molecular basis for the different substrate specificities
In an attempt to elucidate the molecular basis for the broadened specificity in OpSTS, I
modified amino acid residues in the secologanin binding site of CrSTS that are different
in OpSTS (Figure 4.2 and section 4.4.8). I substituted His283, which hydrogen bonds to
the glucose moiety of secologanin, with Gly, Leu, and Phe, and deleted the four amino
acids present in CrSTS but absent in OpSTS (section 4.2.1). These changes, however,
were not sufficient to expand the aldehyde scope of CrSTS; future experiments may shed
light on the different substrate specificities of these two enzymes (Chapter 7).
4.2.6 Model for stereoselectivity in STS
The stereoselectivity observed in the reaction between 1 and 2 with RsSTS, CrSTS, and
OpSTS is preserved with achiral aldehydes (section 2.4.3), indicating that
stereoselectivity does not rely on the chiral substrate 2. The configuration-determining
step may be the 6-endo-trig cyclizationE29] of iminium 29 (derived from condensation of 1
and 2), which gives a high-energy intermediate 30, containing two stereogenic centers:
C2 and C3; H2 is deprotonated to form 3 (Figure 4.4).E0] I hypothesized that formation of
30 is the configuration determining step, and docked QM/MM models of 30 into OpSTS
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using a molecular mechanics force field to gain insight into the molecular basis of
stereoselectivity (section 4.4.9).
The x-ray structure of RsSTS in complex with secologanin 2 (PDB ID: 2FPC)[22] served
as starting structure for docking of the four six-membered ring structures comprising 30
(section 4.4.9), which are the products of cyclization from cis and trans iminium
precursors 29 from the top or bottom face of the indole plane, respectively. The four
structures of 30 were docked into RsSTS while rotating the C3-C14 and C14-C15 bonds
of the ligand and the following bonds in the tryptamine binding site: Trp149 (@-y),
Val176 (a-p), Val208 (a-p) and Glu309 (a-p, p-y, y-8).
Glu309 (Glu315 in CrSTS) is essential in the catalytic cycle, where it participates as a
general acid/base catalyst. I define a productive docked structure (one that leads to the
formation of product) as one that contains two hydrogen bonds (Tyr151-Glu3O9 and
Glu309-N 4H), a n-stacking interaction between the indole moiety and Phe226, and
proximity of Glu309 to H2. I define a non-productive docked structure as one that differ
in one or more of these criteria. Based on these criteria, only one intermediate, 30-
2(R)3(S), shows all productive interactions, including the proximity of H2 to Glu309, the
Tyrl5l-Glu3O9 (2.8 A) and Glu309-N 4H (2.8 A) hydrogen bonds, and a n-stacking
similar to that observed in the x-ray structures of RsSTS in complex with tryptamine or
an inhibitor (Figure 4.5A).J2 2 ,3 0] Its H-2 epimer, 30-2(S)3(S), which also results in
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N NH31 NH
CHO /~
2 ,OGlc
MeO 2C O
-H20
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c ~,OGlc
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Only
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H j H ,OGlc
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ic kinetic resolution
one configuration
is productive
(in addition to being the
rate-determining step)
+ other C2-C3
diastereomers
that may exist
Figure 4.4 The Pictet-Spengler reaction between tryptamine 1 and secologanin 2 leads to
strictosidine 3 via iminium 29 and the proposed "productive" high-energy intermediate, 30-
2(R)3(S).
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Glu309
30-2(R)3(S)(to stricosidine 3)Tyr151
Interactions:
Glu3O.Oe... HO-Tyrl5l
Tyr191 x-stacking
G1u309-#... H2
Glu309-0r... H-44
Absent Interactions:
WA
' Proude intenmediate 30:
H-2 pointing towards Glu309
PhO226 hydrogen bonds and x-stacking present
Glu3O9
30-2(S)3(S)(to strctosdmne 3)Tyr151
2.9 A
Interactions:
Giu3O9.Oe... HO-Tyrl5l
Absent Interactions:
x-stacing H-2
GIu3O9-Os... H2
GIu3O9-Ot... H-N4
Nnrutvintermediate 30:
H-2 pointing away from Gu309
Ph*226 missing hydrogen bonds and x-stacking
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Tyr151
Interactions:
GIu3O-Os... HO-Tyr151
Gu309-Oe... H-N4
Absent Interactions:
x-stacking
Glu309-Os... H2
Glu309 changed position
V Nanrouctveintennediae 30:
H-2 pointing towards G1u309, though Glu309 is reoriented
Phe226 contains key hydrogen bonds but lacks x-stacking
Tyr1s
Interactions:
Glu309-O... HO-Tyr151
Phe226 x-stacklng
Glu309-Oe... H-N4
Absent Interactions: 3.6 A.GIu30-Ok... H2
D Pt28intermediate 30:H-2 pointing away from Glu309hydrogen bonds and x-stacking present
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GIu309
30-2(R)3(R)
(to vincoside)
G1u309
30-2(S)3(R)
(to vincoside)
,,klom
Gu3O9
Tyr151
3.9 A 3 
3.0 A
Interactions:
G1009-0a.. HO-Tyr151 A
x-stacking
Glu309-Oe... H2
Glu309-Oe... H-NH 3.9 A
Absent interactions:
NIA
/
Phe226
Gu3O9
Tyr151
Interactions:
GIu309-Oe... HO-Tyr151
x-stacking
Glu309-Oe... H-N4
Absent interactions:
WA
F Ph.226
Figure 4.5 (A-D) High-energy reaction intermediates 30 docked into the active site of RsSTS
(PDB ID: 2FPC) as described in the text and in section 4.4.9. Each panel shows interactions that
are present or absent: an intermediate is defined as non-productive if it lacks one or several of
these interactions. Intermediates with 3(S) configuration, leading to strictosidine 3, are shown in a
white-tone CPK color scheme: intermediates with 3(R) configuration, leading to vincoside, are
depicted with a blue-tone CPK color scheme. (E) X-ray crystal structure of RsSTS in complex
with tryptamine (PDB ID: 2FPB). (F) X-ray crystal structure of RsSTS in complex with
strictosidine (PDB ID: 2V91).
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(PD8 ID: 2FPB)
3
(PDB 10: 2V91)
\
. .......................
30-2(R)3(R, Glu309
Tyr151
secoiridold
moiety
tetrahydro-p-carboline
moiety
Phe226
Figure 4.6 Overlay of the docked high-energy intermediates 30. One intermediate, 30-2(R)3(R),
which leads to vincoside, docks in a way that reorients Glu309.
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strictosidine formation only preserves the Glu309-Tyrl51 (2.9 A) interaction (Figure
4.5B). The diastereomer of 30-2(S)3(S), 30-2(R)3(R), twists the Glu309 side-chain
orientation and lacks the it-stacking interaction (Figures 4.5C and 4.6). The H-2 epimer
of 30-2(S)3(S), 30-2(S)3(R), leading to vincoside formation has all key interactions
(Figure 4.5D), but displays the H2 proton on the opposite face of the indole plane
compared to Glu309. Therefore, I hypothesize that the general base, Glu309, can
deprotonate 30-2(R)3(S) (closest distance is 3.4 A), while Glu309 cannot deprotonate 30-
2(S)3(R). Since kinetic data suggests that the iminium-cyclization step is reversible, the
"wrong" stereoisomer may reform the iminium and then have another chance to cyclize.
In summary, based on the docked structures, facial deprotonation is likely key for
determining the stereochemical outcome. This facial deprotonation model is consistent
with the reversible nature of the Pictet-Spengler reaction, but should be interpreted
cautiously, since it has not been experimentally validated. However, this model serves as
a basis for understanding and engineering the stereoselectivity of Pictet-Spenglerases
(Chapter 7).
4.3 Conclusions
This chapter describes the first report of a Pictet-Spenglerase with broad substrate
specificity. The broader aldehyde substrate specificity is potentially useful for
biocatalytic applications. Future experiments involve increasing the thermostability of
OpSTS that would allow reaction at higher temperatures and, presumably, lead to higher
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product yields (Chapter 7). The broader tryptamine substrate specificity makes OpSTS a
candidate for constructing transgenic plants to produce new monoterpene indole alkaloid
analogs.
The evolutionary distance between the apocynaceae plant family, from which CrSTS and
RsSTS are derived, and the rubiaceae family, from which OpSTS is derived, may explain
the different substrate specificities. Rubiaceae plants contain chiral tetrahydro-p-
carbolines different from those found in the apocynaceae family, 3 1 and although the
enzymes that catalyze the formation of the precursor for these rubiaceae natural products
are unknown, I speculate that they contain a Pictet-Spenglerase that resembles OpSTS.
Screening of rubiaceae plants for new STS homologs and assay of the predicted
substrates can experimentally test this possibility.
OpSTS catalyzes the formation of the 3(S) stereogenic center even with smaller
aldehydes; I presented a stereochemical model that accounts for how STS maintains high
stereoselectivity irrespective of the size and chirality of the aldehyde substrate. This
model may facilitate mutagenesis to alter the stereoselectivity of OpSTS.
4.4 Experimental methods
4.4.1 General methods and analytical techniques
All purchased chemicals were used as received from the supplier. Achiral aldehydes were
obtained from VWR distributors or Sigma-Aldrich, except THPCH2CHO 10, which was
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obtained from Biofine International (Blaine, WA), and CyCH 2CHO 11, which was
obtained from BetaPharma (New Haven, CT); secologanin was obtained by extraction of
Lonicera tatarica as previously described.[3 2]
UPLC and MS analysis were performed in tandem using an Acquity Ultra Performance
BEH C18 column with a 1.7 [m particle size, 2.1 x 100 mm dimension, and a flow rate
of 0.6 mL min-'. MS analysis was carried out using a Micromass LCT Premier TOF Mass
Spectrometer with an ESI source. Both modules are from Waters Corporation (Milford,
MA). The capillary and sample cone voltages were 3000 V and 30 V, respectively. The
desolvation and source temperatures were 300 and 100 'C, respectively. The cone and
desolvation gas flow rates were 60 and 800 L h-1. HPLC analysis was performed on a
Beckman Coulter Gold System equipped with a 125 solvent module, 125 autosampler
and a 168 detector. Data were processed (integrated) using 32Karat (v 7). Analytes were
separated on a reverse-phase column (HiBar RT 250-4, RP-select B, 5 tm). Chiral HPLC
analysis was performed on an Agilent 1100 series LC (Agilent Technologies, Inc., Santa
Clara, CA). Data were processed using ChemStation for LC (Rev. A 10.01 [1635]).
Analytes were separated on a normal-phase chiral column (Chiralcel OD-H 0.46 cm x 25
cm) from Daicel Chemical Industries, LTD; Chiral Technologies, Inc., West Chester,
PA). 1H NMR and 13C NMR spectra were recorded on Varian 300 MHz, Varian 500
MHz, or Brucker 400 MHz spectrometers.
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AB
Figure 4.7 Precipitation of tetrahydro-p-carbolines in the synthesis of racemic standards. (A)
Tryptamine 1 and hexanal 14 were added in equimolar ratio to maleic acid (pH 2) buffer. (B) The
reaction solidifies after 20 min at 60 *C. Water was then added and the precipitate was filtered
and washed in water to obtain the analytically pure tetrahydro-p-carboline product.
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4.4.2 Chemical synthesis of authentic standards
Authentic standards were synthesized using a chemical Pictet-Spengler reaction in
aqueous maleic acid buffer (1 M substrate concentration, 10 mM, pH 2.0). During
incubation at 60 "C or on standing, the tetrahydro-p-carboline product precipitated
(Figure 4.7). After filtration, and several washes with water, the dried precipitate
contained >99% pure product.
All authentic standards were verified by 1H and 13C NMR (Appendix B) and used as
authentic standards for ee and absolute configuration determination (sections 4.4.5-4.4.6),
to confirm enzyme catalyzed product formation, and to obtain response factors for HPLC
kinetics (section 4.4.7).
J-((tetrahydro-2H-pyran-4-yl)methyl)-2,3,4,9-tetrahydro-JH-pyrido[3,4-b]indole (from 1
and 10)
NH
a N
H
Tryptamine hydrochloride (1 M) was added to the tetrahydropyran aldehyde 10 (1 M) in
aqueous maleic acid buffer (10 mM, pH 2.0) and the mixture was incubated at 60 "C for
18 h. The precipitate was recovered, washed with water, and dried: 1H NMR (MeOD): 8
7.48 (1H, dt, J= 0.9, 7.9), 7.36 (1H, dt, J= 0.9, 8.2), 7.16 (1H, td, J= 1.1, 8.2), 7.06 (1H,
td, J= 0.9, 8.0), 4.86-4.82 (1H, m), 4.03-3.96 (2H, m), 3.75 (1H, dt, J= 1.3, 4.1, 12.4),
3.55-3.44 (3H, m), 3.12-3.07 (2H, m), 2.21-2.15 (1H, m), 1.95-1.83 (3H, m), 1.68 (1H,
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td, J = 1.9, 13.1), 1.50-1.37 (2H, m); 13C NMR (MeOD): 8 137.61, 129.58, 126.73,
122.80, 119.91, 118.34, 111.63, 106.54, 68.03, 67.87, 51.08, 42.39, 39.94, 33.93, 32.40,
31.09, 18.80; UV-max: 228, 279 nm; ESI-MS(C17H 23N2O*) m/z calculated: 271.1810
[M+H]*, found: 271.1805 [M+H]*.
1-(cyclohexylmethyl)-2,3,4,9-tetrahydro-JH-pyrido[3,4-b]indole (from 1 and 11)
NH
N
H
Tryptamine hydrochloride was added to the cyclohexyl aldehyde 11 in aqueous maleic
acid buffer (10 mM, pH 2.0) and the mixture was incubated at 60 "C for 20 h. The
precipitate was recovered, washed with water, and dried: 1H NMR (MeOD): 8 7.47-7.44
(1H, m), 7.36 (1H, td,J= 0.8, 8.2), 7.14 (1H, ddd,J= 1.1, 7.1, 8.2), 7.04 (1H, ddd,J=
1.0, 7.1, 8.0), 4.81-4.74 (1H, m), 3.71 (lH, ddd, J= 3.5, 5.5, 12.5), 3.41 (1H, ddd, J=
5.5, 9.9, 12.6), 3.09 (1H, dddd, J= 1.9, 5.5, 9.8, 15.4), 3.05-2.99 (lH, m), 2.12 (1H, ddd,
J= 3.7, 10.2, 14.3), 2.08-2.00 (1H, m), 1.87-1.60 (6H, m), 1.49-1.34 (2H, m), 1.33-1.22
(1H, m), 1.19-1.02 (2H, m); 13C NMR (MeOD): 8 137.59, 129.95, 126.75, 122.69,
119.84, 118.31, 111.64, 106.39, 51.57, 42.46, 40.53, 34.56, 33.59, 32.41, 26.74, 26.54,
26.16, 18.81; ESI-MS(Ci 8 H25N2*) m/z calculated: 269.2012 [M+H]*, found: 269.2014
[M+H]*.
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1-isobutyl-2,3,4,9-tetrahydro-JH-pyrido[3,4-b]indole (from 1 and 12)
NH
SN
H
Tryptamine hydrochloride (1 M) was added to isovaleryl aldehyde 12 (1 M) in aqueous
maleic acid buffer (10 mM, pH 2.0) and the mixture was incubated at 60 "C for 18 h. The
precipitate was recovered, washed with water, and dried. The white shiny powder had
poor solubility, but could be dissolved in DMSO-d6 after sonication and brief heating. IH
NMR (10:1, MeOD/DMSO-d 6) 8 7.50 (1H, td, J= 1.0, 7.8), 7.39 (lH, td, J= 0.9, 8.2),
7.17 (1H, ddd, J= 1.2, 7.1, 8.2), 7.08 (lH, ddd, J= 1.0, 7.1, 8.0), 4.82-4.79 (1H, m), 3.74
(1H, ddd, J= 3.9, 5.3, 12.6), 3.47 (1H, ddd, J= 5.9, 9.3, 12.6), 3.16-3.02 (2H, m), 2.08
(1H, ddd, J= 3.9, 10.2, 14.2), 1.99 (1H, dqd, J= 3.9, 6.5, 19.5), 1.85 (1H, ddd, J= 3.9,
10.3, 14.2), 1.15 (3H, d, J= 6.4), 1.10 (3H, d, J= 6.5); "C NMR (DMSO-d6 ): 8 137.22,
131.64, 126.98, 122.74, 120.07, 119.09, 112.46, 106.81, 51.51, 41.94, 24.67, 24.53,
22.51, 19.16; ESI-MS(C1 5H21N2*) m/z calculated: 229.1699 [M+H]*, found: 229.1697
[M+H]*.
1-benzyl-2,3,4,9-tetrahydro-JH-pyrido[3,4-b]indole (from 1 and 13)
NH
H-
Tryptamine hydrochloride (1 M) was added to benzyl aldehyde 13 (1 M) in aqueous
maleic acid buffer (10 mM, pH 2.0) and the mixture was incubated at 60 "C for 20 h. The
precipitate was recovered, washed with water, and dried: IH NMR (MeOD): 8 7.55-7.37
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(m, 7H), 7.21 (1H, ddd,J= 1.1, 7.1, 8.2,), 7.11 (1H, dd,J= 1.0, 7.1, 8.0), 5.06-5.01 (1H,
m), 3.79-3.73 (1H, m), 3.62 (1H, ddd, J = 3.6, 5.3, 12.5), 3.36 (1H, ddd, J= 5.7, 9.6,
12.6), 3.21-3.01 (3H, m); 13C NMR (MeOD, MHz): 8 136.68, 135.82, 130.10, 129.87,
127.71, 126.26, 122.36, 119.54, 118.59, 111.90, 106.72, 54.20, 41.90, 37.76, 18.45; ESI-
MS(Ci 8 H19N 2*) m/z calculated: 263.1543 [M+H]*, found: 263.1540 [M+H]*.
1-pentyl-2,3,4,9-tetrahydro-JH-pyrido[3,4-b]indole (from 1 and 14)
NH
H
Tryptamine hydrochloride (1 M) was added to n-hexanal 14 (1 M) in aqueous maleic acid
buffer (10 mM, pH 2.0) and the mixture was incubated at 60 *C for 45 min. The
precipitate was recovered, washed with water, and dried: 1H NMR (MeOD): 8 7.48 (1H,
dt, J= 0.9, 7.9), 7.36 (1H, dt, J= 0.9, 8.2), 7.15 (1H, td, J= 1.1, 8.2), 7.06 (1H, td, J=
0.9, 8.0), 4.69 (1H, dd, J= 4.1, 8.9) 3.73 (1H, ddd, J= 3.8, 5.5, 12.5), 3.44 (1H, ddd, J=
5.6, 9.6, 12.6), 3.11 (1H, dddd, J= 1.9, 5.6, 9.5, 15.1), 3.05 (1H, dddd, J= 1.3, 3.8, 5.3,
16.3), 2.31-2.23 (1H, m), 1.97-1.89 (1H, m), 1.64-1.54 (2H, m), 1.53-1.37 (4H, m), 0.97
(3H, t, J= 7.1); 13C NMR (MeOD): 8 138.36, 130.32, 127.46, 123.48, 120.59, 119.10,
112.39, 107.18, 55.17, 43.19, 33.38, 32.79, 25.92, 23.48, 19.54, 14.37; ESI-
MS(C1 6H23N2*) m/z calculated: 243.1856 [M+H]*, found: 243.1851 [M+H]*.
143
1-ethyl-2,3,4,9-tetrahydro-]H-pyrido[3,4-b]indole (from 1 and 15)
NH
H
Tryptamine hydrochloride (1 M) was added to propanal 15 (1 M) in aqueous maleic acid
buffer (10 mM, pH 2.0) and the mixture was incubated at 60 "C for 20 h. The precipitate
formed upon standing (approximately 48 h), was recovered, washed with water, and
dried: 1H NMR (MeOD): 8 7.47 (1H, td, J= 0.9, 7.9), 7.37 (1H, td, J= 0.9, 8.2), 7.15
(1H, ddd, J= 1.1, 7.1, 8.2), 7.06 (1H, ddd, J= 1.0, 7.1, 8.0), 4.63-4.57 (1H, m), 3.71 (1H,
ddd, J= 3.7, 5.6, 12.5), 3.39 (1H, ddd, J= 5.5, 9.7, 12.6), 3.10 (lH, dddd, J= 2.0, 5.6,
9.7, 15.3), 3.01 (1H, dddd, J= 1.4, 3.7, 5.3, 16.3), 2.33 (1H, dqd, J= 4.2, 7.6, 15.1), 2.05-
1.93 (1H, m), 1.19 (3H, t, J= 7.5); 13C NMR (MeOD): 8 138.30, 130.14, 127.42, 123.46,
120.57, 119.13, 112.38, 107.25, 56.19, 43.15, 26.33, 19.52, 9.93; ESI-MS(Cl 3H17N2+)
m/z calculated: 201.1386 [M+H]*, found: [M+H]* 201.1385.
1-cyclohexyl-2,3,4,9-tetrahydro-JH-pyrido[3,4-b]indole (from 1 and 16)
NH
N
H
Tryptamine hydrochloride (1 M) was added to cyclohexyl aldehyde 16 (1 M) in aqueous
maleic acid buffer (10 mM, pH 2.0) and the mixture was incubated at 60 "C for 20 h. The
precipitate was recovered, washed with water, and dried: 1H NMR (MeOD): 8 7.45 (1H,
d, J= 7.9), 7.38 (1H, d, J= 8.2), 7.14 (lH, ddd, J= 1.1, 7.2, 8.2), 7.04 (1H, ddd, J= 1.0,
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7.2, 8.0), 4.60-4.57 (1H, m), 3.71 (1H, ddd, J = 3.2, 5.5, 12.4), 3.38 (1H, ddd, J = 5.4,
10.1, 12.5), 3.10 (1H, dddd, J= 2.0, 5.6, 10.1, 15.8), 3.04-2.95 (1H, m), 2.35-2.22 (1H,
m), 1.98-1.68 (4H, m), 1.57-1.10 (6H, m); 13C NMR (MeOD): 8 137.64, 128.27, 126.71,
122.76, 119.84, 118.31, 111.65, 107.40, 59.19, 43.15, 40.32, 30.12, 27.07, 26.82, 26.43,
26.41, 18.70; ESI-MS(C17H 23N2*) m/z calculated: 255.1856 [M+H]*, found: 255.1858
[M+H]*.
4.4.3 Cloning of opsts into pET-28a(+) and expression and purification of OpSTS and
CrSTS
The opsts gene (GI: 13928597) was codon optimized for expression in E. coli. The
nucleotides encoding the first 25 amino acids in the published peptide sequence (GI:
13928598) were omitted to remove a putative signal peptide (SignalP 3 .0).25,261 Upstream
Nco I and downstream Xho I restriction sites (underlined), a sequence that encodes for a
hexa-histidine tag (yellow), and a stop codon (red) were added to codon optimized opsts
to give the following nucleotide sequence:
CCATGGGCTCTCCTGAGTTTTTCGAATTTATTGAAGCACCGTCTTATGGTCCAAATGCGTATGCGTTCGACAGCGACGGCGAGTTGTATGC
GAGCGTGGAAGACGGTCGTATTATCAAGTACGACAAGCCTTCTAACAAATTCCTGACTCATGCTGTTGCCAGCCCGATCTGGAACAATGC
CCTGTGTGAGAATAATACCAACCAAGACCTGAAGCCGCTGTGCGGTCGCGTCTACGACTTTGGTTTTCATTATGAAACGCAGCGCCTGTA
CATTGCAGATTGCTACTTCGGCTTGGGCTTTGTTGGTCCGGACGGCGGTCACGCGATTCAACTGGCAACCTCCGGTGATGGCGTTGAGTTC
AAGTGGCTGTACGCGTTGGCGATCGACCAACAGGCAGGCTTCGTCTACGTGACGGACGTTTCTACTAAGTACGATGATCGTGGTGTTCAG
GACATTATTCGCATTAATGATACCACGGGTCGCCTGATTAAGTATGACCCTTCGACCGAAGAGGTGACCGTGCTGATGAAAGGCCTGAAT
ATTCCGGGCGGTACCGAGGTTAGCAAAGACGGTAGCTTTGTGCTGGTTGGTGAGTTCGCGTCGCATCGTATCCTGAAGTACTGGCTGAAG
GGTCCGAAGGCCAATACCAGCGAGmCTGCTGAAGGTGCGCGGTCCAGGTAATATCAAACGTACCAAAGATGGTGATTTCTGGGTTGCG
TCCAGCGATAACAACGGCATCACGGTGACGCCACGTGGTATCCGCTTCGATGAGTTTGGCAACATTCTGGAGGTCGTTGCTATTCCGCTG
CCGTATAAAGGTGAACATATCGAGCAGGTCCAAGAACACGACGGCGCCCTGTTCGTGGGTAGCCTGTTTCATGAGTTCGTCGGCATCCTG
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CATAACTATAAGAGCAGCGTTGACCATCATCAGGAAAAGAACTCGGGTGGTCTGAACGCGAGCTTCAAGGAGTTCTCTTCGTrrTGGATCT
CATCATCACCATCACCACECGIAG
The designed nucleotide sequence was synthesized and supplied as a sequenced construct
in pJ201:12909 by DNA2.0 (Menlo Park, CA). Plasmid pJ201 (containing opsts) was
subjected to a double restriction endonuclease reaction using Nco I and Xho I and the
digestion products were ligated into pET-28a(+) (Novagen, EMD Biosciences, Merck
KgaG, Darmstadt, Germany) using T4 DNA ligase. DNA sequencing was used to
confirm the integrity of the resulting construct, pOpSTS. pOpSTS was transformed into
E. coli BL21(DE3) for expression. pCrSTS was also available in E. coli BL21(DE3)
(Chapter 3).[1 Purification of OpSTS and CrSTS were carried out as described
previously.117 1 The enzymes were buffer exchanged into sodium phosphate buffer (0.05
M, pH 7.0, 20% glycerol), analyzed by SDS-PAGE (Figure 4.8) and stored in 0.02 mL
aliquots at -20 *C. The enzyme preparations tolerated repeated freeze-thaw cycles and are
stable for at least one year without noticeable loss of activity. Crude extracts of E. coli
BL2I(DE3) that lacked plasmid and boiled OpSTS or CrSTS preparations did not
catalyze the Pictet-Spengler reaction. Moreover, no chemical background reaction was
detectable after two days of incubation of 2 mM tryptamine 1 and 2 mM secologanin 2 or
aldehydes 10-20 in pH 7.0-buffer.
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Figure 4.8 Purified, concentrated, and buffer exchanged OpSTS (1.2 mg mL- ) and CrSTS (4.1
mg mL-) were loaded onto SDS-PAGE gels, separated, and stained using coomassie brilliant
blue. The expected molecular weight of OpSTS and CrSTS is 37 kDa; the approximate loading
was: OpSTS (9 [Lg) and CrSTS (30 [Lg).
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4.4.4 Immobilization of OpSTS on CNBr-activated Sepharose 4B and enzymatic
synthesis of tetrahydro-p-carbolines
CrSTS from partially purified plant tissue extract was previously immobilized on
Sepharose 4B by the group of M. Zenk and used for the preparative synthesis of gram-
quantities of strictosidine 3.[27] OpSTS (2 U total activity, where 1 U = 1 [tmol
strictosidine formed per minute) was immobilized on cyanogen bromide (CNBr)-
activated Sepharose 4B (1.4 mL) according to the manufacturer's instructions (71-7086-
00 AD, GE Healthcare, Uppsala, Sweden). Immobilized OpSTS was active, where 1 U
total activity was immobilized on the resin (51% recovered yield). Immobilized OpSTS
could be reused at least three times with no noticeable loss of activity, similar to Zenk's
previous observations with CrSTS.271
Enzyme-catalyzed reactions (total volume: 4 mL) contained sodium phosphate buffer
(0.025 M, pH 7.0), tryptamine 1 (1 mM), aldehyde analog (5 mM), and immobilized
OpSTS (0.02 U, based on strictosidine-forming activity). After incubation for four days
at 100 rpm and 30 'C, the Sepharose beads were settled and the supernatant was extracted
three times with DCM and once with EtOAc. The combined organic layers were
evaporated in vacuo and the residue was dissolved in 2 mL of 1:1 MeCN-water. The
tetrahydro-p-carboline product was isolated by semi-preparative HPLC using a solvent
gradient of 30-100% MeCN in water with 0.1% TFA over 20 min. The collected fractions
were concentrated in vacuo and the residue was separated by chiral HPLC (section 4.4.5).
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n-Pentyl-tetrahydro-p-carboline, from substrates 1 and 14, was isolated from a scaled up
reaction (mg-scale) using immobilized OpSTS.
4.4.5 Determination of enantiomeric excess (ee)
Purified enzymatic products, obtained using enzymatic synthesis with immobilized
OpSTS, were dissolved in isopropanol and injected on a chiral HPLC column. For all
tetrahydro-p-carbolines except the CH2THP analog (derived from 10), a solvent
composition of 10% i-PrOH in hexanes for 10 min, followed by a gradient of 10-30% i-
PrOH in hexanes over 40 min was used. For the product of tryptamine 1 and aldehyde 10,
a solvent composition of 20% i-PrOH in hexanes for 10 min followed by a gradient of
20-25% i-PrOH in hexanes over 40 min was used. The authentic standards prepared as
described in section 4.4.2 were run in parallel to enzymatic reactions. Peaks were
detected by UV light at 230 nm, close to the maximal absorption of the tetrahydro-p-
carbolines products. The products of compounds 1 and 10-11, 13-14 separated on
Chiracel OD-H (Chiral Technologies, Inc., PA); 2.6 cm x 25 cm; with the following
retention times: Chemical standards (tetrahydro-p-carboline C3-substituent): CH 2THP
(E1: 17 min, 18 min, E2: 24 min, 26 min); CH 2Cy (E1: 19 min, E2: 23 min); benzyl (E1:
21 min, E2: 27 min); n-pentyl (El: 17 min, E2: 23 min). Enzymatic products (tetrahydro-
p-carboline C3-substituent): CH 2THP (El: 16 min, 17 min; E2: not found), ee >98%;
CH 2Cy (El: not found, E2: 23 min), ee >98%; CH 2Cy (El: not found, E2: 23 min), ee
>98%; n-pentyl (El: not found, E2: 22 min), ee >98%. Despite considerable efforts
using different chiral HPLC columns and mobile phases, the enantiomers of the
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Figure 4.9 Chiral HPLC trace for determination of the absolute configuration of the enzymatic
products. i N-acetyl derivatized OpSTS product from 1 and 14. ii Chiral authentic standard
prepared according to reference 4. ii Co-injection of i and ii.
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Figure 4.10 Models for 30 were generated based on the orientation of secologanin 2 in the active
site of RsSTS and quantum mechanically derived structures of 6-exo-trig products.
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tetarhydro-p-carboline product resulting tryptamine 1 and isobutanal 12 could not be
separated. The chiral HPLC traces can be found in Appendix B.
4.4.6 Determination of absolute configuration
n-Pentyl tetrahydro-p-carboline (derived from 14), prepared from an enzymatic reaction
using immobilized-OpSTS (section 4.4.4), was dissolved in DCM and N-acetylated with
acetic anhydride (1.0 eq) in the presence of TEA (1.0 eq) at -80 "C. The reaction was
monitored by LC-MS, and upon completion, the reaction was quenched by MeOH and
concentrated in vacuo. The residue was dissolved in 2:1 hexanes/EtOAc and purified by
flash column chromatography (SiO 2 , 2:1, hexanes/EtOAc) yielding a white solid. The
purified N-acetylated enzymatic product was compared to an authentic standard of the
3(S) enantiomer of N-acetylated n-pentyl-tetrahydro-p-carboline (ee = 95%), prepared as
described in ref. 3 (Figure 4.9). Since only one enantiomer formed in the enzymatic
reaction, and since this enantiomer coeluted with the authentic 3(S) standard, a 3(S)
configuration was assigned to the enzymatic product. It is assumed that the absolute
configuration of the other enzymatic products is also 3(S).
4.4.7 Enzyme assays and kinetics
Aldehydes 10-20
A stock (1 M) in DMSO of each aldehyde analog was carefully prepared and then diluted
with water (final concentration of 10 mM) to minimize DMSO in the enzyme assay
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(0.1% v/v solvent in each assay). Enzyme assays (0.2 mL reaction volume) contained
tryptamine 1 (1 mM) and aldehyde analog 10-20 (1 mM) in sodium phosphate buffer
(0.05 M, pH 7.0) and reactions were initiated by the addition of OpSTS (0.2 mol%
relative to the substrate concentration) or CrSTS (1.0 mol%). The reactions were
quenched by injection onto the HPLC column (27 [tL). The area under the product peak
was converted to concentration via a standard curve obtained by injecting known
amounts of authentic standard (section 4.4.2) onto the HPLC. The reaction rates were
normalized by the enzyme concentration in the reaction and reported as kobs [min-].
Secologanin 2
Pseudo steady-state kinetics for OpSTS and CrSTS with secologanin 2 was carried out by
fixing the concentration of tryptamine 1 (1 mM) while varying the concentration of 2.
Each reaction (0.2 mL) contained sodium phosphate buffer (0.025 M, pH 7.0), internal
standard (NAA, 0.075 mM), tryptamine 1 (1 mM), and secologanin 2 (10, 20, 40, 100,
250 or 1000 tM), equilibrated to 30 "C. The reaction was initiated by adding either
OpSTS (1.6 nM) or CrSTS (0.90 nM). At time points (10, 20, 30, and 40 min), an aliquot
(0.05 mL) was removed from the reaction and quenched in sodium hydroxide (4 N, 1 [tL,
pH >12). This quench forms strictosamide quantitatively within minutes.[331 The
quenched samples were stored at 10 "C in the HPLC autosampler tray until injected
(0.027 mL) on the HPLC column. The chromatogram was integrated and the area under
the peaks corresponding to strictosamide and NAA were noted. The relative area was
compared to a standard curve where known amounts of strictosamide had been injected
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under conditions identical to the kinetic assays. The kinetic data were collected three
times for each concentration of secologanin 2 and the average initial rate (<15%
conversion) was corrected for enzyme concentration and plotted against the concentration
of 2. The data were fit by non-linear regression analysis according to the Michaelis-
Menten equation to obtain Vmax (U mg%), Km ( M), and Vmax/KM (U mg-1 mM').
Tryptamine analogs
Pseudo steady-state kinetic analysis was performed by varying the concentration of
tryptamine analog and keeping the secologanin 2 concentration at 1 mM (Km2 = 0.021
mM). Each reaction (0.1 mL) contained sodium phosphate buffer (0.125 M, pH 7.0),
internal standard (NAA, 0.075 mM), secologanin 2 (1 mM), and tryptamine analog
(0.025, 0.050, 0.10, 0.25, and 0.50 mM for 5-methoxytryptamine 24; 0.010, 0.025, 0.050,
0.10, and 0.50 mM for 2'(R)-tryptophanol 25), equilibrated to 30 "C. The reaction was
initiated by adding OpSTS (1.4 [M). At time points (15, 30, 45, and 60 min), an aliquot
(0.025 mL) was removed from the reaction and added to 0.1 mL MeOH to precipitate
salts and protein. The quenched samples were stored at 10 *C in the HPLC autosampler
tray until injected (0.027 mL) on the HPLC column. The chromatogram was integrated
and the area under the peaks corresponding to the strictosidine analog and NAA were
noted. The relative area was compared to a standard curve where known amounts of
strictosidine 3 had been injected under conditions identical to the kinetic assays. The
kinetic data were collected three times for each concentration of tryptamine analog 24 or
25, and the average initial rate (<15% conversion) was corrected for enzyme
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concentration and plotted against the concentration of 24 or 25. The data were fit by non-
linear regression analysis according to the Michaelis-Menten equation to obtain Vm, (U
mg'1), Km (jIM), and Vmax/KM (U mg~1 mM-1).
4.4.8 Site-directed mutagenesis
Site-directed mutagenesis was carried out using the complementary primer method using
Stratagene's Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA). The primers listed
in Table 4.4 were used.
Table 4.4 Primers used for site-directed mutagenesis.
Primer name Primer sequence (5'->3')
del-fwda GTTTCCTCATCTGAAGGTCAACACGGTCGTG
del-reva CACGACCGTGTTGACCTTCAGATGAGGAAAC
His283Gly-fwd GGACGGTGGTCAAGGCGGTCGTGTTGTTTC
His283Gy-rev GAAACAACACGACCGCCTTGACCACCGTCC
His283Leu-fwd GGACGGTGGTCAAGTGGGTCGTGTTGTTTC
His283Leu-rev GGACGGTGGTCAACACGGTCGTGTTGTTTC
His283Phe-fwd GGACGGTGGTCAATTCGGTCGTGTTGTTTC
His283Phe-rev GGACGGTGGTCAAGAAGGTCGTGTTGTTTC
[a] del = deletion of residues 277-280 in the C. roseus sequence.
The following CrSTS sequence was used as template to construct site-directed mutants:
TCACCAATCTTGAAGAAGATCTTCATCGAGTCTCCATCTTACGCTCCAAACGCTTTCACTTTCGACTCTAC
TGACAAGGGATTCTACACTTCCGTTCAGGACGGTAGAGTTATCAAGTACGAGGGTCCAAACTCTGGTTTC
ACTGACTTCGCTTACGCTTCTCCATTTTGGAACAAGGCTTTCTGTGAGAACTCTACTGACCCAGAGAAGA
GACCATTGTGTGGTAGAACTTACGACATCTCCTACGACTACAAGAACTCCCAGATGTACATTGTTGACGG
TCACTACCACTTGTGTGTTGTTGGTAAGGAAGGAGGTTACGCTACTCAATTGGCTACATCCGTTCAGGGT
GTTCCATTCAAGTGGTTGTACGCTGTTACTGTTGACCAGAGAACTGGTATCGTTTACTTCACTGACGTTTC
CTCTATTCACGACGATTCTCCAGAAGGTGTTGAGGAGATCATGAACACTTCCGACAGAACTGGTAGATTG
ATGAAGTACGACCCATCCACTAAGGAGACTACTTTGTTGTTGAAGGAGTTGCACGTTCCAGGTGGTGCTG
AGATTTCTGCTGACGGTTCCTTCGTTGTTGTTGCTGAGTTCTTGTCCAACAGAATCGTTAAGTACTGGTTG
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GAGGGTCCAAAGAAGGGTTCTGCTGAGTTCTTGGTTACTATCCCAAACCCAGGTAACATCAAGAGAAACT
CCGATGGTCACTTCTGGGTTTCCTCATCTGAAGAATTGGACGGTGGTCAACACGGTCGTGTTGTTTCCAGA
GGTATCAAGTTCGACGGTTTCGGTAACATCTTGCAGGTTATCCCATTGCCACCACCATACGAAGGTGAAC
ACTTCGAGCAAATTCAAGAGCACGACGGATTGTTGTACATTGGTTCCTTGTTTCACTCCTCCGTTGGTATC
TTGGTTTACGACGACCACGATAACAAGGGAAACTCCTACGTTTCCTCC
4.4.9 Molecular modeling
Molecular mechanics was performed using Sybyl Molecular Expert Modeling Software
(Version 7.3 including the FlexiDock application, Tripos, Inc.). Energy minimizations
were carried out until the energy of the system remained constant, using a dielectric
constant scaling factor of 4, a non-bonded cutoff at 8 A, and a 1-4 scaling factor of 0.5.
The steepest descent algorithm was used in the beginning of each energy minimization,
followed by the Powell algorithm. The x-ray structure of RsSTS in complex with
secologanin 2 (PDB ID: 2FPC) 22 1 was first edited to remove the B monomer. The termini
were capped, hydrogens were added in random orientations and His307 was defined as
protonated. Kollman All Atom types were assigned with Pullman charges for the
biopolymer and ligands. Geometry minimization of only the enzyme hydrogens and
water molecules was followed by minimization including the side-chains and lastly, the
main-chain. The free carbon atom on C14 (obtained after deletion of acetaldehyde and
two protons on secologanin 2 in the minimized crystal structure) was joined to one of the
methyl hydrogen atoms of the small-molecule QM-derived structures (Figure 4.10),
which had been loaded into the molecular modeling software. The atoms were defined
with Kollman types. N4 and C7 were assigned a formal positive charge of unity that was
distributed as partial charges according to Pullman.
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CHAPTER 5
SYNTHESIS AND BIOCHEMICAL EVALUATION OF DES-VINYL SECOLOGANIN
AGLYCONES WITH ALTERNATIVE STEREOCONFIGURATION
Part of this chapter is published as a communication in
Tetrahedron letters 2009, 50, 7118-7120.
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5.1 Introduction
Biogenetic compounds are polyfunctional molecules that occupy a central position in
biosynthetic pathways and are, therefore, precursors for a multitude of natural products.E1
For example, the seco-iridoid p-D-glucoside, secologanin 1, is the precursor for all
monoterpene indole alkaloids (MIAs) in several medicinal plants, including
Catharanthus roseus, Ophiorrhiza pumila, and Rauvolfia serpentina. [2] In these plants 1
reacts with tryptamine 2 to form strictosidine 3; a reaction catalyzed by strictosidine
synthase (STS). Secologanin 1 is a densely functionalized molecule that contains three
stereogenic centers on its dihydropyran core [2(S)3(R)4(S)], and only this stereoisomer of
1 occurs naturally (Figure 5.1).
Galan et al. modified secologanin 1 by semi-synthesis - the ester group by
transesterification reactions and the vinyl group by olefin metathesis reactions. 3 STS
does not accept secologanin analogs with olefin substitutions, but C. roseus cell cultures
that contain STS convert secologanin analogs with alternate ester groups into MIA
analogs. 4 Access to aglycone analogs and alternative stereosiomers of 1, however, is not
possible by semi-synthesis (Dr. C. Galan, unpublished). These analogs can be
synthesized using a tandem Knoevenagel-hetero-Diels-Alder (KHDA) reaction where an
electron-rich vinyl ether reacts with an in situ-formed diene.["'1' This chapter describes
the application of the KHDA domino reaction in the synthesis of a series of des-vinyl
secologanin aglycone stereoisomers.[71 I show that STS accepts more than one
stereoisomer,[7] and describe a synthetic route to des-vinyl strictosidine analogs with
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Figure 5.1 Secologanin 1 is a densely functionalized molecule with three stereogenic centers on
its dihydropyran (DPH) core. The glycoside is linked in a p-anomer configuration.
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Figure 5.2 (A) Rauvolfia serpentina STS in complex with secologanin (PDB ID: 2FPC). The
glucose moiety (red) hydrogen bonds with two histidine residues (His277 and His307). (B)
Without the glucose group (gray) the secologanin binding pocket could potentially accommodate
substrates with different geometries.
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photo-labile acetal protective groups. These orthogonally protected molecules, which are
stable to deglucosylation by strictosidine glucosidase (SGD), are potentially useful in the
temporal control of alkaloid biosynthesis.
5.2 Results and discussion
The x-ray crystal structure of R. serpentina STS in complex with secologanin 1 (PDB ID:
2FPC) suggests that the glucose moiety forms hydrogen bonds with His277 and His307
(Figure 5.2).8] I hypothesized that the glucose moiety plays a key role in correctly
orienting secologanin and, therefore, impedes catalysis using alternative secologanin
stereoisomers; removing or replacing the glucose moiety would leave sufficient space in
the secologanin binding site to accommodate the alternative stereoisomers.
5.2.1 Synthesis of KHDA substrates
Tietze's tandem Knoevenagel-hetero-Diels-Alder reaction (KHDA) gives 2,4-
disubstituted dihydropyrans from three accessible substrates: an enol, an aldehyde, and a
vinyl ether.E1 '5 '6 3 Tietze et al. describe the synthesis of enol 5 in two steps (Figure 5.3,
reactions a-b) (section 5.4.3).E93 The first step is a conjugate addition reaction between
ethyl vinyl ether 10 and trichloroacetyl chloride 4. The second step is the reaction of the
a,p--unsaturated carbonyl intermediate with formic acid to give 4. 1H NMR revealed that
4 exists as the cis-enol isomer (enol/aldehyde, 96:4, only cis).
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The aldehyde substrate of the KHDA reaction is a monoprotected malondialdehyde, since
the prochiral aldehyde atom of secologanin 1 must be protected until the final step in the
synthesis. Previous reports use a cyclic acetal protective group, which cannot be removed
selectively in the presence of another acid-labile acetal (C2). I envisioned that an acyclic
acetal, which permits the use of milder deprotection conditions, would leave the C2-
acetal intact. This turned out to be true and KHDA reactions that proceed at room
temperature employ diethoxyacetal 8. Acetal 8, however, decomposes upon heating and
KDHA reactions that require heating therefore use the more stable dioxane aldehyde 9,
although the dioxane protective group is difficult to remove, leading to low yields in the
final deprotection step (section 5.2.3).
Several protocols, based on non-selective deprotection-reprotection sequences, exist for
the synthesis of monoprotected malondialdehydes. These protocols require two arduous
purification steps resulting in low yields (typically, 30-50%). I therefore sought a more
convenient source of dialdehyde equivalent. Dess-Martin periodinane (DMP)I1 1.15]
triggered the formation of aldehydes 8 and 9 via oxidation of the commercially available
alcohols: 3,3-diethoxy-1-propanol 6 and 2-(5,5,-dimethyl-1,3-dioxan-2-yl)ethanol 7,
respectively, in high yields (>90%) (Figure 5.3, reactions c and d).
Vinyl ethers with ethyl, i-butyl (i-Bu), t-butyl (t-Bu), and cyclohexyl (Cy) substituents
10-13 (R group in Figure 5.3) are commercially available; o-nitrobenzyl vinyl ether 16
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Figure 5.3 Synthesis of starting materials for the KHDA reaction: (a) ethyl vinyl ether 10 (1.5
eq), pyridine (1 eq); (b) formic acid, 88% over 2 steps; (c) DMP (1.1 eq), DCM, 90%; (d) DMP
(1.2 eq), DCM, 97%; (e) vinyl acetate (2 eq), [IrCl(cod)]2 (2 mol-%), NaCO3 (0.6 eq) or NaOAc
(1.2 eq), toluene, 56-80%.
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and 4,5-dimethoxy-2-nitrobenzyl vinyl ether 17 are synthesized in the dark from the
corresponding alcohols 14-15 and vinyl acetate in a vinyl transfer reaction catalyzed by
the air-stable dimeric Ir(I)-complex, [Ir(cod)Cl] 2 (Figure 5.3, reaction e) (section
5.4.3).[16]
5.2.2 Synthesis of des-vinyl secologanin analogs
The KHDA reaction between chloroacetyl 5, aldehyde 8, and vinyl ethers 10-13, in the
presence of potassium fluoride, resulted in the formation of a mixture of cyclodduct
stereoisomers (Figure 5.4A, section 5.4.3). After a brief silica gel chromatography step
that partially purified the desired regioisomers, [5] methanolysis in the presence of 1,8-
diazabicycloundec-7-ene (DBU) lead to the formation of methyl esters 18-21. Finally,
mild hydrolysis of the acyclic acetal of 18-21 in aqueous oxalic acid and silica gel[17 l
afforded aldehydes 22-25. The two sets of enantiomers separate during silica gel
chromatography; the 2,4-trans and 2,4-cis configurations are distinguished by the
splitting of the acetal proton signal ~ 5 ppm: cis: (t, J= 2-3), trans: (dd, J= 2-3, 7-8).PI
O-nitrobenzyl ethers can be deprotected with UV-light (350 nm) to generate
nitrosobenzaldehyde along with the deprotected alcohol. 18 Thus, substitution of the
glucose moiety of secologanin 1 for an o-nitrobenzyl group generates an unstable hemi-
acetal upon irradiation at 350 nm. This photodeprotection reaction is analogous, but
orthogonal, to the SGD-catalyzed deglucosylation reaction, since only the synthetic
strictosidine analog contains a photocleavable group.
169
0 OH
C13C0C
5
EtO OEt
OHC
8
-5 OR
a10-13 -
Compound R=
1 s-D-Glc 3-vinyl
10, 18, 22 Et
11, 19,23 i-Bu
12,20,24 t-Bu des-vinyl
13,21,25 Cy
trans/cis
selectivity, %
70
60
50
40
30
20-
10- R
0-
= Et
CHO
OEt 4 20R
OR c NO
O 83-94%. MeO2 trans-22-25C CHO
R'I= CC13O
R'= OMe, 18-21
4-22 %, MeO 2C cis-22-25
R = Cy
R = i-Bu R = t-Bu
22 23
compound
Figure 5.4 (A) Synthesis of des-vinyl secologanin 0-analogs. (a) postassium fluoride (50 mg
mmol-1 10-13), DCM; (b) DBU (0.01 eq), MeOH, 14-22% over 2 steps; (c) oxalic acid and silica
gel (each 10% w/v), THF/water (4:1), 83-94%. (B) Diastereoselectivity of C. roseus STS for 22-
25.
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Figure 5.5 Synthesis and application of o-nitrobenzyl protected des-vinyl secologanin 0-analog
27. (A) Synthesis of dioxane protected methyl ester 26. (a) postassium fluoride (50 mg mmol-1
16), toluene, A; (b) DBU (0.01 eq), MeOH, 43% over 2 steps. (B) Synthesis and deprotection of a
tetrahydro-p-carboline derived from 27. (a) aq. HCl in THF/water (4:1), A, 14%; (b) tryptamine
2, TFA (cat.), DCM; (c) irradiation at 350 nm (Appendix C).
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The heated KHDA reaction (performed in the dark, to prevent unwanted
photodecomposition) between chloroacetyl 5, aldehyde 9, and o-nitrobenzyl vinyl ether
16, followed by methanolysis, prepared dioxane-protected methyl ester 26 in two steps
with 43% overall yield (Figure 5.5A). After considerable optimization, I found
deprotection conditions that produced aldehyde 27 in low yield (14%), albeit with good
recovery of the starting material (Figure 5.5A and section 5.4.3).
5.2.3 Biochemical characterization of des-vinyl secologanin analogs
There were no previous reports on the characterization of des-vinyl secologanin analogs
as substrates for STS. I therefore determined the activity of STS with each diastereomer
of aldehydes 22-25 by monitoring the appearance of tetrahydro-s-carboline products 30-
33 in the presence of tryptamine 2 using LC-MS (Figure 5.4B, section 5.4.2). STS
catalyzed the Pictet-Spengler reaction with all aldehyde substrates: the 2,4-trans
configuration of secologanin 1 and the unnatural 2,4-cis configuration (Appendix C). For
smaller aldehydes 22-24, the trans/cis selectivity is low (de = 5-10%), whereas for 25 the
selectivity for the trans configuration is significantly higher (de >60%) (Figure 5.4B).
Consequently, increased acetal substituent size correlates with a preference by STS for
the trans configuration - the relative stereochemistry of the natural substrate, secologanin
1.
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Enzyme assays with photolabile o-nitrobenzyl ether analogs revealed that they are not
accepted by STS, since no product forms when 27 is incubated when tryptamine 2 in the
presence of the enzyme. Therefore, the secologanin binding site is likely not compatible
with the larger aromatic O-substituent. Nevertheless, I used a chemical Pictet-Spengler
reaction between tryptamine 2 and 27 in the presence of TFA in DCM (Figure 5.5B).
Under these conditions the tetrahydro-p-carboline product formed with good conversion
(Appendix C). Subsequent irradiation by UV-light at 350 nm led to the appearance of the
expected deprotected compound (Figure 5.5B and Appendix C), though one of the next
enzymes in the MIA pathway - a partially purified reductase (N. Yerkes, unpublished) -
showed no activity under the deprotection conditions.
5.3 Conclusions
This chapter describes the total synthesis and biochemical evaluation of a series of des-
vinyl secologanin analogs (22-25 and 27). STS accepts unnatural stereoisomers and the
stereochemical flexibility of STS is higher when the acetal substituent is smaller. There
is, thus, a trade-off between higher activity and relaxed stereoselectivity. For example,
STS from the camptothecin-producing plant, 0. pumila, catalyzes the Pictet-Spengler
reaction between tryptamine 2 and small achiral aldehydes, but with rates -1000-fold
lower than when using secologanin 1.[191 Des-vinyl secologanin derivatives are all better
substrates for STS than the achiral aldehydes, though 22-25 are, qualitatively, still less
accepted than 1. Because STS prefers secologanin 1, the secologanin binding site of STS
requires larger aldehydes for optimal activity, preferably aldehydes that contain the
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Figure 5.6 (A) Aldehydes of increasing size and hydrophilicity are preferred by STS. (B) The
glucose and seco-iridoid moieties form several interactions with the secologanin binding site. By
decreasing size of the aldehyde substrate, the binding site accommodates alternate aldehyde
stereoisomers, albeit at the cost of reduced activity.
174
OHC,,
'C)
rer 18
low activity
OC O-P-D-Glc
MeO2C
EtO OEt
OH
6
13
O O0
7 C
HO
14
NH2
H
2
EtO OEt
H CHO
N0 2
EtO OEt EtO OEt
Me0 2 C N0 MeO2 C N
19
CHO
NO N
MeO2C
24
20
C13C Cl
4
0 ( 0
CHO
10
HO
MeONO2
MeO
15OMe
16 17
EtO OEt CHO
MeO 2C O e2
21
CHO
MeO 2C N 0
25
O OH
5
11 12
EtO OEt
1O2
MeO2C
18
CHO
yO - 0
0- NO
2 23
CHO 0 2N N
N~0
Me0 2C 27
CHO 0 2N OMe
0O OMe
MeO2 C N 0
34
Figure 5.7 Structures of compounds mentioned in this chapter.
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glucose moiety (Figure 5.6A). 20 1 The glucose moiety, however, restricts the ability of
STS to form unnatural stereoisomers (Chapter 6) and removing the glucose moiety allows
the turnover of alternative stereoisomers (Figure 5.6B). Mutations targeting the substrate
binding sites of STS modulate substrate specificity,2 1 ,2 2 1 and mutations that decrease the
volume or change the electrostatic properties of the secologanin binding site could
potentially increase the activity of STS with smaller, more hydrophobic, analogs of 1.
The introduction of an orthogonal acetal protective group to strictosidine 3 avoids the
deglucosylation process and enables the selective cleavage of the unnatural o-nitrobenzyl
ether linkage using UV light. This strategy may be useful in the temporal control of
pathway induction. However, installing the vinyl group is likely key for practical use,
since that would allow access to the full profile of monoterpene indole alkaloids.
5.4 Experimental methods
5.4.1 General methods and analytical techniques
All chemicals were used as received from the supplier. All glassware were oven dried,
evacuated, and filled with argon. STS was expressed in E. coli BL21(DE3) and purified
by affinity chromatography using a hexa-His tag as previously described. [22]
UPLC analysis was performed using an Acquity Ultra Performance BEH C18 column
with a 1.7 ptm particle size, 2.1 x 100 mm dimension, and a flow rate of 0.6 mL min-'.
The column elution was coupled to MS analysis carried out using a Micromass LCT
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Premier TOF Mass Spectrometer with an ESI source. Both modules are from Waters
Corporation (Milford, MA). The capillary and sample cone voltages were 3000 V and 30
V, respectively. The desolvation and source temperatures were 300 and 100 'C,
respectively. The cone and desolvation gas flow rates were 60 and 800 L h-1. Analysis
was performed with MassLynx 4.1 and integrations were carried out using QuantLynx.
1H NMR and 13C NMR spectra were recorded on Varian 300 MHz, Varian 500 MHz, or
Brucker 400 MHz spectrometers.
5.4.2 Diastereoselectivity of STS
Secologanin aglycone analogs 22-25 (1 mM) were incubated with tryptamine 2 (0.5 mM)
in the presence of C. roseus STS (0.5 RM) in sodium phosphate buffer (0.025 M, pH 7.0)
at 30 *C. Control reactions containing enzyme storage buffer were treated the same way
and were used for comparison. The reaction mixtures were quenched by addition of
HPLC-grade MeOH containing yohimbine (internal standard) and then analyzed by
UPLC-MS using the following method: 25% 5 min, 25-90% 3 min, 90-25% 1 min, 25%
1 min; flow-rate: 0.6 mL min-'; MS-method: m/z 200-700 detected as centroided masses
in W-mode using a reference compound (reserpine). Exact masses: compound 28: (0-
ethyl), ESI-MS(C 2 H27N204+) m/z calculated: 371.1971 [M+H]*, found: 371.1976
[M+H]*; Compound 29: (0-i-Bu), ESI-MS(C 23H31N2 04+) m/z calculated: 399.2284
[M+H]*, found: 399.2366 [M+H]*; Compound 30: (0-t-Bu), ESI-MS(C 23H31 N204*) m/z
calculated: 399.2284 [M+H]*, found: 399.2379 [M+H]*; Compound 31: (0-Cy), ESI-
MS(C 25H33N204*) m/z calculated: 425.2440 [M+H]*, found: 425.2488 [M+H]*. The
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initial rate was monitored by integrating the product peaks and normalizing the areas to
the internal standard peak (yohimbine). Relative rates representing the
diastereoselectivity of STS are reported as the average of three experiments.
5.4.3 Chemical synthesis of des-vinyl secologanin analogs
1,1, 1-trichloro-4-ethoxybut-3-en-2-one 32
C13C C1 0
4 , C 3C 0O
neat 32
10
Ethyl vinyl ether 10 (33 mL, 75 mmol, 1.5 eq) was added to trichloroacetyl chloride 4 (28
mL, 50 mmol, 1.0 eq) under argon at 0 *C. The reaction was allowed to warm to room
temperature and was stirred for 17 h. Pyridine (20 mL, 55 mmol, 1.1 eq) was then added
dropwise under vigorous stirring at 0 *C resulting in a color change from yellow to dark
red, accompanied by gas evolution and the formation of a precipitate. The reaction was
allowed to warm to room temperature until TLC (hex/ether, 5:1) indicated complete
conversion (- h). The reaction was first diluted with 10 volumes of water and then
extracted with ether. Filtration of emulsified organics through a combined celite - silica
gel plug facilitated removal of salts. Evaporation of the solvent left a red oil that was
purified by flash column chromatography (SiO 2, hex/EtOAc, 15:1) to afford 32 as a
yellow oil. rf = 0.56 (hex/ether, 5:1); 1H NMR (300 MHz, CDCl 3): 8 7.86 (dt, 1H, J =
0.34, 12.1), 6.15 (d, 1H, J= 12.1), 4.10 (dq, 2H, J= 0.34, 7.1), 1.40 (t, 3H, J= 7.1); 13C
NMR (125 MHz, CDCl 3): 8 181.38, 167.79, 97.04, 96.42, 68.98, 14.72.
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Formic acid (50 mL) was added to 1,1,1-trichloro-4-ethoxybut-3-en-2-one 32 (10 mmol)
and the mixture was stirred at room temperature until TLC (hex/ether, 5:1) indicated
complete conversion (24 h). The reaction was extracted with ether (5 x 60 mL) and the
combined organic fractions were carefully evaporated under reduced pressure (20 *C), to
afford a volatile yellow oil in analytical purity (8.4 g, 44 mmol, 88% over 2 steps).
Compound 4 is not stable under silica gel chromatography conditions but is stable for
several months when stored at -80 *C. 1H NMR (300 MHz, CDCl 3): 6 12.44 (s, 1H), 7.61
(d, 1H, J= 5.7), 6.18 (d, IH, J= 5.7); 13 C NMR (75 MHz, CDCl 3): 8 186.9, 171.6, 95.7.
3,3-diethoxypropanal 8
EtO OEt EtO OEt
DMP
DCM CHO
OH6 8
Dess-Martin periodinane (DMP, 4.8 g, 11 mmol, 1.1 eq) was added to a solution of 3,3-
diethoxy-1-propanol 6 (1.5 g, 10 mmol, 1.0 eq) in DCM (100 mL) at 0 *C. The reaction
was stirred at 0 *C for 5 min, warmed to room temperature and then stirred for an
additional 45 min. The reaction was diluted with DCM (100 mL) and quenched by the
successive addition of a saturated aqueous solution of sodium bicarbonate (50 mL) and a
concentrated aqueous solution of sodium thiosulfate (50 mL) until the white precipitate
dissolved. The layers were separated and the aqueous layer was extracted with DCM (3 x
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20 mL). The combined organic layers were washed with a (1:1) mixture of sodium
bicarbonate/sodium thiosulfate, water, and brine, and dried over anhydrous sodium
sulfate. After evaporation of the solvent in vacuo, the residue was purified by column
chromatography (SiO 2 , hex/ether, 3:1) to afford 3,3-diethoxy-1-propanal 8 (1.3 g, 9.0
mmol, 90%). rf = 0.56 (hex/ether 1:3); 'H NMR (300 MHz, CDCl 3): 8 9.72 (t, 1H, J=
2.3), 4.93 (t, 1H, J= 5.5), 3.65 (qd, 1H, J= 7.1, 9.3), 3.52 (qd, 1H, J= 7.1, 9.3), 2.70 (dd,
1H, J = 2.3, 5.5), 1.78 (t, 1H, J = 7.1); 13C NMR (75 MHz, CDCl 3): 8 200.17, 98.85,
62.30, 48.22, 15.40.
2-(5,5-dimethyl-1,3-dioxan-2-yl)ethanal 9
o o DMP , O O
DCM
CHO
OH
7 9
A reaction between DMP (5.1 g, 12 mmol, 1.2 eq) and 2-(5,5-dimethyl-1,3-dioxan-2-
yl)ethanol 7 (1.6 g, 10 mmol, 1.0 eq) was treated as described for the synthesis of 3,3-
diethoxy-1-propanal 8. Purification by flash column chromtography (SiO 2 , hex/ether 3:1)
afforded aldehyde 9 (1.5 g, 9.7 mmol, 97%) as a clear oil. rf = 0.69 (hex/ether 1:3); IH
NMR (300 MHz, CDCl 3): 6 9.81 (1H, t, J= 2.4), 4.86 (1H, t, J= 4.5), 3.61 (2H, d, J=
10.0), 3.45 (2H, d, J= 10.5), 2.68 (1H, dd, J= 2.4, 4.6), 1.17 (3H, s), 0.72 (3H, s); ESI-
MS(CsH 1 403+) m/z calculated: 159.1016 [M+H]*, found: 159.1008 [M+H]*
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In a Schlenk flask under a stream of argon in the dark, [IrCl(cod)] 2 (0.067 g, 0.1 mmol,
0.01 eq) was added to a toluene solution (10 mL) of o-nitrobenzyl alcohol 14 (1.5 g, 10
mmol, 1.0 eq), sodium carbonate (0.64 g, 6.0 mmol, 0.6 eq) and vinyl acetate (1.7 g, 20
mmol, 2.0 eq). The mixture was heated to 100 *C and stirred at this temperature for 7 h.
The reaction was then diluted with wet ether (20 mL) and filtered through SiO 2, eluting
with ether. After evaporation of the solvents, the residue was purified by flash column
chromatography (SiO 2, hex/DCM, 2:1) to afford vinyl ether 16 (1.0 g, 5.6 mmol, 56%). rf
= 0.57 (hex/DCM, 1:2); 1 H NMR (300 MHz, CDCl 3): 8 8.10 (dd, 1H, J= 1.3, 8.2), 7.69
(td, 11, J= 0.4, 7.0), 7.64 (dt, 1H, J= 0.3, 7.9), 7.44 (dt, 1H, J= 0.7, 7.3), 5.86 (dd, 1H,
J= 6.5, 14.0), 5.15 (s, 2H), 4.33 (dd, 1H, J= 2.5, 14.3), 4.13 (dd, 1H, J= 2.4, 6.8); "C
NMR (75 MHz, CDCl 3): 6 151.19, 146.95, 134.05, 133.87, 128.60, 128.35, 124.992,
88.56, 66.93; ESI-MS(C9 H9 NO3*) m/z calculated: 202.0475 [M+Na]*, found: 202.0482
[M+Na]*.
4,5-dimethoxy-2-nitrobenzyl vinyl ether 17
0 OH NO2  [IrCl(cod)12  0 NO2
NaOAc
M tolueneMe
10 15 A 17 Oe
OMe OMe
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In a Schlenk flask under a stream of argon in the dark, [IrCl(cod)] 2 (0.027 g, 0.04 mmol,
0.02 eq) was added to a toluene solution (5 mL) of 4,5-dimethoxy-2-nitrobenzyl alcohol
15 (0.42 g, 2.0 mmol, 1.0 eq), sodium carbonate (0.17 g, 1.6 mmol, 0.6 eq), and vinyl
acetate (0.34 g, 4.0 mmol, 2.0 eq). The mixture was heated to 110 *C and stirred at this
temperature for 3 h. The reaction was then diluted with wet ether (20 mL) and filtered
through SiO 2 eluting with ether. After evaporation of the solvents, the residue was
purified by flash column chromatography (SiO 2, hex/EtOAc, 5:1 to 2:1) to afford vinyl
ether 17 (0.30 g, 1.2 mmol, 62%). 1H NMR (300 MHz, CDCl 3): 8 7.73 (s, 1H), 7.22 (s,
1H), 6.57 (dd, 1H, J= 6.8, 14.3), 5.18 (s, 2H), 4.39 (dd, 1H, J= 2.4, 14.3), 4.16 (dd, 1H,
J = 2.4, 6.8), 3.98 (s, 3H), 3.94 (s, 3H); ESI-MS(C1 1 H1 4NO5*) m/z calculated: 240.0866
[M+H]*, found: 240.0869 [M+H]*.
methyl 4-(2,2-diethoxyethyl)-2-ethoxy-3,4-dihydro-2H-pyran-5-carboxylate 18
O OH
C13C O 
EtO OEt
5 10 KF DBU
DCM MeOH MeO 2C O
CHO 188
Potassium fluoride (100 mg) was added to a solution of trichloroacetyl 5 (1.0 g, 5.2
mmol, 2.0 eq) and 3,3,-diethoxy-1-propanal 8 (0.58 g, 5.2 mmol, 2.0 eq) in anhydrous
DCM (10 mL) under an argon atmosphere, accompanied by a color change from yellow
to orange-red. Ethyl vinyl ether 10 (0.19 g, 0.25 mL, 2.6 mmol, 1.0 eq) was then added
dropwise and the reaction was allowed to stir at 22 "C for 16 h. The reaction was diluted
with ether and filtered through water-deactivated aluminum oxide (eluted with ether).
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After evaporation of the solvents, the residue was partially purified by flash column
chromatography (SiO 2 , hex/MTBE, 5:1). The partially purified cycloadducts (0.52 mg)
were dissolved in anhydrous methanol (20 mL) and DBU was added (0.1 mL). When
TLC indicated a completed reaction (10 min), the solvent was evaporated under reduced
pressure and the residue was purified by flash column chromatography (hex/ether, 5:1) to
afford ester 18 as a clear oil (0.15 g, 0.49 mmol, 19% over 2 steps, 63:37 cis vs. trans
cycloadduct). cis-18: 1H NMR (600 MHz, CDCl 3): 8 ppm 7.43 (s, 1H), 5.10-5.07 (m,
1H), 4.64 (dd, 1H, J= 5.1, 7.0), 3.93 (dq, 1H, J= 7.1, 14.3), 3.70-3.40 (m, 5H), 3.66 (s,
3H), 2.66-2.59 (m, H), 2.10-2.03 (m, 1H), 2.03-1.89 (m, 2H), 1.80 (ddd, 1H, J= 2.9),
1.21 (t, 3H, J= 7.1), 1.19-1.13 (m, 6H); 13C NMR (200 MHz, CDCl3): 8 ppm 168.0lb,
167.85a, 153.44b, 152.25a, 110.63a, 109.80b, 101.70b, 101.52a, 98.44a,b, 65.30b,
64.74a, 62.41b, 61.78a, 59.85b, 59.25a, 51.32a,b, 51.30ab, 38.53b, 36.15a, 31.46b,
29.60a, 26.60b, 24.54a, 15.52-15.29; trans-18: 'H NMR (600 MHz, CDCl 3): 8 ppm 7.43
(s, 1H), 4.97 (dd, 1H, J= 1.7, 9.1), 4.58 (t, 1H, J= 5.7), 3.79 (dq, 1H,J= 7.1, 14.2), 3.70-
3.40 (m, 5H), 3.66 (s, 3H), 2.75-2.70 (m, 1H), 2.10-2.03 (m, 1H), 2.03-1.89 (m, 2H), 1.72
(ddd, 1H, J= 5.9, 9.1, 14.3), 1.47 (ddd, 1H, J= 5.4, 9.8, 14.5, 1.21), 1.19-1.13 (m, 9H,
b); ESI-MS(C15H2606) m/z calculated: 325.1622 [M+Na]*, found: 325.1623 [M+Na]*.
methyl 2-ethoxy-4-(2-oxoethyl)-3,4-dihydro-2H-pyran-5-carboxylate 22
EtO OEt
oxalic acid CHO
O ,, silica gel
5, 1, 0 THF/waterMeO2C MeO 2C O 22
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A slurry (1 mL water with 100 mg dissolved oxalic acid and 100 mg silica gel) was
added to a solution of acetal 18 (0.15 g, 0.50 mmol) in THF (4 mL) and the mixture was
stirred at 75 *C for 3 h. One water volume-equivalent of toluene was added to the
reaction and the solvents were evaporated under reduced pressure. The residue was
dissolved in ether with 1% TEA and filtered through silica gel. The filtrate was
evaporated under reduced pressure and the residue was purified by flash column
chromatography (SiO 2 , hex/MTBE/TEA, 5:1:0.01) to afford separated diastereomers of
22 (d.e. >95%): cis-adduct (76 mg, 0.33 mmol, 66%); trans-adduct (24 mg, 0.10 mmol,
21 %). cis-22: 1H NMR (CDCl 3, 400 MHz): 5 9.74 (t, 1H, J= 1.2), 7.50 (d, 1H, J= 0.5),
5.14 (t, 1H, J= 2.5), 3.78 (dq, 1H, J= 7.1, 9.5), 3.68 (s, 3H), 3.50 (dq, 1H, J= 7.1, 9.5),
3.11-3.05 (m, 1H), 2.99 (ddd, 1H, J= 1.3, 9.6, 17.7), 2.75 (ddd, 1H, J= 1.0, 3.4, 17.4),
2.00 (td, 1H, J= 2.2, 14.4), 1.89 (ddd, IH, J= 2.8, 6.7, 14.4), 1.16 (t, 3H, J= 7.1; 13C
NMR (CDCl 3, 100 MHz): 5 202.43, 167.67, 153.10, 108.81, 97.96, 64.87, 51.46, 47.87,
30.06, 22.34, 15.29; trans-22: 'H NMR (CDCl 3, 500 MHz): 5 9.74 (t, 1H, J= 1.2), 7.49
(d, 1H, J= 1.1), 4.97 (dd, 1H, J= 2.4, 7.5), 3.90 (dq, 1H, J= 7.1, 9.5), 3.68 (s, 3H), 3.58
(dq, 1H, J= 7.1, 9.5), 3.24-3.18 (m, 1H), 2.87 (ddd, 1H, J= 1.2, 4.2, 16.9), 2.38 (ddd,
1H, J= 2.2, 9.0, 16.9), 1.93 (ddd, 1H, J= 6.2, 7.3, 13.7), 1.77 (ddd, 1H, J= 2.4, 5.2,
13.9), 1.21 (t, 3H, J = 7.1); ESI-MS(C 11H1605)) m/z calculated: 251.0890 [M+Na]*,
found: 251.0884 [M+Na]*.
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Methyl 4-(2,2-diethoxyethyl)-2-isobutoxy-3,4-dihydro-2H-pyran-5-carboxylate 19
0 OH
C13C EtO OEt
5 KF DBU O
EtO OEt 11 DCM MeOH 0MeO 2C
CHO 19
8
Potassium fluoride (0.2 g) was added to a solution of 3,3-diethoxy-1-propanal 8 (0.48 g,
3.3 mmol, 1.5 eq) and 1,1,1-trichloro-4-hydroxybut-3-en-4-ol 5 (0.63 g, 3.3 mmol, 1.5
eq) in anhydrous DCM (10 mL) under an argon atmosphere. The mixture quickly
changed color from yellow to dark orange. Isobutyl vinyl ether 11 was then added drop-
wise (0.22 g, 2.2 mmol, 1 eq) and the reaction was continued for 21 h, and then diluted
with ether and filtered through deactivated aluminum oxide. After evaporation under
reduced pressure, the residue was purified by flash column chromatography (SiO 2 6.2 x
2.5 cm, 7-mL fractions, hex/MTBE, 10:1). The pure fractions were combined and the
solvent evaporated under reduced pressure to yield trichloroacetyl cycloadducts (107 mg,
0.26 mmol, 17%) as a pale yellow oil. A second compound was isolated and verified as
the alternate (but undesired) cycloadduct (63 mg, 7%). Attempted rearrangement in acid
(pTsOH in chloroform) did not transform this compound into the desired product with rf
= 0.70 (hex/MTBE, 1:1). To a solution of this product (105 mg, 0.25 mmol) in anhydrous
methanol (3 mL) under argon atmosphere was added DBU (100 mg) and the reaction was
stirred for 20 min at room temperature. Most of the solvent was evaporated under
reduced pressure, the yellow oil was dissolved in ether and filtered through a short silica
gel column. The eluant was evaporated under reduced pressure and the residue contained
analytically pure methyl ester 19 (81 mg, 0.25 mmol, 99%). cis-19: 1H NMR (300 MHz,
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CDC13): 6 7.42 (s, 1H), 5.07 (t, 1H, J= 2.7), 4.65 (dd, 1H, J= 5.6, 6.6), 3.65 (s, 3H),
3.68-3.40 (m, 4H), 3.52 (dd, 1H, J= 6.5, 9.1), 3.19 (dd, 1H, J= 6.4, 9.1), 2.66-2.57 (m,
1H), 2.11 (td, 1H, J= 2.3, 14.2), 2.02-1.70 (m, 4H), 1.19-1.10 (m, 6H), 0.84 (dd, 6H, J=
1.4, 6.7); 13C NMR (125 MHz, CDCl 3): 6 167.99, 152.20, 110.60, 101.77, 98.81, 96.09,
61.93, 58.77, 51.28, 36.05, 29.11, 28.62, 24.29, 19.41, 15.47, 15.54. trans-19: 'H NMR
(300 MHz, CDCl 3): 6 7.42 (s, 1H), 4.94 (dd, 1H, J= 2.2, 9.0), 4.57 (t, 1H, J= 5.7), 3.65
(s, 3H), 3.68-3.40 (m, 5H), 3.25 (dd, 1H, J= 6.9, 9.3), 2.72 (dq, 1H, J= 3.5, 6.4), 2.02-
1.70 (m, 4H), 1.46 (ddd, 1H, J= 5.4, 9.7, 14.3), 1.19-1.10 (m, 6H), 0.87 (dd, 6H, J= 2.2,
6.7); 13C NMR (125 MHz, CDCl 3): 6 167.84, 153.46, 109.78, 101.77, 98.81, 76.44,
62.33, 59.97, 51.28, 38.46, 31.40, 26.35, 19.35, 15.54, 15.47; ESI-MS(C 7H3oO6 ) m/z
calculated: 353.1940 [M+Na]*, found: 353.1957 [M+Na]*.
Methyl 2-isobutoxy-4-(2-oxoethyl)-3,4-dihydro-2H-pyran-5-carboxylate 23
EtO OEt CHO
oxalic acid o
0 -I silica gel
MeO 2C 0 THF/water MeO 2C19 23
A slurry (1 mL water with 100 mg dissolved oxalic acid and 100 mg silica gel) was
added to a solution of acetal 19 (80 mg, 0.25 mmol) in THF (4 mL). The mixture was
stirred at 60 *C for 3 h. The reaction was quenched by addition of solid anhydrous
sodium bicarbonate (200 mg). After filtration, the solvent was evaporated under reduced
pressure. The residue was purified by flash column chromatography (SiO 2,
hex/MTBE/TEA, 5:1:0.01) to afford separated diastereomers of 23 (d.e. >95%): cis-
adduct (28 mg, 0.10 mmol, 54%); trans-adduct (20 mg, 0.078 mmol, 39 %). cis-23: IH
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NMR (500 MHz, CDC13): 8 9.75 (t, 1H, J= 1.3), 7.49 (d, 1H, J= 0.7), 5.11 (t, 1H, J=
2.5), 3.68 (s, 3H), 3.51 (dd, 1H, J= 6.7, 9.2), 3.21 (dd, 1H, J= 6.4, 9.2), 3.14-3.05 (m,
1H), 2.99 (ddd, 1H, J= 1.4, 9.6, 17.4), 2.80-2.70 (m, 1H), 2.03 (td, 1H, J= 2.1, 14.5),
1.93-1.84 (m, 1H), 1.80 (dd, 1H, J = 6.6, 13.4), 0.85 (d, 6H, J = 6.6); 13 C NMR (125
MHz, CDCl 3): 8 202.32, 167.65, 153.04, 108.84, 98.39, 76.26, 51.43, 48.00, 29.83,
28.58, 22.24, 19.46, 19.44.trans-23: 1H NMR (500 MHz, CDCl 3): 6 9.74 (t, 1H, J= 1.8),
7.49 (d, 1H, J= 1.1), 4.95 (dd, 1H, J= 2.4 7.2), 3.67 (s, 3H), 3.61 (dd, 1H, J= 6.6, 9.2),
2.27 (dd, 1H, J= 6.8, 9.2), 3.24-3.18 (m, 1H), 2.88 (ddd, 1H, J= 1.5, 4.2, 17.0), 2.38
(ddd, 1H, J= 2.1, 9.0, 17.0), 1.96 (td, 1H, J= 6.4, 13.7), 1.84 (td, 1H, J= 6.7, 13.4), 1.76
(ddd, 1H, J= 2.4, 5.5, 13.9), 0.88 (dd, 6H, J= 3.4, 6.7); 13C NMR (125 MHz, CDCl 3): 6
201.28, 167.51, 154.15, 108.29, 98.17, 76.32, 51.45, 48.65, 32.49, 28.62, 23.79, 19.42,
19.38; ESI-MS(Cl3 H2005+) m/z calculated: 279.1208 [M+Na]*, found: 279.1209
[M+Na]+.
Methyl 2-tert-butoxy-4-(2,2-diethoxyethyl)-3,4-dihydro-2H-pyran-5-carboxylate 20
0 OH
C13C O 
EtO OEt
5 KF DBU O
EtO OEt 12 DCM MeOH M o
" CHO MeO2C 2CHO 20
8
Potassium fluoride (0.17 g) was added to a solution of 3,3,-diethoxy-1-propanal 8 (0.44 g,
3.0 mmol, 1.5 eq) and trichloroacetyl 5 (0.46 g, 2.4 mmol, 1.2 eq) in anhydrous DCM (10
mL) under an argon atmosphere, accompanied by a color change from yellow to orange-
red. tert-butyl vinyl ether 12 (0.20 g, 2.0 mmol, 1.0 eq) was added dropwise and the
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reaction was allowed to stir at 22 "C. A precipitate formed initially, but dissolved after
continued stirring. After a total of 21 h, the reaction was diluted with ether and filtered
through water-deactivated aluminum oxide (eluted with ether). After evaporation of the
solvents, the residue was partially purified by flash column chromatography (SiO 2 ,
hex/MTBE/TEA, 8:1:0.01) to afford a mixture of cycloadducts as a yellow oil. The
partially purified cycloadducts were then dissolved in anhydrous methanol (3 mL) and
DBU (0.1 mL) was added. When TLC indicated a completed reaction (20 min), the
solvent was evaporated under reduced pressure and the residue was purified by flash
column chromatography (hex/MTBE/TEA, 5:1:0.01) to afford ester 20 as a clear oil (0.12
g, 0.28 mmol, 14% over 2 steps, 1.7:1.0 cis vs. trans). cis-20: 'H NMR (300 MHz,
CDCl 3): 8 7.42 (s, 1H), 5.07 (t, 1H, J = 2.7), 4.65 (dd, 1H, J= 5.6, 6.6), 3.65 (s, 3H),
3.68-3.40 (m, 4H), 3.52 (dd, 1H, J= 6.5, 9.1), 3.19 (dd, 1H, J= 6.4, 9.1), 2.66-2.57 (m,
1H), 2.11 (td, 1H, J= 2.3, 14.2), 2.02-1.70 (m, 4H), 1.19-1.10 (m, 6H), 0.84 (dd, 6H, J=
1.4, 6.7); "C NMR (125 MHz, CDCl 3): 6 167.99, 152.20, 110.60, 101.77, 98.81, 96.09,
61.93, 58.77, 51.28, 36.05, 29.11, 28.62, 24.29, 19.41, 15.47, 15.54. trans-20: 1H NMR
(300 MHz, CDCl 3): 8 7.42 (s, 1H), 4.94 (dd, 1H, J= 2.2, 9.0), 4.57 (t, 1H, J= 5.7), 3.65
(s, 3H), 3.68-3.40 (m, 5H), 3.25 (dd, 1H, J= 6.9, 9.3), 2.72 (dq, 1H, J= 3.5, 6.4), 2.02-
1.70 (m, 4H), 1.46 (ddd, 1H, J= 5.4, 9.7, 14.3), 1.19-1.10 (m, 6H), 0.87 (dd, 6H, J= 2.2,
6.7); 13C NMR (125 MHz, CDCl 3): 6 167.84, 153.46, 109.78, 101.77, 98.81, 76.44,
62.33, 59.97, 51.28, 38.46, 31.40, 26.35, 19.35, 15.54, 15.47. ESI-MS(C17H3oO6 ) m/z
calculated: 353.1940 [M+Na]*, found: 353.1957 [M+Na]*.
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Methyl 2-tert-butoxy-4-(2-oxoethyl)-3,4-dihydro-2H-pyran-5-carboxylate 24
EtO OEt oxalic acid CHO
S silica gel1< THF/water O.1
MeO2 C 20 eO2 24
A slurry (1 mL water with 100 mg dissolved oxalic acid and 100 mg silica gel) was
added to a solution of acetal 20 (0.12 g, 0.35 mmol) in THF (4 mL). The mixture was
stirred at 60 *C for 90 min. The reaction was quenched by addition of 200 mg solid
anhydrous sodium bicarbonate. After filtration, the solvent was evaporated under reduced
pressure. The residue was purified by flash column chromatography (SiO 2,
hex/MTBE/TEA, 5:1:0.01) to afford separated diastereomers of 24 (d.e. >95%): cis-
adduct (39 mg, 0.15 mmol, 44%); trans-adduct (19 mg, 0.075 mmol, 22 %). cis-24: IH
NMR (500 MHz, CDCl 3): 8 9.74 (t, 1H, J= 1.3), 7.49 (d, 1H, J= 0.6), 5.38 (t, 1H, J=
2.8), 3.67 (s, 3H), 3.09 (qd, 1H, J= 4.4, 9.0), 2.99 (ddd, 1H, J= 1.4, 9.5, 17.7), 2.77 (ddd,
1H, J= 1.3, 4.0, 17.7), 1.87 (dd, 2H, J= 3.0, 4.4), 1.20 (s, 9H); 13C NMR (125 MHz,
CDCl3): 8 202.6, 167.8, 153.6, 108.3, 92.9, 76.2, 51.4, 48.0, 31.4, 28.7, 22.8. trans-24:
IH NMR (500 MHz, CDCl 3): 8 9.74 (dd, 1 H, J= 1.8, 2.2), 7.49 (d, 1H , J= 1.0), 5.20 (dd,
1H, J= 2.5, 7.8), 3.67 (s, 3H), 3.24-3.18 (m, 1H), 2.86 (ddd, 1H, J= 1.5, 5.4, 16.7), 2.38
(ddd, 1H, J= 2.3, 8.9, 16.7), 1.89 (ddd, 1H, J= 5.9, 7.9, 13.8), 1.67 (ddd, 1H, J= 2.5,
3.7, 13.9), 1.24 (s, 9H); 13C NMR (125 MHz, CDCl3): 8 201.4, 167.6, 154.7, 101.7, 92.6,
76.5, 51.4, 49.0, 33.7, 28.7, 24.3; ESI-MS(Cl3H200 5) m/z calculated: 279.1208 [M+Na]*,
found: 279.1200 [M+Na]*.
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Methyl-2-(cyclohexyloxy)-4-(2,2-diethoxyethyl)-3,4-dihydro-2H-pyran-5-carboxylate 21
C0 O EtO OEt
5 KF DBU O
EtO OEt 13 C MeOH M O
CHO 21
8
Potassium fluoride (0.20 g) was added to a solution of 3,3-diethoxy-1-propanal 8 (0.51 g,
3.5 mmol, 1.5 eq) and trichloroacetyl 5 (0.67 g, 3.5 mmol, 1.5 eq) in anhydrous DCM
(10 mL) under an argon atmosphere, accompanied by a color change from yellow to
orange-red. Cyclohexyl vinyl ether 13 (0.29 g, 2.3 mmol, 1.0 eq) was added dropwise and
the reaction was allowed to stir at 22 "C for 21 h. The reaction was diluted with ether and
filtered through water-deactivated aluminum oxide (eluted with ether). After evaporation
of the solvents, the residue was partially purified by flash column chromatography (6.2
cm SiO2, hex/MTBE, 10:1) to afford a crude mixture of cycloadducts as a yellow oil
(2.1:1 cis/trans raio, rf = 0.75, hex/MTBE 1:1). The partially purified cycloadducts (0.38
g) were then dissolved in anhydrous methanol (3 mL) and DBU (0.1 mL) was added.
When TLC indicated a completed reaction (10 min, rf = 0.67, hex/MTBE, 1:1), the
solvent was evaporated under reduced pressure and the residue was purified by flash
column chromatography (SiO 2, hex/MTBE, 10:1) to afford ester 21 as a clear oil (0.19 g,
0.52 mmol, 15% over 2 steps). cis-21: 1H NMR (300 MHz, CDCl 3): 8 7.42 (d, 1H, J =
0.8), 5.32 (t, 1H, J= 3.1), 4.64 (dd, 1H, J= 4.7, 7.4), 3.65 (s, 3H), 3.67-3.57 (m, 2H),
3.50-3.41 (m, 2H), 2.03 (ddd, 1H, J= 4.1, 7.4, 13.8), 1.99-1.85 (m, 4H), 1.77 (ddd, 1H, J
= 3.0, 6.6, 14.0), 1.20 (s, 9H), 1.19-1.13 (m, 6H); 1 3C NMR (125 MHz, CDCl 3): 8 152.8,
110.2, 101.4, 93.3, 75.8, 61.8, 58.9, 51.2, 38.9, 36.1, 30.9, 28.7, 25.0, 15.5. trans-21: 1H
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NMR (300 MHz, CDCl 3): 8 7.42-7.41 (m, 1H), 5.20 (dd, 1H, J= 2.4, 9.5), 4.55 (t, 1H, J
= 5.5), 3.64 (s, 3H), 3.69-3.57 (m, 2H), 3.49-3.41 (m, 2H), 2.74-2.68 (m, lH), 2.48 (ddd,
1H, J= 1.5, 5.6, 7.2), 1.98-1.85 (m, 2H), 1.49 (ddd, 1H, J= 5.7, 9.8, 14.2), 1.73-1.67 (m,
1H), 1.23 (s, 9H), 1.18-1.13 (m, 6H); 13 C NMR (125 MHz, CDCl 3): 6 154.0, 109.3,
102.2, 93.1, 76.3, 62.4, 60.4, 51.2, 39.8, 32.7, 28.7, 26.9, 15.5; ESI-MS(C 7H3106) mI/z
calculated: 353.1935 [M+Na]*, found: 353.1941 [M+Na]*.
Methyl 2-(cyclohexyloxy)-4-(2-oxoethyl)-3,4-dihydro-2H-pyran-5-carboxylate 25
EtO OEt oxalic acid CHO
O > silica gel 
MeO2C THF/water MeO2C t
21 25
A slurry (1 mL water with 100 mg dissolved oxalic acid and 100 mg silica gel) was
added to a solution of acetal 21 (0.18 g, 0.52 mmol) in THF (4 mL). The mixture was
stirred at 60 0C for 90 min. The reaction was quenched by addition of 200 mg solid
anhydrous sodium bicarbonate. After filtration, the solvent was evaporated under reduced
pressure. The residue was purified by flash column chromatography (SiO 2,
hex/MTBE/TEA, 5:1:0.01) to afford separated diastereomers of 25 (d.e. >95%). Major
diastereomer, cis-adduct, 79 mg, 0.28 mmol, 54%. Minor diastereomer, trans-adduct, 25
mg, 0.09 mmol, 17%. cis-25: 1H NMR (500 MHz, CDCl 3): 6 9.74 (t, 1H, J= 1.3), 7.49
(d, 1H, J= 0.6), 5.27 (t, lH, J= 2.6), 3.67 (s, 3H), 3.65-3.59 (m, 1H), 3.10-3.05 (m, 1H),
3.02 (ddd, 1H, J= 1.3, 9.6, 17.5), 2.78-2.72 (m, 1H), 1.97 (td, 1H, J= 2.3, 14.4), 1.88
(ddd, 1H, J= 2.8, 6.5, 14.4), 1.82-1.72 (m, 2H), 1.68-1.58 (m, 2H), 1.48-1.41 (m, 1H),
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1.40-1.13 (m, 5H); 13C NMR (125 MHz, CDC13): 8 202.53, 167.73, 153.26, 108.70,
96.10, 76.55, 51.40, 48.02, 33.45, 31.59, 30.43, 25.72, 23.91, 23.74, 22.45; trans-25: 1H
NMR (500 MHz, CDCl 3): 6 9.74 (t, 1H, J= 1.8), 7.48 (d, 1H, J= 1.1), 5.10 (dd, 1H, J=
2.4, 7.5), 3.67 (s, 3H), 3.68-3.62 (m, 1H), 3.21 (td, 1H, J= 5.1, 14.6), 2.86 (ddd, 1H, J=
1.5, 4.2, 16.9), 2.38 (ddd, 1H, J= 2.2, 8.9, 16.9), 1.93 (ddd, 1H, J= 6.1, 7.4, 13.7), 1.89-
1.82 (m, 2H), 1.74 (ddd, 1H, J= 2.4, 5.2, 13.9), 1.72-1.67 (m, 2H), 1.53-1.47 (m, 1H),
1.42-1.15 (m, 5H); 13C NMR (125 MHz, CDCl 3): 6 201.36, 167.58, 154.37, 108.07,
96.15, 51.44, 48.80, 39.78, 33.61, 32.86, 32.03, 25.67, 24.26, 24.14, 24.00; ESI-
MS(C 1 5H2205*) m/z calculated: 283.1545 [M+H]*, found: 283.1544 [M+H]*.
Methyl 4-((5,5-dimethyl-1,3-dioxan-2-yl)methyl)-2-(2-nitrobenzyloxy)-3,4-dihydro-2H-
pyran-5-carboxylate 26
0 OH
C3C NO2  O2 N
5 / KF DBU : 0
toluene MeOH
OO 16 MeO2C O26
CHO
9
2-(5,5-dimethyl-1,3-dioxan-2-yl)ethanal 9 (0.68 g, 4.0 mmol, 2.0 eq) and 1,1,1-trichloro-
4-hydroxybut-3-en-2-one 5 (0.76 g, 4.0 mmol, 2.0 eq) were dissolved in toluene (8 mL)
and potassium fluoride was added (100 mg). A 2-mL solution of 2-nitrobenzyl vinyl ether
16 (0.36 g, 2.0 mmol, 1.0 eq) was added drop-wise to this solution and the mixture was
heated to 100 "C for 4 h, and then diluted with ether and filtered through water-
deactivated aluminum oxide. The solvents were evaporated under reduced pressure to
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yield a yellow oil. Chloroform (20 mL) was added together with a few crystals of
pTsOH. The flask was left standing 12 h and then filtered through SiO 2. After
evaporation of the solvents, the residue was purified by flash column chromatography
(16x 2.5 cm SiO 2, hex/MTBE, 25:1 to 15:1 to 9:1 to 4:1, 8-mL fractions) to give partially
purified cycloadducts (fractions 7-33 were combined). The recovered product was then
purified (DCM/hex, 2:1 to 8:3) to give a pale yellow foam of >90% pure cycloadducts
(0.47 mg, 46%). 1H NMR (600 MHz, CDCl 3): 6 8.08 (s, 1H, a), 8.08-8.01 (in, 1H, a,b),
7.78-7.71 (m, 1H, a,b), 7.67-7.54 (in, 1H, a,b), 7.48-7.36 (m, 1H, a,b), 5.41-5.37 (in, 1H,
a,b), 5.36-5.00 (m, 2H, a,b), 4.57-4.46 (in, 1H, a,b), 3.63-3.25 (m, 4H, a,b), 3.15-2.89 (in,
1H, a,b), 2.42 (td, 0.55H, J= 1.7, 14.4, a), 2.33 (td, 0.45H, J= 2.5, 13.4, b), 2.14-1.60 (m,
3H, a,b), 1.15 (s, 1.6H, a), 1.12 (s, 1.4H, b), 0.68 (s, 1.6H, a), 0.67 (s, 1.4, b); 13C NMR
(125 MHz, CDCl 3): 6 167.82a, 167.64b, 152.87b, 151.72a, 134.43a, 134.25b, 134.02a,
133.91b, 128.86b, 128.77a, 128.38b, 128.22a, 124.94b, 124.89a, 110.95a, 110.33b,
102.04a, 101.51b, 98.55a, 93.39b, 68.35a, 67.94b, 56.52, 51.45a, 51.44b, 39.69b, 38.43a,
31.81b, 30.36a, 30.28b, 29.52a, 25.72b 23.75a, 23.31(2C), 22.10a, 22.08b, 25.72b,
23.75a, 23.31a, 22.10, 22.08; ESI-MS(C 21 H24NO7 Cl3) m/z calculated: 508.0691 [M+H]*,
found: 508.0675 [M+H]*. The partially purified cycloadducts (81.9 mg, 0.16 mmol) were
dissolved in anhydrous methanol (2 mL) and DBU was added (0.05 mL). The mixture
was stirred for 10 minutes and then concentrated in vacuo. The residue was dissolved in
hex/MTBE (1:1) and filtered through a short column of SiO2 eluting with the same
solvent mixture. Evaporation of the solvents in vacuo yielded methyl ester 26 as an
inseparable mixture of diastereomers (66.3 mg, 0.16 mmol, 98%) in analytical purity.
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The NMR signals corresponding to the major stereoisomer is indicated by 'a'; the minor
stereoisomer is indicated by 'b'. 1H NMR (400 MHz, CDCl 3): 8 8.13-8.09 (m, 1H, a,b),
7.82-7.76 (m, 1H, a,b), 7.69-7.62 (m, 1H, a,b), 7.50-7.43 (m, 2H), 5.36-5.01 (m, 3H, a,b),
4.65-4.52 (m, 1H, a,b), 3.73 (s, 1.7H, a), 3.72 (s, 1.3H, b), 3.66-3.56 (m, 2H, a,b), 3.51-
3.38 (m, 2H), 2.98-2.92 (m, 0.4H, b), 2.88-2.83 (m, 0.6H, a), 2.40-2.34 (m, 0.6H, a),
2.27-2.21 (m, 0.4H, b), 2.20-1.80 (m, 2.6H, a,b), 1.66-1.59 (ddd, 0.4H, J= 4.7, 9.2, 14.0,
b), 1.22 (s, 1.7H, a), 1.20 (s, 1.3H, b), 0.74 (s, 1.7H, a), 0.73 (s, 1.3H, b); 13 C NMR (75
MHz, CDCl 3): 8 167.81a, 167.63b, 152.86b, 151.71a, 134.42a, 134.24b, 134.01a,
133.90b, 128.84b, 128.76a, 128.37b, 128.21a, 124.93b, 124.87, 110.94a, 110.32b,
102.02a, 101.50b, 98.54a, 98.48b, 77.41a, 77.37b, 77.29(2C), 68.34a, 67.93b, 51.44a,
51.42b, 39.68b, 38.42a, 31.80b, 30.35a, 30.27b, 29.51a, 25.70b, 23.73a, 23.30(2C),
22.09, 22.07; ESI-MS(C21H27NO8Na) m/z calculated: 444.1634 [M+Na]*, found:
444.1624 [M+Na]*.
Methyl 2-(2-nitrobenzyloxy)-4-(2-oxoethyl)-3,4-dihydro-2H-pyran-5-carboxylate 27
O O O2N CHO O2NHCl(aq.)
THF/water
MeO2C O A MeO 2C 2726
Acetal 26 (0.63 mmol) was added to 5 mL THF and 5 mL H20 for a final concentration
of 0.2 mM HCl and the mixture was stirred at 50 *C for 17 h. After that time, 5 drops of
10 M HCl were added, the temperature was increased to 65 *C, and the reaction was
stirred for a total of 43 h. The solvents were evaporated in vacuo in a heated water bath
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and the residue was dissolved in EtOAc. The EtOAc was washed with saturated aqueous
solutions of sodium bicarbonate, water then brine; the aqueous layers were back extracted
with EtOAc. The combined organic layers were evaporated and the residue was purified
by flash column chromatography (SiO 2, 13x3 cm, 7-mL fractions, hex/MTBE, 2:1) to
afford aldehyde 27 (29 mg, 14%) as an inseparable mixture of diastereomers. Starting
material could also be recovered (110 mg, 53%). (major diastereomer, cis): 'H NMR (500
MHz, CDCl 3): 8 9.78 (t, 1H, J= 1.4), 8.04 (dd, 1H, J= 1.1, 8.2), 7.74-7.59 (m, 2H), 7.50
(d, 1H, J= 0.9), 7.47-7.42 (m, 1H), 5.29 (t, 1H, J= 2.4), 5.15 (d, 1H, J= 14.9), 4.99 (d,
1H, J= 14.7), 3.69 (s, 3H), 3.19-3.12 (m, 1H), 2.91 (dd, 1H, J= 1.7, 9.6), 2.86-2.84 (m,
1H), 2.16-2.08 (m, 1H), 2.00 (dddd, 1H, J = 0.5, 3.1, 6.9, 14.6); 13C NMR (125 MHz,
CDCl 3): 8 200.07, 167.41, 152.66, 147.65, 134.01, 133.88, 128.90, 128.67, 125.05,
109.23, 98.18, 68.36, 51.55, 48.03, 29.82, 22.15; (minor diastereomer, trans): 'H NMR
(500 MHz, CDCl3): 6 9.77 (t, 1H, J= 1.6), 8.07 (dd, 1H, J= 1.2, 8.2), 7.74-7.70 (m, 1H),
7.66-7.59 (m, 1H), 7.47-7.42 (m, 1H), 5.24 (d, 1H, J= 14.9), 5.18 (dd, 1H, J= 2.5, 6.8),
5.07 (d, 1H, J= 14.9), 3.69 (s, 3H), 3.30-3.23 (m, 1H), 2.98 (dd, 1H, J= 1.4, 4.1), 2.94
(dd, 1H, J= 1.6, 4.0), 2.82-2.80 (m, 1H), 2.15-2.08 (m, 1H), 1.85 (ddd, 1H, J= 2.5, 6.3,
13.9); 13 C NMR (125 MHz, CDCl3 ): 8 200.96, 167.28, 153.59, 147.28, 133.95, 133.66,
128.85, 128.53, 125.00, 108.94, 97.84, 67.98, 51.52, 48.34, 32.29, 23.47; ESI-
MS(C 16H17NO7) m/z calculated: 336.1078 [M+H]*, found: 336.1078 [M+H]*.
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Methyl-4-(2,2-diethoxyethyl)-2-(4,5-dimethoxy-2-nitrophenoxy)-3,4-dihydro-2H-pyran-5-
carboxylate 33
0 NO 2
0 OH
C3C0 0 O2N OMe
5 OMe KF DBU OOMe0 -
toluene MeOH OMe
0 0 MeO2C 33
CHO
9
2-(5,5-dimethyl-1,3-dioxan-2-yl)ethanal 9 (0.15 g, 1.0 mmol, 2.0 eq) and 1,1,1-trichloro-
4-hydroxybut-3-en-2-one 5 (0.25 g, 1.3 mmol, 2.6 eq) were dissolved in DCM (5 mL)
and potassium fluoride was added (50 mg). To this mixture 4,5-dimethoxy-2-nitrobenzyl
vinyl ether 17 (0.12 g, 0.51 mmol, 1.0 eq) was added drop-wise. The mixture was stirred
at room temperature for 20 h, then diluted with ether and filtered through water-
deactivated aluminum oxide. The solvents were evaporated under reduced pressure and
the residue was purified by flash column chromatography (SiO 2, hex/MTBE/TEA,
5:1:0.01 to 100:1 MTBE/TEA) to yield partially purified cycloadducts. The combined
fractions were concentrated to give a residue (26 mg), which was dissolved in anhydrous
MeOH (2 mL). DBU was added (0.10 mL) to the solution, the mixture was stirred at
room temperature for 10 min, and the MeOH was then evaporated in vacuo. The residue
was purified by flash column chromatography (SiO 2, hex/MTBE/TEA, 2:1:0.01) to give
methyl ester 33 (25 mg, 0.055 mmol, 11% over 2 steps) as an inseparable mixture of
diastereomers. The NMR signals corresponding to the major stereoisomer is indicated by
'a'; the minor stereoisomer is indicated by 'b'. 1H NMR (400 MHz, CDCl 3): 8 7.72-7.66
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(in, 1H, a,b), 7.46-7.42 (in, 1H, a,b), 7.23-7.13 (in, 1H, a,b), 5.43-4.97 (in, 3H, a,b), 4.75-
4.51 (m, 1H, a,b), 3.96-3.89 (m, 6H, OMe-a,b), 3.69 (s, 1.8H, a), 3.68 (s, 1.2H, a), 3.68-
3.61 (m, 2H, a,b), 3.55-3.39 (in, 2H, a,b), 2.86-2.66 (in, 1H), 2.37-2.27 (m, 1H), 2.20-
1.87 (in, 3H), 1.25-1.09 (6H); ESI-MS(C 23H32NO1o*) m/z calculated: 482.2021 [M+H]*,
found: 482.2014 [M+H]+.
Methyl-2-(4,5-dimethoxy-2-nitrophenoxy)-4-(2-oxyethyl)-3,4-dihydro-2H-pyran-5-
carboxylate 34
0 0 0 2N OMe CHO O2N , OMe
O HCl(aq.) o 0 OMeOMe THF/water
MeO2C O A MeO 2C33
A slurry of silica gel (100 mg) and oxalic acid (100 mg) in water (1 mL) was prepared
and added (0.5 mL) to a solution of acetal 33 (25 mg, 0.055 mmol) in tetrahydrofuran
(THF, 2 mL). The resulting mixture was stirred at 65-70 "C for 3 h and then quenched by
addition of solid sodium bicarbonate (100 mg). After filtration, the solvent was
evaporated under reduced pressure and the residue was purified by flash column
chromatography (SiO 2, hex/MTBE/TEA: 2:1:0.01) to yield aldehyde 34 as unseparable
diastereomers (3.4 mg, 0.0086 mmol, 25%). The NMR signals corresponding to the
major stereoisomer is indicated by 'a'; the minor stereoisomer is indicated by 'b'. 1H NMR
(400 MHz, CDCl 3): 8 9.80-9.75 (m, 1H, a,b), 7.70 (s, 0.2H, b), 7.70 (s, 0.8H, a), 7.54-
7.51 (m, 0.7H, a), 7.49 (d, 0.2H, J= 1.2), 5.40-4.99 (m, 3H, a,b), 3.38-3.13 (m, 1H), 3.97
(s, 2.5H, b), 3.94 (s, 3.5H, a), 3.71 (s, 2.1H, a), 3.69 (s, 0.9H, b), 3.38-3.13 (m, 1H, a,b),
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3.07-2.84 (m, 1.7H, a,b), 2.42 (ddd, 0.3H, J= 1.7, 9.2, 17.2, b), 2.20-2.11 (m, 1H, a,b),
2.04 (ddd, 0.8H, J = 3.2, 6.9, 14.7, a), 1.87 (ddd, 0.3H, J = 2.4, 6.2, 13.9, b); ESI-
MS(Ci 8 H22NO 9*) m/z calculated: 396.1289 [M+H]*, found: 396.1292 [M+H]*.
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CHAPTER 6
IDENTIFYING AND BYPASSING STEREOSELECTIVITY IN
THE EARLY STEPS OF ALKALOID BIOSYNTHESIS
Part of this chapter is published as a communication in
Organic and Biomolecular Chemistry 2009, 7, 4166-4168.
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6.1 Introduction
Stereo configuration often determines how a natural product interacts with biological
systems. For example, different stereosiomers can have different pharmacological
profiles.1 '2 Biosynthetic enzymes, however, typically allow the production of only one
natural product stereoisomerE33 Fermentation of natural products with alternate
stereochemistry must therefore bypass the stereochemical restrictions of biosynthetic
pathway enzymes.
Several monoterpene indole alkaloids (MIAs) produced by Catharanthus roseus have
important biological activities (Chapter 1).E'5 Some MIAs are single isomers; others are
stereoisomer mixtures. The heteroyohimbine alkaloids, a subclass of MIAs, exist in the
plant cells as different stereoisomers where each stereoisomer has a different bioactivity.
Ajmalicine (raubasine) 5a acts as a smooth muscle relaxant and as an al anti-adrenergic,
while tetrahydroalstonine 5b acts as an a2 anti-adrenergic (Figure 6.1).E6-83 Access to
alternative stereoisomers of 5a and 5b, and alternative stereoisomers of other MIAs,
would provide diversified compound libraries for bioactivity screening.
MIA biosynthesis starts with a strictosidine synthase (STS)-catalyzed reaction between
tryptamine 1 and secologanin 2 to yield strictosidine 3a (Figure 6.1).-"l The stereogenic
centers of strictosidine 3a, the key intermediate for all MIAs,E93 derive from the densely
functionalized secologanin dihydropyran (C15, C20, and C21) or the prochiral aldehyde
carbon, which becomes the C3 stereogenic center of strictosidine (Figure 6.1).
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NH2
H 1
MeO 2C'
N 3 NH
STS H 19 SGD
O1-O-0 OH15 21
OH MeO 2C HOHO OH
)H 6H
3a, strictosidine, 3(S)
3b, vincoside, 3(R) (not observed)
Reductase
activity
NADPH
5a, ajmalicine: 19(S), 20(R)
5b, tetrahydroalstonine: 19(S), 20(S)
5c, epi-ajmalicine: 19(R), 20(R)
Figure 6.1 Early steps of monoterpene indole alkaloid biosynthesis in Catharanthus roseus.
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spont.
The second step of the MIA pathway is the strictosidine-p-D-glucosidase (SGD)
catalyzed deglucosylation of 3a to form hemiacetal 4.[12,133 Compound 4 is then
channeled into one or several MIA pathway branches, though the rearrangements and
enzyme-catalyzed steps of these branching reactions are poorly understood (Chapter
1).14] Entry into the heteroyohimbine class of alkaloids (5a-c) is likely controlled by one
or several NADPH-dependent reductases (Figure 6. 1).15 -17]
This chapter that describes the total synthesis of glucosylated des-vinyl strictosidine
stereoisomers (12a and 12, Figure 6.2) and the identification of stereochemical
restrictions in the early steps of MIA biosynthesis,E18 ] that if bypassed, may allow the
generation of libraries of heteroyohimbine stereoisomers from heterologously expressed
protein.E19]
6.2 Results and discussion
6.2.1 SGD-catalyzed deglucosylation of C3 stereoisomers
SGD promotes not only the deglucosylation of its natural substrate, 3(R)-strictosidine 3a,
but also the epimer, 3(S)-vincoside 3b."20 SGD has an 80-fold higher catalytic efficiency
(Vmax/KM) with 3a compared to 3b (Table 6. 1).E18] The change in Vmax/KM is due to a
change in the maximal rate (Vmax); the Michaelis constant (Km) is the same for the two
epimers (Table 6.1).E18]
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Table 6.1 Kinetic constants for deglucosylation and reduction of strictosidine 3a and
vincoside 3b.
ma Km VmaVKM
SGD [U mg-1] [mM]b [U mg 1 mM-1]b
3a 14.0 0.7 0.15 ±0.03 93 ±30
3b 0.17 0.02 0.15 ±0.04 1.1 ±0.5
b max KM VmaxlKM
Reductase [U mg-'] [mM] [U mg-1 mM-1]
Deglucosylated 3a 0.027 + 0.001 0.10 ± 0.02 0.26 ± 0.04
Deglucosylated 3b 0.012 ± 0.0003 0.66 ± 0.04 0.019 ± 0.001
[a] Activity quantified by monitoring the disappearance of starting material at pH 6.0, 30 'C. [b] 1 U = 1 pmol
product formed per minute at pH 7.0 and 30 *C.
The x-ray crystal structure of SGD from the closely related medicinal plant Rauvolfia
serpentina (PDB: 2FJ6) shows that the C3 carbon atom of strictosidine 3a is near the
surface of the protein while the glucose moiety is in the interior of the binding site.13 I
hypothesize that the glucose moiety of 3a and 3b binds in an identical fashion in the
active site of SGD, while the binding pocket for the more distal regions of the substrate,
including the C3 carbon, is sufficiently flexible to accommodate 3b.J21-23 An x-ray crystal
structure of SGD in complex with vincoside 3b may clarify the molecular basis of the
relaxed stereoselectivity.
6.2.2 Synthesis of des-vinyl strictosidine
Chapter 5 described the synthesis and biochemical evaluation of des-vinyl secologanin
analogs without glucosylation, and therefore, it was only possible to study the
stereoselectivity of STS. To examine how different stereoisomers of des-vinyl analogs
function in a biosynthetic context, I developed a method to synthesize glucosylated des-
vinyl secologanin.
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I accessed alternative configurations at C2 and C4 by applying the previously reported
synthesis of acetal-protected des-vinyl secologanin aglycones.[ 24-261 The key step is, as for
the previously described 0-analogs (Chapter 5), Tietze's tandem Knoevenagel-hetero-
Diels-Alder (KHDA) reaction, which assembles a 2,4-disubstituted dihydropyran from 7,
8, and an electron rich dienophile (e.g. vinyl ether). I adopted this strategy to obtain, for
the first time, 0-glucosylated des-vinyl strictosidine 12a and its stereoisomers 12 (Figure
6.2). Ir-catalyzed vinyl transfer from vinyl acetate to the corresponding alcohol formed
the KHDA substrate, 2,3,4,6-tetrabenzyl vinyl-glucose 6.[271 The KHDA reaction of 6, 7,
and 8, in the presence of potassium fluoride, afforded cycloadducts, and after partial
purification of the desired regioisomers, methanolysis generated methyl ester 9 (section
6.4.2 and Figure 6.2, steps a-b). Pd-catalyzed debenzylation of 9 led to acetal-protected
secologanin 10 as a mixture of inseparable stereoisomers (Figure 6.2, step c), and after a
challenging acetal hydrolysis step, des-vinyl secologanin 11 was carried partially purified
into either an enzymatic or a non-enzymatic Pictet-Spengler reaction to generate
tetrahydro-p-carboline products 12a or 12 (Figure 6.2 and section 6.4.3).
Enzymatic synthesis by STS using 1 and 11 as substrates produced a single isomer 12a
(Figure 6.2, step e) which was purified by preparative HPLC and characterized by 1H
NMR (section 6.4.3 and Appendix D). The doublet of a doublet at 5.8 ppm suggested a
dihydropyran 2,4-trans configuration, [24,25] and the doublet at 4.8 ppm with a J-coupling
constant of 7.8 Hz indicated a $-anomeric configuration for the glycoside linkage;[ 28] the
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Figure 6.2 Synthesis of 12, 12a, 13, and 13a. (a) KF, toluene; (b) DBU, MeOH, 38% over 2
steps; (c) Pd/C, MeOH, 77%; (d) PPTS (2 eq, 0.2 M), acetone/H 20 (2:1), ~10%; (e) tryptamine 1,
C. roseus STS, NaPi (0.05 M, pH 7.0), 89%; (f) tryptamine 1, maleic acid buffer (0.01 M, pH
2.0); (g) C. roseus SGD, citrate-phosphate buffer (0.15 M, pH 6.0); h) B. stearothermophilus a-
glucosidase, almond p-glucosidase, SGD, citrate phosphate buffer (0.15 M, pH 6.0); (i) reductase
activity from C. roseus cell suspension culture, NADPH, sodium phosphate buffer (0.05 M, pH
7.0).
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same relative configuration as strictosidine 3a (Figure 6.1). Therefore, STS stringently
prefers the 2,4-trans-p-glucoside of 11 when challenged with an array of stereoisomers.
Chemical synthesis by acid catalysis (maleic acid buffer, pH 2.0) afforded isomers 12,
from 1 and 11 (Figure 6.2, step f), which were isolated by preparative HPLC and
characterized by 1H NMR (section 6.4.3 and Appendix D). UPLC-MS resolved six peaks,
each with a mass consistent with des-vinyl strictosidine 12 (m/z 505) (Figure 6.3A (i): pk
1-6). Therefore, chemical synthesis of 12 bypasses the stringent stereospecificity of STS
and provides stereoisomers for assessing stereochemical restrictions of subsequent
biosynthetic steps.
6.2.3 Deglucosylation of des-vinyl strictosidine
The second enzyme in the pathway, SGD, turns over both 3a and 3b (section 6.2.1), and
as expected, SGD efficiently catalyzed the deglucosylation of the single tetrahydro-p-
carboline isomer 12a, suggesting that the vinyl group is not essential for deglucosylation
activity.
When SGD was incubated with all isomers of 12, only two of the six separable peaks
decreased in area (Figure 6.3A (ii): pk 1 and pk 3), suggesting that SGD, in addition to
STS, imposes stereochemical restrictions in the MIA biosynthetic pathway. Pk 3 co-
elutes with 12a (not shown) and the minor decrease in peak area suggests turnover of
only the H15/H21-trans configuration of 3. Pk 1, however, contains two stereoisomers
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Figure 6.3 LC-MS traces that show: (A) Remaining starting material after deglucosylation of 12
(mlz 505.1 + 0.5) by C. roseus SGD (i), almond p-glucosidase (p, iii), and B. stearothermophilus
a-glucosidase (a, iv). (i) no-enzyme control. NMR spectra of isolated peaks are found in
Appendix D. (B) Products of the reductase assay. (i) ajmalicine 5a standard (mlz 353); (ii)
reduction of deglucosylated d4-vincoside 3b (ml: 357); (iii) reduction of deglucosylated d4-
strictosidine 3a (m/: 357); (iv) reduction of deglucosylated 12a yields a single product, 13a; (v)
reduction of 12 yields two separatable stereoisomers 13.
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with H15/H21-cis configuration, as evidenced by the triplet signals at 5.9 and 5.7 ppm
assigned to H21 (section 6.4.3 and Appendix D).[24 ,2s3 The two isomers in pk 3 have p-
anomeric configuration since the J-coupling constant between Hi' and H2' is 8.0 Hz.[283
Therefore, although SGD accommodates alternatives stereoisomers, the anomeric
configuration must be P for turnover to occur.
The complete deglucosylation of 12 is necessary for a comprehensive assessment of the
stereoselectivity of the NADPH-dependent reductase - the subsequent enzyme in the
heteroyohimbine alkaloid biosynthetic pathway. SGD only deglucosylates a few
stereoisomers, but I hypothesized that bacterial glucosidases may have broader substrate
scopes,[293 which would enable the deglucosylation of all stereoisomers. Therefore, I
assayed 12 with the commercially available enzymes: Bacillus stearothermophilus a-
glucosidase and almond p-glucosidase. Almond p-glucosidase is considerably more
permissive than SGD, catalyzing the deglucosylation of isomers of 12 in four out of the
six peaks that could be resolved by LC (Figure 6.3A (iii): pk 1, 3, 5, and 6; and Appendix
D); B. stearothermophilus a-glucosidase facilitated the removal of the other two peaks
(Figure 6.3A (iv): pk 2 and 4; and Appendix D). Hence, by using glucosidases from
different, unrelated, metabolic pathways, it is possible to bypass the native biosynthetic
pathway to fully deglucosylate 12.
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6.2.4 NADPH-dependent reduction of C3 stereoisomers
In the heteroyohimbine biosynthetic pathway, one or several reductases catalyze the
NADPH-dependent reduction of deglycosylated strictosidine 3a to form MIAs such as
5a-c (Figure 6.1). A cell-free extract from C. roseus cell suspension cultures, obtained by
N. Yerkes in the O'Connor lab, reconstituted the reductase activity. Controls showed that
3a, SGD, NADPH, and the reductase activity are each a necessary component for the
formation of a reduced product; the product elutes near an authentic standard of
ajmalicine 5a (m/z 353, Figure 6.3B). N. Yerkes determined the steady-state kinetics for
reduction of the natural substrate, deglucosylated strictosidine 3a, and the unnatural
substrate, deglucosylated vincoside 3b (Table 6.1). The reductase shows a 15-fold
catalytic preference (Vnax/KM) for the 3(S) configuration of strictosidine 3a (0.26 U M-1
mg-) over the 3(R) stereochemistry of vincoside 3b (0.019 U M 1 mg-1). This is mainly
due to a 7-fold difference in Km (0.1 mM compared to 0.7 mM with 3a and 3b,
respectively). The catalytic differentiation between 3a and 3b suggests that the reductase
activity derives from a MIA pathway. However, since the enzyme is a cleared cell-lysate
we cannot rigorously exclude the involvement of additional reductases in the turnover of
deglucosylated 3a and 3b.
6.2.5 NADPH-dependent reduction of deglucosylated des-vinyl strictosidine
The reductase activity, provided by N. Yerkes, converts deglucosylated des-vinyl
strictosidine 12a into 13a (Figure 6.2, section 6.4.5, and Appendix D), and 12 into two
separatable reduced products 13. One separatable peak of 13 co-elutes with 13a (Figure
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6.3B). Since the reduced product contains two stereogenic centers and only two
diastereomers separate under the chromatographic conditions, we concluded that the
second peak contains the second diastereomer. Since 12 is completely deglucosylated by
the mixture of glucosidases, and because all deglucosylated isomers 12 are completely
consumed upon addition of the reductase activity (Figure 6.4), the reductase turns over all
secologanin dihydropyran configurations. Therefore, heteroyohimbine alkaloid
biosynthesis appears to contain reductases that are capable of reducing a variety of
substrates; this promiscuity may prove useful in the chemoenzymatic synthesis of
compound libraries.
6.3 Conclusions
The first step of the heteroyohimbine alkaloid biosynthetic pathway, catalyzed by STS,
has a stringent substrate specificity, including stereoselectivity, to ensure the integrity of
the first committed intermediate in MIA biosynthesis, strictosidine 3a. SGD shows strict
stereocontrol, but accepts at least one unnatural dihydropyran stereoisomer with
H1i5/H21 -cis relative stereo configuration. Chemical synthesis and the recruitment of
glucosidases from unrelated metabolic pathways highlighted the potential to bypass
stereochemical restrictions in MIA biosynthesis and to diversify alkaloid production. C.
roseus cell culture extracts provided a reductase fraction, which harbors at least one
enzyme that converts unnatural stereoisomers to reduced alkaloids in vitro. Once cloned,
this enzyme can be useful in heterologous expression systems to yield novel
heteroyohimbine alkaloid derivatives.
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Figure 6.4 LC-MS traces show that deglucosylated des-vinyl strictosidine 12 (i, m/z 325) is
completely converted by the reductase activity to form 13 (iii, m/z = 327), as evidenced by the
absence of m/z 325 in the reductase-supplemented reaction in LC-MS analysis (ii, m/z 325). Trace
(i) shows the product of incubation of 12 with B. stearothermophilus a-glucosidase, almond p-
glucosidase, and C. roseus strictosidine-p-D-glucosidase, without reductase. Traces (ii) and (iii)
are extracted masses from the same reaction, where reductase has been added. The two peaks
with m/z 325 observed in trace (ii) correspond to the isotope peaks of m/z 327.
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6.4 Experimental methods
6.4.1 General methods and analytical techniques
All chemicals were used as received from the supplier without further purification. All
glassware were oven dried, evacuated, and filled with argon. Secologanin was purified
from Lonicera tatarica as previously described.[301 Strictosidine 3a and strictosidine
analogs were either prepared enzymatically using CrSTS or using chemical synthesis in
aqueous maleic acid buffer (0.1 M, pH 2.0) and isolated by preparative HPLC. STS and
SGD were expressed in E. coli BL21(DE3) and purified by affinity chromatography
using a hexa-His tag as previously described.E311 a-Glucosidase from B. stearo-
thermophilus (104 U mg-1, where 1 U = 1 ptmol D-glucose from p-nitrophenyl a-D-
glucoside per minute at pH 6.8 at 37 'C) and s-glucosidase from almonds (26 U mg-,
where 1 U = 1 pmol of salicin per minute at pH 5.0 at 37 'C) were purchased from
Sigma-Aldrich (St. Louis, MO).
UPLC analysis was performed using an Acquity Ultra Performance BEH C18 column
with a 1.7 pm particle size, 2.1 x 100 mm dimension, and a flow rate of 0.6 mL min~ .
The column elution was coupled to MS analysis carried out using a Micromass LCT
Premier TOF Mass Spectrometer with an ESI source. Both modules are from Waters
Corporation (Milford, MA). The capillary and sample cone voltages were 3000 V and 30
V, respectively. The desolvation and source temperatures were 300 and 100 *C,
respectively. The cone and desolvation gas flow rates were 60 and 800 L h-1. Analysis
was performed with MassLynx 4.1 and integrations were carried out using QuantLynx.
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Proton nuclear magnetic resonance (1H NMR and 13C NMR) spectra were recorded on
Varian 300 MHz, Varian 500 MHz, or Brucker 400 MHz spectrometers.
6.4.2 Synthesis of acetal-protected des-vinyl secologanin 10
2-(5,5-dimethyl-1,3-dioxan-2-yl)ethanal 7
o 0 DMP O O
DCM
CHO
OH
14 7
Dess-Martin periodinane (DMP, 5.1 g, 12 mmol, 1.2 eq) was added to a solution of 2-
(5,5-dimethyl-1,3-dioxan-2-yl)ethanol 14 (1.6 g, 10 mmol, 1.0 eq) in DCM (100 mL) at 0
*C. The reaction was stirred at 0 'C for 5 min, warmed to room temperature and then
stirred for an additional 45 min. The reaction was diluted with DCM (100 mL) and
quenched by the successive addition of a saturated aqueous solution of sodium
bicarbonate (50 mL) and a concentrated aqueous solution of sodium thiosulfate (50 mL).
The layers were separated and the aqueous layer was extracted with DCM (3 x 20 mL).
The combined organic layers were washed with a (1:1) mixture of sodium
bicarbonate/sodium thiosulfate and dried over anhydrous sodium sulfate. After
evaporation of the solvent in vacuo, the residue was purified by flash column
chromtography (SiO 2, hex/ether 3:1) to afford 2-(5,5-dimethyl-1,3-dioxan-2-yl)ethanal 7
(1.5 g, 9.7 mmol, 97%) as a clear oil.[3 2] 1H NMR (CDCl 3): 6 9.81 (t, 1H, J = 2.4), 4.86 (t,
1H, J = 4.5), 3.61 (d, 2H, J = 10.0), 3.45 (d, 2H, J = 10.5), 2.68 (dd, 1H, J = 2.4, 4.6),
1.17 (s, 3H), 0.72 (s, 3H); 13C NMR (CDCl 3): 5 199.57, 97.81, 77.17, 48.48, 29.99,
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22.84, 21.75; ESI-MS(C8 Hl5O 3*): m/z calculated: 159.1016 [M+H]*, found: 159.1014
[M+H]*.
a/p-vinyl-2,3,4,6-tetra-O-benzyl-glucopyranose 6
OBn OBn
HO 0 [IrCl(cod)] 2  0O ~NaOAc 9
-Ok BnO OBn toluene BnO OBn
OBn A 6Bn
15 16 6
In a Schlenk flask under a stream of argon, [IrCl(cod)] 2 (0.050 g, 0.074 mmol, 0.02 eq)
was added to a toluene solution (7.5 mL) of vinyl acetate 15 (0.64 g, 7.4 mmol, 2.0 eq),
2,3,4,6-tetra-O-benzylglucopyranose 16 (2.0 g, 3.7 mmol, 1.0 eq), and sodium acetate
(0.36 g, 4.4 mmol, 1.2 eq). The mixture was heated to 95 'C and stirred at this
temperature for 90 min. A second portion of vinyl acetate 15 was then added (0.32 g, 3.7
mmol, 1.0 eq) and the reaction was allowed to continue for a total of 2 h. The reaction
was diluted with wet ether (40 mL) and filtered through SiO2 eluting with ether. After
evaporation of the solvent, the residue was purified by flash column chromatography
(SiO 2 , hex/EtOAc, 4:1) to afford vinyl-2,3,4,6-tetra-O-benzyl-glucopyranose 6 (1.7 g, 3.0
mmol, 80%) as an oil (0.62:0.38 mixture of a- and p-anomers), which solidified on
standing. 'H NMR (CDCl3): 6 7.44-7.05 (m, 20H), 6.48 (dd, 0.62H, J = 6.4, 13.9), 6.36
(dd, 0.38H, J = 6.5, 14.1), 5.10-4.39 (m, 10H), 4.24 (ddd, 1H, J = 1.7, 6.5, 16.4), 3.87-
3.41 (m, 6H); ESI-MS(C 36H39 0 6 ): m/z calculated: 567.2741 [M+H]*, observed:
567.2752 [M+H]*.
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Methyl 4-((5,5-dimethyl-1,3-dioxan-2-yl)methyl)-2-(a/p3-glucopyranose)-3,4-dihydro-2H-
pyran-5-carboxylate 9
O OH OBn
C13C O ' O ,,,,)"O O OBn
BnO OBn 
O O ,,,
OBn toluene MeO2C BnO OBnO O 6 6Bn
OHC
1,1,1-trichloro-4-hydroxybut-3-en-2-one 8 (1.4 g, 7.4 mmol, 2.0 eq), synthesized as
described previously[331 and 2-(5,5-dimethyl-1,3-dioxan-2-yl)ethanal 7 (1.3 g, 8.2 mmol,
2.2 eq) were dissolved in toluene (7.5 mL) at 0 'C. Potassium fluoride was added (0.19 g)
and the resulting mixture quickly changed color to orange. 1-Vinyl-2,3,4,6-tetra-O-
benzyl-glucopyranose 6 (2.1 g, 3.7 mmol, 1.0 eq) was then added drop-wise and the
resulting reaction was heated to 100 *C. After a total reaction time of 8 h, the reaction
was diluted with ether and filtered through water-deactivated aluminum oxide.
Evaporation of the solvent and purification of the residue by flash column
chromatography (SiO 2 , hex/MTBE, 8:1 to 5:1) afforded partially purified cycloadduct
(six stereoisomers by NMR, four major stereoisomers). The cycloadducts were dissolved
in anhydrous methanol (10 mL) and DBU was added (0.1 mL). After 20 min stirring at
room temperature, the solvent was evaporated and the residue was purified by flash
column chromatography (SiO 2, hex/MTBE, 5:1 to 3:1) to afford analytically pure methyl
4-((5,5-dimethyl- 1,3-dioxan-2-yl)methyl)-2-(a/p-glucopyranose)-3,4-dihydro-2H-pyran-
5-carboxylate 9 (1.2 g, 1.4 mmol, 38%) as a mixture of diastereomers. 'H NMR
(CDC13), overlapping signals: 5 7.48-7.06 (m, 1H), 7.37-7.06 (m, 20H), 5.58 (t, 0.20H, J
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= 2.9), 5.51-5.45 (in, 0.3 1H), 5.40 (t, 0.17H, J = 2.9), 5.34-5.27 (m, 0.42H), 5.02-4.64 (m,
4H), 4.64-4.39 (m, 5H), 3.80-3.22 (m, 8H), 2.93-2.75 (m, 1H), 2.37-1.75 (m, 4H), 1.66-
1.50 (m, 1H), 1.25-1.03 (m, 3H), 0.74-0.52 (m, 3H); ESI-MS(C 48H570a1): m/z
calculated: 809.3895 [M+H]+, found: 809.3880 [M+H]+.
Methyl 4-((5,5-dimethyl-1,3-dioxan-2-yl)methyl)-2-(a/pf-glucopyranose)-3,4-dihydro-2H-
pyran-5-carboxylate 10
9 OBn OH
0 0~ Pd/C 5:: 0 0 0
0e2  n~~~ MeOHIH 2O -
M2C BO Bn MeO 2C HOYO
9 On10 6H
To a solution of the tetrabenzylated starting material 9 (1.1 g, 1.4 mmol) in MeOH (50
mL) was added water (1.5 mL) and then Pd/C (cat.). The flask was evacuated and filled
with an H2-atmosphere. The resulting heterogenous mixture was stirred for 2 h at room
temperature or until TLC (DCM/MeOH, 9:1) indicated complete conversion. Filtration
through celite and evaporation of the solvents afforded a yellow oil that was subjected to
flash column chromatography (SiO 2 , DCM/MeOH, 9:1) to afford the debenzylated
product 10 as a white foam (0.45 g, 1.0 mmol, 74%); 1H NMR (MeOD): 5 7.51-7.45 (m,
1H1), 5.67 (t, 0.26H, J = 2.5), 5.59-5.54 (m, 0.38H), 5.50 (t, 0.22H, J = 2.5), 5.47 (dd,
0.11H, J = 2.3, 9.2), 5.26 (d, 0.12H, J = 3.7), 5.16 (d, 0.21H, J = 3.7), 4.72 (d, 0.17H, J =
7.9), 4.67-4.60 (m, 1H), 4.57 (t, 0.38H, J = 4.3), 4.52 (d, 0.24H, J = 7.8), 3.92-3.77 (m,
1H), 3.72-3.68 (m, 3H), 3.69-3.40 (m, 6H), 3.26-3.09 (m, 1H), 2.94-2.73 (m, 1H), 2.37-
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1.79 (m, 4H), 1.62 (ddd, 0.3H, J = 4.8, 9.7, 14.2), 1.17 (s, 3H), 0.73 (s, 3H); ESI-
MS(C 2oH 33011): m/z calculated: 449.2019 [M+H]+, found: 449.2025 [M+H]+.
6.4.3 Synthesis of des-vinyl strictosidine 12a and 12 and deglucosylation of 12
Deprotection of acetal-protected des-vinyl secologanin 10
0 CHO OHO OH 0 0
0 O:acetone/water MeO2C HO OH
MeO 2C HO OH OH
10 OH 11
PPTS (1.56 mmol, 2 eq) was added to a solution of methyl 4-((5,5-dimethyl-1,3-dioxan-
2-yl)methyl)-2-(glucopyranose)-3,4-dihydro-2H-pyran-5-carboxylate 10 (0.35 g, 0.78
mmol) to make a 0.2 M solution of PPTS in acetone/water (2:1). The mixture was heated
to 65 'C for 35 h, after which it was quenched by addition of solid sodium carbonate (0.5
g). After filtration, the solvents were evaporated in the presence of toluene. Purification
by normal phase flash column chromatography (SiO 2, DCM/MeOH, 85:15) followed by
reverse-phase flash column chromatography (C18-SiO 2, packed in MeOH, equilibrated to
H20, run with H20/MeOH, 99:1 to 8:2) afforded partially purified aldehyde 11 (68 mg,
est. 20% yield). NMR signals at 6 9.80-9.60 (m) are indicative of the aldehyde functional
group; signals associated with the dioxane protective group are absent; and, the aldehyde
exists at least partially in its hydrated form due to the low intensity of the aldehyde proton
signal (NMR spectrum in Appendix D). ESI-MS(C 15H23010*) m/z calculated: 363.1286
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[M+H]*, found: 363.1287 [M+H]*. Partially purified 11 was used in the Pictet-Spengler
reactions with tryptamine 1.
Enzymatic synthesis of des-vinyl strictosidine 12a
CHO OH
O STS, pH 7.0 N NH 0 OH
srr H): H I
MeO2C HO OH tryptamine 1
OH MeO 2C HO OH
11 OH
12a
To a solution of the partially purified des-vinyl secologanin 11 (68 mg, 0.17 mmol, 8.5
mM, 1.0 eq) in sodium phosphate buffer (20 mL, 50 mM, pH 7.0) was added tryptamine
1 hydrochloride (44 mg, 0.22 mmol, 11 mM, 1.3 eq) and C. roseus STS (0.25 mL, 1
mol%). The reaction was followed by HPLC until no further product was formed. MeOH
was added (200 mL) and the resulting precipitate was removed by filtration. After
evaporation of most of the solvent the enzymatic product was purified by preparative
HPLC (detection at 239 nm; solvent system: 25-50% MeCN in water with 0.1% TFA
over 20 min; rt,sM = 4.5 min, rt,product = 8.5 min). The mobile phase was evaporated in
vacuo and dried to yield an amorphous solid (2 mg, 0.004 mmol), which consisted of a
single diastereomer 12. 1H NMR (MeOD): 6 7.76 (s, 1H, H-17), 7.45 (d, IH, J = 7.8, H-
12), 7.30 (d, IH, J = 8.1, H-9), 7.13 (dt, IH, J = 1.0, 7.1, H-10), 7.02 (dt, IH, J = 0.9, 8.0,
H-I1), 5.75 (dd, IH, J = 2.9, 9.2, H-2), 4.77 (d, IH, J = 7.8, H-I'), 4.65 (d, IH, J = 8.1, H-
3), 3.93 (dd, IH, J = 1.9, 11.7), 3.75 (s, 3H, OMe), 3.59 (dd, IH, J = 7.0 11.8), 3.52-2.95
(m, 9H), 2.48 (ddd, 1H, J = 3.7, 10.0, 13.9), 2.06-1.92 (m, 3H, H-14); ESI-
MS(C 2 5H3 3N209*) m/z calculated: m/z 505.2181 [M+H]+, found: 505.2180 [M+H]+.
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Chemical synthesis and deglucosylation of des-vinyl strictosidine isomers 12
CHO OH |N
N NH
maleic acid, pH 2.0 H HOH
MeO2Ct H OH tryptamine 1 O
OH MeO2C HO , OH
11 OH
12
Des-vinyl secologanin 11 was reacted with tryptamine 1 hydrochloride in maleic acid
buffer (10 mM, pH 2.0) for 48 h at 37 'C. The reaction products were collectively
purified by preparative HPLC as described for the enzymatic product to afford an
amorphous solid. Since the reaction products were complex mixtures of multiple
diastereomers, complete structural characterization could not be performed. However,
several representative signals in each 1H NMR spectrum could be used to assign certain
structural elements. (For NMR and LC-traces, see Appendix D.) To monitor the
deglucosylation reaction of the different des-vinyl secologanin stereoisomers, either
almond p-glucosidase (5 U) or B. stearothermophilus a-glucosidase (15 U) was added to
12 (0.24 mM final concentration) in citrate-phosphate buffer (0.15 M, pH 6.0) and
aliquots (5 p.L) were quenched at appropriate time points, analyzed by LC-MS, and
integrated and normalized to an internal standard (yohimbine). The LC-MS
chromatograms are shown in Appendix D and summarized as follows.
Pk 1: Two stereoisomers: 2,4-cis (t, 6 5 ppm), p-anomers (d, J = 8.0 Hz).[28] Pk 1 is
turned over by SGD and almond p-glucosidase. Pk 2: One stereoisomer: 2,4-cis (t, 6 5
ppm), and a-anomer (d, J = 3.8 Hz). Pk 2 is turned over by the a-glucosidase. Pk 3 and 4:
222
Several stereoisomers, 2,4-trans and 2,4-cis configurations, as evidenced by the br-s and
dd in the 5-6 ppm region, and a mixture of alpha and beta anomers. Pk 3 is turned over by
SGD and almond-p-glucosidase; Pk 4 is turned over by a-glucosidase. Pk 5 and 6:
Several stereoisomers, 2,4-trans and 2,4-cis configurations, as evidenced by the br-s and
dd in the 5-6 ppm region. 2,4-cis appears to be dominating in these two peaks. Both a and
P anomers are present. Pk 5 is converted by both a- and p-glucosidases; Pk 6 likely
contains mainly p-anomers, since it is converted mainly by almond p-glucosidase.
6.4.4 Isolation of reductase activity from cell suspension cultures
Cells were recovered from two-week-old C. roseus PC510 cell suspension cultures
(DSMZ, Germany) by filtration through cheesecloth. The cells were suspended in borate
buffer (0.1 M, pH 7.0) containing polyvinylpyrrolidone (PVP, 0.3% w/v) and $-
mercaptoethanol (20 mM) and ground in a blender (4 *C, 10 min). The cell extract was
centrifuged (10min, 6,000g, 4 'C) and subjected to ammonium sulfate precipitation near
0 'C. The 40-70% fraction was recovered and desalted by passing the solution through a
Sephadex G25 column and eluting with sodium phosphate buffer (30 mM, pH 7.0),
supplemented with sodium chloride (50 mM) and glycerol (10% v/v). The desalted eluent
was concentrated using a centrifugal filter device (AmiconUltra 10-kDa cut-off,
Millipore Corp., Billerica, MA), aliquoted for single-use fractions, and stored at -20 'C.
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6.4.5 Deglucosylation and reduction of 12 and 12a to form 13 and 13a, respectively
N N OH N* N N
glucosidase H reductase
MeO2C HO OH MOMeO 2C OH
OH
12 or 12a 13 or 13a
Des-vinyl secologanin 12a, a single isomer, was incubated with C. roseus SGD in citrate-
phosphate buffer (0.15 M, pH 6.0) for 30 min at 30 'C and then with the reductase
fraction (section 6.4.4). The resulting product 13a was purified by semi-preparative
HPLC and analyzed by NMR. 1H NMR (MeOD): 6 7.59 (s, 1H), 7.45 (d, J = 7.9, 1H),
7.34 (td, J = 0.8, 8.1, 1H), 7.11 (ddd, J = 1.2, 7.1, 8.2, 1H), 7.04 (ddd, J = 1.0, 7.1, 8.0,
1H), 4.62-4.55 (m, 1H), 3.77-3.72 (m, 1H), 3.62 (s, 3H), 3.61-3.53 (m, 3H), 2.89-2.73
(m, 3H), 2.39 (ddd, J = 1.9, 3.7, 13.3, 1H), 1.69-1.64 (m, 2H), 1.57 (ddd, J = 5.0, 12.1,
13.2, 1H); ESI-MS(C19 H23N2O3 ) m/z calculated: 327.1703 [M+H]*, found: 327.1701
[M+H]*. Des-vinyl secologanin 12 (0.24 mM final concentration), the mixture of all
isomers, was incubated with both almond P-glucosidase (5 U) and B. stearothermophilus
a-glucosidase (15 U) in citrate-phosphate buffer (0.15 M, pH 6.0) for 30 min at 30 'C,
which resulted in the complete deglucosylation of 12. After complete deglucosylation the
reductase fraction (section 6.4.4) was added; after overnight incubation, all
deglucosylated products had disappeared (Figure 6.3) and the mixture of reduced
products 13 was separated by LC-MS (Figure 6.3)
224
6.4.6 Kinetics
Steady-state kinetic constants for strictosidine 3a (15-1000 pM) or vincoside 3b (30 to
1100 pM) using SGD (73 [tg) was determined in citrate-phosphate buffer (0.15 M, pH
6.0) at 30 0C (0.200 mL reaction volume). Aliquots (10 ptL) were quenched in 1 mL
methanol, containing yohimbine (0.5 pM) as an internal standard, at appropriate time
points. The samples were centrifuged (1 min, 13,000g, 4 0C) to remove particulates and
then analyzed by LC-MS. The starting material and products were separated using a
gradient of 10-40% MeCN in water with 0.1% formic acid over 5 minutes. The
disappearance of strictosidine 3a or vincoside 3b was monitored by peak integration and
normalized to the area of the internal standard. Seven concentrations were analyzed for
each substrate, and the amount of 3a or 3b remaining after reaction at each time point
was correlated to peak area by comparing to a standard curve. Each concentration was
assayed at least three times and the averaged value is reported with standard deviations.
The data were fitted using non-linear regression to the Michaelis-Menten or Northrop
equations using OriginPro 7 (OriginLab, Northhampton, MA).
Steady-state kinetic constants using the reductase activity were obtained by performing a
coupled assay with isotopically labeled strictosidine d4-3a or vincoside d4-3b in the
presence of SGD. The isotope-labeled versions of the substrates were used to ensure that
no trace amounts of alkaloid present in the cell free extract would interfere with kinetic
analyses. Briefly, d4-3a or d4-3b (5 to 3000 pM) were diluted in citrate-phosphate buffer
(0.15 M, pH 6.0, 0.05 mL final volume) and SGD (2.5 pig) was added. Under these
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conditions, the reactions with the highest concentration of deuterated SGD substrate is
completely deglucosylated after 30 min at 30 'C. After 30 min, deglucosylated d4-3a or
d4-3b (50 pL volume) was added to a solution containing NADPH (2.4 mM final
concentration) and cell free extract (prepared as described above, 2.4 mg total protein
mL') to a total volume of 200 pL. The reaction mixture was incubated at 30 'C and
aliquots (15 pL) were quenched at appropriate time points and treated as described for
the SGD kinetic analysis. The increase in the area under the product peak was used to
obtain the initial rates of the reduction reaction. Each concentration was assayed at least
three times and the averaged value is reported with standard deviations. The data were
fitted by the same method as described for SGD kinetics.
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CHAPTER 7
CONCLUSIONS AND FUTURE DIRECTIONS
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7.1 Conclusions
Chapter 2 describes the development of two new screening methods to visually detect
STS activity. E'2 In the first method, a yellow colored pigment forms between a
deglucosylated strictosidine intermediate and tryptamine.E1 3 The second method also
depends on the deglucosylation of strictosidine, but addition of the dye BTB results in a
blue to yellow color change.E2 3 The color change may result from formation of an ion pair
between the positively charged deglucosylated intermediate and the negatively charged
form of BTBJ2 3 The adaptation of the BTB-containing method for detecting STS activity
on agar plates could facilitate screening of thousands of STS producing S. cerevisiae
colonies.
Chapter 3 describes the use of the pigment-based assay to screen saturation mutagenesis
libraries of STS in multi-well plates.E1 3 Screening of four libraries with mutations in the
tryptamine binding site identified two enzyme variants, Val2l4Met and Phe232Leu STS,
which catalyze the formation of new strictosidine analogs with substitution on the
tetrahydro-p-carboline moiety, including chlorinated and brominated derivatives.E1 3 The
Val to Met mutation allows substitutions at the 5-position of tryptamine; the Phe to Leu
mutation increases the volume of the tryptamine binding pocket to tolerate 2'-
substitutions. C. roseus hairy-root cultures derived from seedlings transfected with the
Val2l4Met mutant of STS are able to form chlorinated MIA analogs not formed in the
wild-type plant.E3 1 Therefore, Val2l4Met STS functions in the context of a metabolic
pathway, despite its low activity with unnatural substrates. The agar plate adapted
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screening method might be useful for the screening of multi-site saturation mutagenesis
libraries for expanded substrate scopes or increased catalytic activity with substrate
analogs.
Chapter 4 describes the characterization of OpSTS, which has broader amine and
aldehyde substrate scopes compared to its closest homologs, CrSTS and RsSTS.J41 For
example, OpSTS catalyzes the asymmetric biocatalytic formation of a variety of
tetrahydro-p-carbolines; the first reported biocatalytic route to these molecules. The high
enantiomeric excess (>98%) of the product that forms in the reaction between tryptamine
and achiral aldehydes indicates that the seco-iridoid portion of the aldehyde, while
important for an optimal catalytic rate, is not essential for maintaining the
stereoselectivity of the Pictet-Spengler reaction. OpSTS also catalyzes the Pictet-
Spengler reaction between secologanin and a variety of tryptamine analogs. For example,
2'(R)-tryptophanol, a substrate for Phe232Leu STS, and 5-methoxytryptamine that is not
a substrate for CrSTS or any mutant of CrSTS, are substrates for OpSTS. As I mentioned
in section 4.2.5, efforts to interconvert the substrate specificities of CrSTS and OpSTS
failed, but future experiments may provide a molecular basis for the broader substrate
scopes (section 7.2). It is possible that the electronics at the entry to the active site
determines which substrates are accepted, by guiding the appropriate substrates into the
binding pocket. Therefore, mutagenesis to the surface residues may change the substrate
scope. Chapter 4 also describes a model for STS stereoselectivity.[ 4] In this model, a Glu
residue acts as a general base to deprotonate one out of the four possible intermediates -
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the isomer that results in the 3(S) stereogenic center of strictosidine. The model predicts
that the stereoselectivity can be altered by inverting the active site, thereby relocating the
catalytic base to the opposite face of the indole ring.
Section 7.2 describes potential use of the BTB-containing agar plate screening method to
increase the activity of Val2l4Met STS, to investigate the molecular basis of the broad
substrate specificity of OpSTS, to create a vincoside synthase, and to evolve a more
thermostable OpSTS.
Chapters 5 and 6 describe the total synthesis of a series of des-vinyl secologanin 0-
analogs using a tandem Knoevenagel hetero-Diels-Alder reaction as the key step.['' 6 ]
When secologanin is replaced by smaller acetal groups, CrSTS accepts not only the 2,4-
trans dihydropyran configuration of secologanin, but also the unnatural 2,4-cis
configuration.E5 1 The activity is dramatically lower when the glucose is replaced with a
smaller group, likely due to the loss of productive non-covalent interactions between the
glycoside and the enzyme; mutagenesis of the secologanin binding site may increase the
activity and specificity with the unnatural aldehydes.
Total synthesis also affords a stereoisomer mixture of (glucosylated) des-vinyl
secologanin.[6] Incubation of this stereoisomer mixture with a reconstituted
heteroyohimbine alkaloid pathway that can generate ajmalicine, or an isomer of
ajmalicine, identified stereochemical restrictions in the early steps of alkaloid
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Figure 7.1 Chemo-enzymatic synthesis of monoterpene indole alkaloid stereoisomers libraries
for biological evaluation.
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biosynthesis (Chapter 6).E63 For example, when the glucose moiety is present, CrSTS
catalyzes the formation of only one product when presented with an aldehyde substrate
that is a mixture of multiple stereoisomers. Furthermore, SGD requires a p-glycoside
linkage but catalyzes the deglucosylation of at least one unnatural (2,4-cis) stereoisomer.
Chemical synthesis and the recruitment of enzymes from unrelated biosynthetic pathways
bypasses the stereochemical restrictions and allowed an experiment that shows that the
NADPH-dependent reductase converts all tested stereoisomers. By using a combination
of glucosidases and a synthetic mixture of strictosidine stereoisomers, it may be possible
to generate novel alkaloid libraries for bioactivity evaluation (Figure 7.1). Cloning of the
plant NADPH-reductase and expression in a heterologous system will likely increase
chemo-enzymatic product titers.
7.2 Future directions
The pH-indicator assay system adapted to agar plates, described in section 2.2.5, should
ions allow screening of larger enzyme libraries (1,000-10,000 variants), which enables
the pursuit of an answer to the following questions: What is the molecular basis of the
broader substrate specificity of OpSTS? How can we improve the activity of STS with
tryptamine analogs? How can we obtain a vincoside-forming enzyme? Is it possible to
improve the activity of OpSTS of CrSTS with tryptamine analogs?
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7.2.1 Molecular basis of the broader substrate scope with OpSTS
Enzyme specificity is challenging to manipulate because it often depends on the small
contribution of many, including distant, side-chain and main-chain interactions. The
intriguingly broad amine and aldehyde scopes of OpSTS are not easily explained by
comparing amino acid residues in the substrate binding pockets of OpSTS and RsSTS
(Chapter 4). However, a promising strategy may be to gradually modify the sequence of
CrSTS to resemble that of OpSTS until the desired switch in specificity occurs. Since
some part of the DNA sequence of opsts confers the broader substrate specificity,
different stretches of DNA in the opsts and crsts genes could be swapped. For example,
DNA shuffling of the C. roseus and 0. pumila strictosidine synthase genes by treating
with DNaseI, followed by self-reassembly and splicing-overlap extension PCRs leads to a
random shuffled library (Figure 7.2A). 7 1 Alternatively, defined overlapping gene
fragments could be obtained by PCR and then reassembled to give defined chimerae
(Figure 7.2A). The resulting random and defined chimerae may then be evaluated for
activity with natural substrates using the BTB-containing agar plate screen, to eliminate
inactive library members. The active chimerae can then be individually expressed and
assayed in 96-well plates similar to methods described in Chapter 3 (Figure 7.2B).
7.2.2 Optimizing the activity of STS toward substrate analogs
Optimizing the activity of OpSTS or CrSTS toward substrate analogs may result in a
useful biocatalyst for synthetic transformations and an improved production titer of MIA
alkaloids in transgenic plant cultures. Amino acid substitutions can lead to the
238
Chimer"e ram dtretion
so defined chimeaw
overlapping gene f-amnts
of known identity
_ _ _ _ _hits
Library 10ree(agar plate) 2 a(substrate anlos
Figure 7.2 (A) Library construction based on DNA shuffling that results in a random or defined
library of chimerae. (B) Gene libraries introduced into S. cerevisiae can be screened for activity
toward the natural substrates to eliminate inactive members. The active chimerae can then be
carried into a secondary screen using substrate analogs.
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introduction of repulsive interactions with adjacent residues or substrates. This may be
counteracted by mutagenesis of the residues adjacent to the substitution. For the
Val214Met STS mutant, the two adjacent residues (213 and 215) could be subjected to
saturation mutagenesis using a single complementary primer pair. The resulting library,
transformed into S. cerevisiae could then be screened using the BTB-containing agar
plate method for activity toward 5-methyl-, 5-chloro-, or 5-bromotryptamine. Remote
substitutions could also have unexpected effects on activity with substrate analogs and
error-prone PCR may be a potentially useful complement to more focused strategies.
7.2.3 Reengineering the stereoselectivity of STS
The stereochemical model of STS presented in Chapter 4 predicts that relocation of the
catalytic Glu residue may allow the formation of the 3(R) stereogenic center found in
vincoside. A successful redesign would be an compelling example of rational design and
would validate this stereoselectivity hypothesis. The ability to form the alternative
stereoisomer also has a practical application, as it would result in an asymmetric
biocatalyst complementary to the 3(S)-forming OpSTS. Site-directed mutants of STS can
be designed based on the model described in Chapter 4, and will likely include Phe232
and Glu315. One strategy is to switch the locations of the residues that interact with the
top and the bottom faces of the indole ring, using a combination of targeted and random
mutagenesis. Although computer modeling may serve as a guide, this project will likely
present considerable challenges.
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7.2.4 Evolving a thermostable STS
Since the asymmetric synthesis catalyzed by STS is effectively irreversible, elevated
temperatures should not affect the enantiomeric excess of the tetrahydro-p-carboline
product. The biocatalytic application of OpSTS could therefore benefit from a higher
tolerance to increased reaction temperatures. The directed evolution of thermostability in
OpSTS is currently in progress. Briefly, error-prone PCR libraries will be transformed
into S. cerevisiae. As the colonies form on indicator plates, individual OpSTS variants are
exported to the media around each colony. After incubation at an elevated temperatures
the plates will be screened for activity as described in Chapter 4. Any hits will be used as
a template for second round of error-prone PCR. The evolved thermostable mutants will
be characterized using circular dichroism and inactivation kinetics and compared to the
wild-type enzyme. Finally the thermostable mutants will be tested for biocatalytic
applications.
7.2.5 Converting STS into paraoxonase
Sequence alignments show that there are hundreds, if not thousands, of STS-like proteins.
However, only a few of these proteins catalyze the Pictet-Spengler reaction. It is likely
that the sequence similarity merely identifies a superfamily with a common protein
structure class - the six-bladed p-propeller fold. For example, several p-propellers with
significant strictosidine synthase sequence identity (~30%) have phosphatase activity
(e.g. human paraoxonase, PON). Other superfamily members are without enzyme activity
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(e.g. hemomucin). The sequence requirements of STS activity are unknown, but it is
interesting to observe that the same structural scaffold can support different activities.
The use of protein structures as scaffolds to support different natural or unnatural
catalytic activities offers tremendous potential for the development of new
biocatalysts. 8 '91 Understanding how to alter protein function without disrupting protein
structure is key for the successful creation of engineered enzymes. One ongoing project is
to introduce PON activity into STS. This would require the introduction of Ca-binding
site. The strategy is based on assembly of genes that gradually modify the gene encoding
RsSTS into the gene encoding PON1. Assembly of genes by a multi-primer self-
assembly PCR reaction followed by cloning of the resulting artificial genes into an
expression vector may be followed by expression and characterization of the chimeric
proteins. Hydrolase activity toward aryl esters and lactones, which are substrates for
PONi but not STS, and the dependence on calcium for activity, will be signs for the
successful conversion of activity. In the case that designed proteins are not active, the
artificial genes may be recombined using DNA shuffling in the presence of the gene
encoding PONI. A successful outcome would cast light on the minimum sequence
requirements for Ca-binding and hydrolase activity in STS. X-ray structure determination
of any active variants may be of considerable interest for the understanding of how
structure evolves as sequences change.
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CHAPTER 3 - APPENDIX A
LC-MS TRACES: FEEDING OF STRICTOSIDINE ANALOGS 8m AND 8o
TO C. ROSEUS HAIRY-RoOT CULTURES
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Figure 3A.1 Chapter 3. LC-MS trace of putative ajmalicine 1 (or isomer of 1) analog. Peaks for
m/z 383 (C2 2H2 7N20 4 calc m/z 383.1971 [M+H]*, observed m/z 383.1955 [M+H]*) exist in the
8m-supplemented culture that are not present in the control (supplemented with 6a). The
corresponding natural MIA, ajmalicine 1 (m/z 353), is present in the control culture.
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Figure 3A.2 Chapter 3. LC-MS trace of unknown compound 14 (retention time, 3.1 min), which
is formed when hairy roots are supplmented with 8m. NMR spectroscopy shows that the
compound is an indole alkaloid. The alkaloid with m/z 426 does not exist in the control culture
(supplemented with 6a). The peak at 4.8 min in the control culture (top trace) is the isotope signal
of the unidentified compound, m/z 395, which is produced in hairy root culture.
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Figure 3A.3 Chapter 3. LC-MS trace of a brominated ajmalicine analog with stereoisomers. Both
isotope peaks are shown (m/z 431 and 433) and bromine isotopes contain 1:1 mixture of M and
M+2. The culture supplemented with 8o contain two peaks (retention times of 11.0 min and 11.4
min) that are not present in the control culture (derived from 6a). The peak at 8.2 min in the top
trace co-elutes with an authentic standard of ajmalicine (not shown).
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Figure 3A.4 Chapter 3. LC-MS trace of putative brominated yohimbine-type alkaloid (retention
time, 9.5 min). Based on the presence of the two characteristic isotope signals expected from a
brominated molecule. The corresponding signals are not observed in the control culture (derived
from 6a). The natural MIA yohimbine elutes at 6.5 min using this LC-method (top trace). The
isotope peaks of the putative ajmalicine analogs (m/z 433, compare to Figure A3) are seen in the
bottom trace.
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Figure 3A.5 Chapter 3. LC-MS trace of a putative brominated alkaloid analog of akuammacine
11 (m/z 323,r, = 8.1 min, NMR evidence in McCoy, E.; O'Connor, S.E. "Directed biosynthesis of
alkaloid analogs in the medicinal plant periwinkle", J. Am. Chem. Soc. 2006, 128, 14276-14277).
Based on the presence of the two characteristic isotope signals expected from a brominated
molecule, we assigned m/z 401 and m/z 403 at 12.1 min as any structural isomer of akuammicine
(11); the corresponding signals are not observed in the control culture.
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CHAPTER 4 - APPENDIX B
CHIRAL HPLC TRACES AND NMR SPECTRA:
0. PUMILA STRICTOSIDINE SYNTHASE
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OpSTS
ii. Product of 1 and 11
iii. Product of 1 and 13
iv. Product of 1 and 14
OpSTS
Figure 4B.1 Chapter 4. Chiral HPLC traces of tetrahydro-p-carbolines. The scale on each of the
traces is 10 min to 40 min.
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CHAPTER 5 - APPENDIX C
LC-MS TRACES:
C. ROSEUS STRICTOSIDINE SYNTHASE-CATALYZED REACTIONS BETWEEN
TRYPTAMINE AND DES-VINYL SECOLOGANIN AGLYCONE O-ANALOGS
267
C roveus STS catalyzed reaction between 1 and 22 (O-Et)
4 h time-point
CIs-30
trans-30
3.5
tine, min
C raseu= STS catalyzed reaction between 1 and 25 (0-Cy)
4 h time-point
cis-33
trans-33
3 3.5 4 4.5 5 5.5 6
time, min
Figure 5C.1 Chapter 5. LC-MS traces of the 4 h time-point in kinetic experiments that were used
to determine the diastereoselectivity of CrSTS. CrSTS has a higher trans/cis-diastereoselectivity
with compound 33 (0-Cy) than compound 30 (O-Et).
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Figure 5C.2 Chapter 5. LC-MS traces for the CrSTS-catalyzed formation of the O-Et analog of
des-vinyl strictosidine 30. For each diastereomer, the no-enzyme control (-CrSTS) is shown in the
top trace.
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Figure 5C.3 Chapter 5. LC-MS traces for the CrSTS-catalyzed formation of the 0-i-Bu analog of
des-vinyl strictosidine 31. For each diastereomer, the no-enzyme control (-CrSTS) is shown in the
top trace.
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Figure 5C.4 Chapter 5. LC-MS traces for the CrSTS-catalyzed formation of the O-t-Bu analog of
des-vinyl strictosidine 32. For each diastereomer, the no-enzyme control (-CrSTS) is shown in the
top trace.
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Figure 5C.5 Chapter 5. LC-MS traces for the CrSTS-catalyzed formation of the O-Cy analog of
des-vinyl strictosidine 33. For each diastereomer, the no-enzyme control (-CrSTS) is shown in the
top trace.
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Figure 5C.6 Synthesis of O-nitrobenzyl strictosidine analog from 28 and 1 in the presence of
either (A) maleic acid buffer (10 mM, pH 2.0) or (B) trifluoroacetic acid (TFA, pH 1) in DCM.
The TFA-catalyzed reaction is higher-yielding.
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Figure 5C.7 Irradiation of o-nitrobenzyl des-vinyl strictosidine using UV-light (320 nm). After
10 minutes of irradiation some starting material remains (m/z 478, 4.7 min, above), while the
expected rearranged deprotected product is formed (m/z 325, 2.4 and 2.6 min, below).
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CHAPTER 6 - APPENDIX D
LC-MS TRACES AND NMR SPECTRA:
SYNTHESIS AND CHARACTERIZATION OF DES-VINYL SECOLOGANIN
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Figure 6D.1 Chapter 6. Deglucosylation of des-vinyl strictosidine isomers 12. Graphs showing
the relative rate of disappearance of UPLC peaks 1-6 using B. stearothermophilus c-glucosidase
(alpha, blue points) or almond p-glucosidase (beta, pink points). Based on these data, pk 1, pk 3,
and pk 6 contain mainly p-anomers, while pk 2 and pk 4 contain mainly a-anomers. Pk 5 appears
to contain both a- and p-anomers. Each data point is the average value of three experiments. The
error of each point is <20%.
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